image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
733ec406f72193988a4883dadbbe8676167970c353bea357e3dde2570cd216ed.png | simple | <table><tr><td>Criterion</td><td>Data extracted</td></tr><tr><td>Country research conducted</td><td>Country</td></tr><tr><td>Study design</td><td>Between-subjects, within-subject, laboratory, field.</td></tr><tr><td>Participant characteristics</td><td>Total sample size; number of male and female participants; mean, median, standard deviation and range for age and BMI and BMI assessment method if assessed (self-report or objectively measured).</td></tr><tr><td>Moderating variables</td><td>Individual differences in eating behaviour traits [dieting status; restrained eating (scale used) or any other psychometric scales]; any other moderators examined.</td></tr><tr><td>Cue type and level of engagement</td><td>Type of cue: Specific item (e.g. slim models, foods); level of engagement: explicit, incidental, sub-conscious; cue validation</td></tr><tr><td>Test food</td><td>Interval between cue exposure and assessment of food intake; Test foods used: snack, meal, sweet, savoury, food name.</td></tr><tr><td>Mechanism for effects tested?</td><td>Yes, no; type of assessment used.</td></tr><tr><td>Main outcome</td><td>Food intake in ounces, piece count, grams and energy intake; assessment method for food intake (weighed, piece count)</td></tr><tr><td>Risk of bias</td><td>Random allocation to conditions, randomisation methods, allocation concealment, blinding (use of a cover story and participants' beliefs about the study aims; whether the researcher was aware of the study aims or condition that had been administered), completion of outcome reporting (excluded participants), procedures used to control for appetite, individual or social setting, administration of psychometric scales.</td></tr></table> |
758dfa3faefc3e970db9a11b329871b1f9783bd5bd3e28125c2a9c30dd8ce4bf.png | complex | <table><tr><td></td><td colspan="2">Intervention Group (n = 39)</td><td colspan="2">Control Group (n = 40)</td></tr><tr><td></td><td>Baseline</td><td>Week 12</td><td>Baseline</td><td>Week 12</td></tr><tr><td>Work-related PA</td><td></td><td></td><td></td><td></td></tr><tr><td>Vigorous PA</td><td>0 (1080)</td><td>0 (1800)</td><td>0 (720)</td><td>0 (540)</td></tr><tr><td>Moderate PA</td><td>0 (1500)</td><td>0 (900)</td><td>0 (1500)</td><td>0 (600)</td></tr><tr><td>Walking</td><td>0 (1620)</td><td>0 (2520)</td><td>0 (1350)</td><td>0 (1650)</td></tr><tr><td>Total</td><td>0 (3000)</td><td>30 (4680)</td><td>0 (2550)</td><td>0 (2730)</td></tr><tr><td>Transportation PA</td><td></td><td></td><td></td><td></td></tr><tr><td>Bicycling</td><td>0 (0)</td><td>0 (0)</td><td>0 (40)</td><td>0 (40)</td></tr><tr><td>Walking</td><td>105 (1680)</td><td>140 (900)</td><td>80 (1680)</td><td>70 (1680)</td></tr><tr><td>Total</td><td>105 (1680)</td><td>140 (900)</td><td>80 (1720)</td><td>70 (1720)</td></tr><tr><td>Housework PA</td><td></td><td></td><td></td><td></td></tr><tr><td>Vigorous outside home</td><td>0 (840)</td><td>0 (840)</td><td>0 (750)</td><td>0 (360)</td></tr><tr><td>Moderate outside home</td><td>0 (2100)</td><td>0 (1680)</td><td>0 (1260)</td><td>0 (840)</td></tr><tr><td>Moderate inside home</td><td>210 (2100)</td><td>150 (840)</td><td>180 (1680)</td><td>120 (1680)</td></tr><tr><td>Total</td><td>360 (4200)</td><td>300 (2520)</td><td>255 (2640)</td><td>202.5 (2520)</td></tr><tr><td>Leisure-time PA</td><td></td><td></td><td></td><td></td></tr><tr><td>Walking</td><td>40 (840)</td><td>100 (840)</td><td>35 (600)</td><td>16.25 (840)</td></tr><tr><td>Vigorous PA</td><td>0 (180)</td><td>0 (120)</td><td>0 (120)</td><td>0 (600)</td></tr><tr><td>Moderate PA</td><td>0 (360)</td><td>0 (60)</td><td>0 (180)</td><td>0 (180)</td></tr><tr><td>Total</td><td>60 (840)</td><td>120 (840)</td><td>60 (600)</td><td>60 (840)</td></tr><tr><td>Combined Domains</td><td></td><td></td><td></td><td></td></tr><tr><td>Total Walking</td><td>225 (3360)</td><td>290 (2850)</td><td>167.5 (1740)</td><td>155 (1925)</td></tr><tr><td>Total Moderate PA</td><td>420 (4380)</td><td>405 (2760)</td><td>360 (2640)</td><td>262.5 (2590)</td></tr><tr><td>Total Vigorous PA</td><td>0 (1080)</td><td>0 (1800)</td><td>0 (720)</td><td>0 (600)</td></tr><tr><td>Total PA</td><td>690 (6300)</td><td>840 (5415)</td><td>640 (4300)</td><td>577.5 (4270)</td></tr><tr><td>Time Spent Sitting</td><td></td><td></td><td></td><td></td></tr><tr><td>Weekday</td><td>1500 (3750)</td><td>1200 (3900)</td><td>1500 (3450)</td><td>1500 (2850)</td></tr><tr><td>Weekend</td><td>480 (1320)</td><td>360 (1200)</td><td>600 (1200)</td><td>600 (1320)</td></tr><tr><td>Total</td><td>1980 (4650)</td><td>1680 (5100)</td><td>2130 (4170)</td><td>2100 (3630)</td></tr></table> |
ce8f450346ee10ca075bd52f96cf9d538ec784cf0db947247d66469fae5f137a.png | complex | <table><tr><td colspan="10"><i>Coefficients<sup>a</sup></i></td></tr><tr><td rowspan="3" colspan="2"> <i>Model</i></td><td colspan="2"><i>Unstandardized Coefficients</i></td><td><i>Standardized Coefficients</i></td><td rowspan="3"><i>t</i></td><td rowspan="3"><i>Sig.</i></td><td colspan="3"><i>Correlations</i></td></tr><tr><td><i>B</i></td><td><i>Std. Error</i></td><td><i>Beta</i></td><td><i>Zero-order</i></td><td><i>Partial</i></td><td><i>Part</i></td></tr><tr><td rowspan="7">1</td><td>(Constant)</td><td>1.556</td><td>0.344</td><td></td><td>4.519</td><td>0.000</td><td></td><td></td><td></td></tr><tr><td>Age</td><td>-0.003</td><td>0.003</td><td>-0.113</td><td>-1.212</td><td>0.227</td><td>-0.141</td><td>-0.087</td><td>-0.076</td></tr><tr><td>Diabetes Mellitus</td><td>0.365</td><td>0.052</td><td>0.453</td><td>7.079</td><td>0.000</td><td>0.475</td><td>0.454</td><td>0.442</td></tr><tr><td>GFR</td><td>0.001</td><td>0.003</td><td>0.022</td><td>0.191</td><td>0.849</td><td>0.169</td><td>0.014</td><td>0.012</td></tr><tr><td>Serum Creatinine</td><td>-0.099</td><td>0.132</td><td>-0.075</td><td>-0.753</td><td>0.452</td><td>-0.134</td><td>-0.054</td><td>-0.047</td></tr><tr><td>Weight</td><td>-0.001</td><td>0.003</td><td>-0.039</td><td>-0.427</td><td>0.670</td><td>-0.035</td><td>-0.031</td><td>-0.027</td></tr><tr><td>Proteinuria</td><td>7.064E-5</td><td>0.000</td><td>0.027</td><td>0.425</td><td>0.671</td><td>0.006</td><td>0.031</td><td>0.027</td></tr></table> |
6d5ba9cddf0798b1dd7e8d9df1835180269b4af06fbd4258c0b826da1f268573.png | complex | <table><tr><td>CoW structure</td><td colspan="3">Computation</td><td colspan="3">Measurement [43]</td></tr><tr><td></td><td>L. ICA</td><td>R. ICA</td><td>BA</td><td>L. ICA</td><td>R. ICA</td><td>BA</td></tr><tr><td>Type 1</td><td>4.81</td><td>4.85</td><td>2.36</td><td>5.07</td><td>5.18</td><td>2.75</td></tr><tr><td>Type 2</td><td>6.14</td><td>3.50</td><td>2.36</td><td>6.12</td><td>3.93</td><td>2.35</td></tr><tr><td>Type 3</td><td>4.80</td><td>5.70</td><td>1.49</td><td>5.28</td><td>5.91</td><td>1.50</td></tr></table> |
fcbdb366b904fc9e2622cab052c386ebc045df91f9741e4bb4461c23d02383a9.png | simple | <table><tr><td>Demographics and clinical characteristics</td><td><i>n</i> (%)</td></tr><tr><td>Age (mean ± SD)</td><td>55.4 ± 17.3</td></tr><tr><td>Male</td><td>131 (76.6)</td></tr><tr><td>Medical use before admission</td><td> </td></tr><tr><td> NSAIDs</td><td>43 (25.1)</td></tr><tr><td> PPIs ≤ 2 weeks</td><td>28 (16.4)</td></tr><tr><td> Antibiotics ≤ 4 weeks</td><td>13 (7.6)</td></tr><tr><td>Prior history of peptic ulcers</td><td>42 (24.6)</td></tr><tr><td>Prior history of <i>H. pylori </i>eradication</td><td>12 (7.0)</td></tr><tr><td>Presenting symptoms</td><td> </td></tr><tr><td> Hematemesis</td><td>88 (51.5)</td></tr><tr><td> Melena</td><td>77 (45)</td></tr><tr><td> Hematochezia</td><td>6 (3.5)</td></tr><tr><td>Preendoscopic PPIs use</td><td> </td></tr><tr><td> High-dose, intravenous</td><td>133 (77.8)</td></tr><tr><td> Low-dose, intravenous</td><td>8 (4.6)</td></tr><tr><td> Oral</td><td>3 (1.8)</td></tr><tr><td> None</td><td>27 (15.8)</td></tr><tr><td>Hemodynamic instability at admission (heart rate > 100 beats per minute and/or systemic blood pressure < 100 mmHg)</td><td>47 (27.5)</td></tr><tr><td>Transfusion requirement</td><td>47 (27.5)</td></tr></table> |
672d04e1dd9594b581c5a1deb432e3258c34f15b16b196b50038e339eb70c9a1.png | complex | <table><tr><td rowspan="2">Cerebral structure</td><td rowspan="2">Embryonic day</td><td colspan="4">Genotype/normalised volume (mm<sup>3</sup> × 10<sup>−2</sup>)</td></tr><tr><td><i>Gldc</i><sup>+/+</sup></td><td><i>Gldc</i><sup>GT1/+</sup></td><td><i>Gldc</i><sup>GT2/+</sup></td><td><i>Gldc</i><sup>GT1/GT2</sup></td></tr><tr><td>Mesencephalic vesicle</td><td>16.518.5</td><td>30 ± 515 ± 2*</td><td>34 ± 413 ± 1*</td><td>35 ± 316 ± 2*</td><td>30 ± 314 ± 2*</td></tr><tr><td>Body of the LVs</td><td>16.518.5</td><td>15 ± 27 ± 1*</td><td>13 ± 28 ± 1**</td><td>11 ± 17 ± 1**</td><td>13 ± 323 ± 9***</td></tr><tr><td>Base of the posterior horn of LVs</td><td>16.518.5</td><td>10 ± 511 ± 5</td><td>10 ± 29 ± 1</td><td>13 ± 512 ± 3</td><td>13 ± 79 ± 6</td></tr><tr><td>Fourth ventricle</td><td>16.518.5</td><td>14 ± 27 ± 1*</td><td>12 ± 15 ± 1*</td><td>14 ± 24 ± 1*</td><td>10 ± 16 ± 1*</td></tr><tr><td>Fourth ventricle choroid plexus</td><td>16.518.5</td><td>95 ± 110 ± 1</td><td>10 ± 18 ± 1</td><td>11 ± 19 ± 4</td><td>80 ± 110 ± 1</td></tr><tr><td>Cerebellum</td><td>16.518.5</td><td>11 ± 0.0122 ± 2*</td><td>13 ± 121 ± 3*</td><td>15 ± 119 ± 1*</td><td>12 ± 121 ± 2*</td></tr></table> |
2f93e4eb9df2791dffb86a94afd894edb9f8c44edbc2593e4c9c37991d134e72.png | simple | <table><tr><td> </td><td>With Hashimoto’s</td><td>Without Hashimoto’s</td><td>P value</td></tr><tr><td>Number of patients</td><td>653</td><td>5456</td><td> </td></tr><tr><td>Age (years)</td><td>44.4±11.9</td><td>46.3±12.3</td><td>0.077</td></tr><tr><td>Gender</td><td> </td><td> </td><td> </td></tr><tr><td>Male</td><td>56</td><td>1482</td><td>0.001</td></tr><tr><td>Female</td><td>597</td><td>3974</td><td> </td></tr><tr><td>Nodule Size (cm)</td><td>1.75±1.23</td><td>2.26±1.48</td><td>0.001</td></tr><tr><td>PTC</td><td>381(58.3%)</td><td>2440(44.3%)</td><td>0.001</td></tr><tr><td>PTC cancer with serum TSH</td><td>358(54.8%)</td><td>2262(41.6%)</td><td>0.001</td></tr></table> |
be8b8611f3f0c4e5716c1129c9f524e691b6d196c302c6d0953909e043566053.png | complex | <table><tr><td rowspan="3">Entry</td><td colspan="4">PA (<i>n</i> = 30)</td><td rowspan="2" colspan="2">Non-PA (<i>n</i> = 18)</td></tr><tr><td colspan="2">U-PA (<i>n</i> = 13)</td><td colspan="2">B-PA (<i>n</i> = 17)</td></tr><tr><td>Combined</td><td>Single</td><td>Combined</td><td>Single</td><td>Combined</td><td>Single</td></tr><tr><td rowspan="2">PAC 30 min/PAC 0 min</td><td>3.3</td><td>1.8</td><td>2.5</td><td>2.3</td><td>2.7</td><td>2.5</td></tr><tr><td>(2.4–4.4)</td><td>(1.5–3.0)</td><td>(1.9–2.9)</td><td>(2.1–2.7)</td><td>(2.4–3.0)</td><td>(2.1–3.4)</td></tr><tr><td><i>p</i>-Value <sup>c</sup></td><td></td><td>0.05</td><td></td><td>0.49</td><td></td><td>0.78</td></tr><tr><td rowspan="2">PAC 60 min/PAC 0 min</td><td>2.9</td><td>1.9</td><td>2.3</td><td>2.3</td><td>2.9</td><td>2.8</td></tr><tr><td>(2.5–5.0)</td><td>(1.7–3.0)</td><td>(2.1–2.9)</td><td>(2.0–2.9)</td><td>(2.7–3.6)</td><td>(2.5–3.5)</td></tr><tr><td><i>p</i>-Value</td><td></td><td>0.09</td><td></td><td>0.52</td><td></td><td>0.71</td></tr><tr><td rowspan="2">PAC/F, 0 min</td><td>14.8</td><td>3.5</td><td>11.8</td><td>2.2</td><td>7.7</td><td>1.3</td></tr><tr><td>(11.5–26.0)</td><td>(1.3–5.7)</td><td>(6.1–15.7)</td><td>(1.5–2.9)</td><td>(4.2–11.9)</td><td>(1.0–1.5)</td></tr><tr><td><i>p</i>-Value</td><td></td><td><0.01</td><td></td><td><0.01</td><td></td><td><0.01</td></tr><tr><td rowspan="2">PAC/F, 30 min</td><td>4.5</td><td>3.8</td><td>1.7</td><td>1.6</td><td>1.3</td><td>1.4</td></tr><tr><td>(1.7–8.5)</td><td>(1.5–5.3)</td><td>(1.4–1.9)</td><td>(1.4–2.0)</td><td>(1.0–1.8)</td><td>(0.9–1.7)</td></tr><tr><td><i>p</i>-Value</td><td></td><td><0.01</td><td></td><td>0.94</td><td></td><td>0.68</td></tr><tr><td rowspan="2">PAC/F, 60 min</td><td>4.1</td><td>3.3</td><td>1.4</td><td>1.5</td><td>1.3</td><td>1.1</td></tr><tr><td>(1.5–6.8)</td><td>(1.6–4.9)</td><td>(1.0–1.6)</td><td>(1.1–1.9)</td><td>(0.9–1.5)</td><td>(0.7–1.6)</td></tr><tr><td><i>p</i>-Value</td><td></td><td>0.05</td><td></td><td>0.23</td><td></td><td>0.85</td></tr></table> |
4e24d568e95e9f37f3b5228c6c11e627ee412bbf33e05521725e38633e1e2e6b.png | complex | <table><tr><td></td><td>β coefficient</td><td colspan="2">95% CI</td><td>p</td></tr><tr><td>EBM score</td><td>−0.33</td><td>−0.53</td><td>−0.12</td><td><0.01</td></tr><tr><td>% admissions in urgency</td><td>0.02</td><td>−0.07</td><td>0.10</td><td>0.95</td></tr><tr><td>ward (surgical/medical)</td><td>0.64</td><td>−4.71</td><td>5.99</td><td>0.81</td></tr><tr><td>% appropriateness in admissions</td><td>−0.66</td><td>−0.77</td><td>−0.55</td><td><0.01</td></tr><tr><td>constant</td><td>85.27</td><td>73.33</td><td>97.20</td><td><0.01</td></tr></table> |
9309f6d8dd2045998d94bf9d0efac38301b95742e5d0399edbe941626b0b2666.png | complex | <table><tr><td></td><td colspan="2">Peri-centenarian Female</td><td colspan="2">Controls Female</td><td></td><td colspan="2">Peri-centenarian Male</td><td colspan="2">ControlMale</td><td></td></tr><tr><td>Genotype</td><td colspan="2">N = 180</td><td colspan="2">N = 156</td><td><i>p</i></td><td colspan="2">N = 181</td><td colspan="2">N = 186</td><td><i>p</i></td></tr><tr><td>5/5</td><td>1</td><td>0.56%</td><td>6</td><td>3.85%</td><td>0.053</td><td>8</td><td>4.42%</td><td>4</td><td>2.15%</td><td>0.253</td></tr><tr><td>5/6</td><td>1</td><td>0.56%</td><td>3</td><td>1.92%</td><td>0.341</td><td>2</td><td>1.10%</td><td>2</td><td>1.08%</td><td>1.000</td></tr><tr><td>5/7</td><td>29</td><td>16.11%</td><td>32</td><td>20.51%</td><td>0.322</td><td>41</td><td>22.65%</td><td>41</td><td>22.04%</td><td>0.901</td></tr><tr><td>5/9</td><td>8</td><td>4.44%</td><td>3</td><td>1.92%</td><td>0.232</td><td>7</td><td>3.87%</td><td>11</td><td>5.91%</td><td>0.470</td></tr><tr><td>6/6</td><td>2</td><td>1.11%</td><td>0</td><td>0.00%</td><td>0.501</td><td>0</td><td>0.00%</td><td>0</td><td>0.00%</td><td>nc</td></tr><tr><td>6/7</td><td>10</td><td>5.56%</td><td>2</td><td>1.28%</td><td>0.041</td><td>5</td><td>2.76%</td><td>13</td><td>6.99%</td><td>0.089</td></tr><tr><td>6/9</td><td>2</td><td>1.11%</td><td>3</td><td>1.92%</td><td>0.666</td><td>1</td><td>0.55%</td><td>3</td><td>1.61%</td><td>0.623</td></tr><tr><td>7/7</td><td>83</td><td>46.11%</td><td>74</td><td>47.44%</td><td>0.827</td><td>82</td><td>45.30%</td><td>77</td><td>41.40%</td><td>0.463</td></tr><tr><td>7/8</td><td>0</td><td>0.0%</td><td>1</td><td>0.64%</td><td>0.464</td><td>0</td><td>0.00%</td><td>0</td><td>0.00%</td><td>nc</td></tr><tr><td>7/9</td><td>41</td><td>22.78%</td><td>29</td><td>18.59%</td><td>0.419</td><td>29</td><td>19.02%</td><td>32</td><td>17.20%</td><td>0.781</td></tr><tr><td>9/9</td><td>3</td><td>1.67%</td><td>3</td><td>1.92%</td><td>1.000</td><td>6</td><td>3.31%</td><td>3</td><td>1.61%</td><td>0.332</td></tr><tr><td>homozygotes</td><td>89</td><td>49.45%</td><td>83</td><td>53.21%</td><td>0.513</td><td>96</td><td>53.04%</td><td>84</td><td>45.16%</td><td>0.144</td></tr><tr><td>Heterozygotes</td><td>91</td><td>50.55%</td><td>73</td><td>46.79%</td><td>0.513</td><td>85</td><td>46.96%</td><td>102</td><td>54.84%</td><td>0.144</td></tr><tr><td>Alleles</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>5</td><td>40</td><td>11.11%</td><td>50</td><td>16.03%</td><td>0.069</td><td>66</td><td>18.23%</td><td>62</td><td>16.67%</td><td>0.627</td></tr><tr><td>6</td><td>17</td><td>4.72%</td><td>8</td><td>2.56%</td><td>0.157</td><td>8</td><td>2.21%</td><td>18</td><td>4.84%</td><td>0.071</td></tr><tr><td>7</td><td>246</td><td>68.33%</td><td>212</td><td>67.95%</td><td>0.934</td><td>239</td><td>66.02%</td><td>240</td><td>64.52%</td><td>0.699</td></tr><tr><td>8</td><td>0</td><td>0.00%</td><td>1</td><td>0.32%</td><td>0.464</td><td>0</td><td>0.00%</td><td>0</td><td>0.00%</td><td>nc</td></tr><tr><td>9</td><td>57</td><td>15.83%</td><td>41</td><td>13.14%</td><td>0.381</td><td>49</td><td>13.54%</td><td>52</td><td>13.98%</td><td>0.915</td></tr></table> |
450e45bb04fb809565c9f63430d59072b242b1cd877d007c9dacf2955185ecfc.png | complex | <table><tr><td>Outcome measures</td><td colspan="2">AT</td><td colspan="2">TAU</td><td rowspan="3">Unpaired <i>t</i> test</td><td rowspan="3"><i>P</i></td></tr><tr><td></td><td colspan="2">(n = 57)</td><td colspan="2">(n = 57)</td></tr><tr><td></td><td>M</td><td>SD</td><td>M</td><td>SD</td></tr><tr><td>ITAQ (0–22)<sup>a</sup></td><td>9.12</td><td>6.14</td><td>9.33</td><td>3.31</td><td>1.52</td><td>0.20</td></tr><tr><td>PANSS</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total score (30–210)<sup>a</sup></td><td>80.19</td><td>11.10</td><td>81.13</td><td>12.01</td><td>1.71</td><td>0.18</td></tr><tr><td>Positive symptoms (7–49)<sup>a</sup></td><td>15.39</td><td>5.12</td><td>15.11</td><td>5.01</td><td></td><td></td></tr><tr><td>Negative symptoms (7–49)<sup>a</sup></td><td>16.31</td><td>5.87</td><td>16.45</td><td>6.87</td><td></td><td></td></tr><tr><td>General psychopathology (16–112)<sup>a</sup></td><td>48.49</td><td>9.12</td><td>49.57</td><td>9.88</td><td></td><td></td></tr><tr><td>SLOF</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Total score (43–215)<sup>a</sup></td><td>140.01</td><td>18.22</td><td>138.34</td><td>17.18</td><td>1.49</td><td>0.20</td></tr><tr><td>Self-maintenance(12–60)<sup>a</sup></td><td>42.11</td><td>5.52</td><td>40.18</td><td>7.08</td><td></td><td></td></tr><tr><td>Social functioning (14–70)<sup>a</sup></td><td>42.00</td><td>5.88</td><td>43.01</td><td>6.91</td><td></td><td></td></tr><tr><td>Community living skills (17–85)<sup>a</sup></td><td>55.90</td><td>8.01</td><td>55.15</td><td>8.33</td><td></td><td></td></tr><tr><td>Adherence rating scale (1–5)<sup>a</sup></td><td>1.48</td><td>0.98</td><td>1.39</td><td>1.01</td><td>1.92</td><td>0.12</td></tr><tr><td>Total non-adherence (f, %)</td><td>(22, 38.80)</td><td>(20, 35.09)</td><td>χ<sup>2</sup> = 1.48</td><td>0.13</td><td></td><td></td></tr><tr><td>Poor to inadequate adherence (f, %)</td><td>(28, 49.12)</td><td>(29, 50.88)</td><td></td><td></td><td></td><td></td></tr><tr><td>Fair to good adherence (f, %)</td><td>(7, 12.28)</td><td>(8, 14.04)</td><td></td><td></td><td></td><td></td></tr><tr><td>Re-hospitalization</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Number<sup>b</sup></td><td>1.41</td><td>0.98</td><td>1.50</td><td>0.92</td><td>1.83</td><td>0.12</td></tr><tr><td>Duration<sup>c</sup></td><td>9.12</td><td>3.98</td><td>10.01</td><td>4.02</td><td>2.33</td><td>0.10</td></tr><tr><td>DAI (0–22)<sup>a</sup></td><td>8.82</td><td>3.03</td><td>9.01</td><td>3.71</td><td>1.51</td><td>0.13</td></tr></table> |
ccbb8020fffde6790a280beaf15b005d55f2a917d3c604344c86209462851519.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">IORT, <i>n</i> = 267<sup>a</sup></td><td colspan="2">EB-APBI, <i>n</i> = 206</td><td rowspan="2"><i>p</i> value</td></tr><tr><td><i>N</i>, median</td><td>%,range</td><td><i>N,</i> median</td><td>%, range</td></tr><tr><td colspan="6">Age</td></tr><tr><td> Years</td><td>68</td><td>59–90</td><td>67</td><td>59–86</td><td>0.683</td></tr><tr><td colspan="6">pT stage</td></tr><tr><td> pTis</td><td>18</td><td>7%</td><td>26</td><td>13%</td><td>0.068</td></tr><tr><td> pT1a</td><td>12</td><td>5%</td><td>14</td><td>7%</td><td></td></tr><tr><td> pT1b</td><td>80</td><td>30%</td><td>50</td><td>24%</td><td></td></tr><tr><td> pT1c</td><td>130</td><td>49%</td><td>89</td><td>43%</td><td></td></tr><tr><td> pT2</td><td>26</td><td>10%</td><td>27</td><td>13%</td><td></td></tr><tr><td colspan="6">pN stage (invasive)</td></tr><tr><td> pN0</td><td>227</td><td>92%</td><td>172</td><td>96%</td><td>0.045</td></tr><tr><td> pN1mi/pN1a</td><td>20</td><td>8%</td><td>6</td><td>3%</td><td></td></tr><tr><td> unknown</td><td>1</td><td>0%</td><td>2</td><td>1%</td><td></td></tr><tr><td colspan="6">BR stage (invasive)</td></tr><tr><td> Grade 1</td><td>81</td><td>33%</td><td>61</td><td>34%</td><td>0.075</td></tr><tr><td> Grade 2</td><td>109</td><td>44%</td><td>91</td><td>51%</td><td></td></tr><tr><td> Grade 3</td><td>56</td><td>23%</td><td>25</td><td>14%</td><td></td></tr><tr><td> unknown</td><td>2</td><td>1%</td><td>3</td><td>2%</td><td></td></tr><tr><td colspan="6">ER (invasive)</td></tr><tr><td> Positive</td><td>232</td><td>94%</td><td>169</td><td>94%</td><td>0.712</td></tr><tr><td colspan="6">PR (invasive)</td></tr><tr><td> Positive</td><td>187</td><td>75%</td><td>138</td><td>78%</td><td>0.611</td></tr><tr><td colspan="6">Her2neu (invasive)</td></tr><tr><td> Positive</td><td>15</td><td>6%</td><td>10</td><td>6%</td><td>0.893</td></tr><tr><td colspan="6">Systemic therapy</td></tr><tr><td> No</td><td>157</td><td>59%</td><td>127</td><td>62%</td><td>0.538</td></tr><tr><td> HT</td><td>91</td><td>34%</td><td>60</td><td>29%</td><td></td></tr><tr><td> CT ± HT</td><td>19</td><td>7%</td><td>17</td><td>8%</td><td></td></tr></table> |
a5e23d71b43e52a50214d431cc7ddcbca6906b1ea6f6eb59abf50a4542afe434.png | simple | <table><tr><td></td><td>Hospitalisations withAKI diagnosis (<i>N</i> = 230)(%)</td><td>Hospitalisations without AKI diagnosis (<i>N</i> = 7574)(%)</td><td><i>P</i> Value</td></tr><tr><td>Age (years)</td><td></td><td></td><td>< 0.001</td></tr><tr><td> < 65</td><td>10.9</td><td>31.4</td><td></td></tr><tr><td> 65-74</td><td>22.2</td><td>29.2</td><td></td></tr><tr><td> 75-84</td><td>41.7</td><td>27.9</td><td></td></tr><tr><td> ≥ 85</td><td>25.2</td><td>11.5</td><td></td></tr><tr><td>Sex (Male)</td><td>53.0</td><td>36.3</td><td>< 0.001</td></tr><tr><td>Smoking history</td><td></td><td></td><td>0.037</td></tr><tr><td> Non-smoker</td><td>28.7</td><td>37.7</td><td></td></tr><tr><td> Ex-smoker</td><td>59.6</td><td>53.4</td><td></td></tr><tr><td> Current smoker</td><td>11.3</td><td>8.6</td><td></td></tr><tr><td> Missing</td><td>0.4</td><td>0.3</td><td></td></tr><tr><td>Co-diagnosis of COPD</td><td>60.4</td><td>50.0</td><td>0.002</td></tr><tr><td>Outpatient eGFR (mL/min/1.73 m<sup>2</sup>)</td><td></td><td></td><td><0.001</td></tr><tr><td> > 60</td><td>33.0</td><td>53.8</td><td></td></tr><tr><td> 45-60</td><td>17.4</td><td>11.0</td><td></td></tr><tr><td> 30-45</td><td>21.3</td><td>4.2</td><td></td></tr><tr><td> 15-30</td><td>10.0</td><td>1.3</td><td></td></tr><tr><td> No measurement</td><td>18.3</td><td>29.8</td><td></td></tr><tr><td>History of AKI</td><td>20.4</td><td>4.4</td><td>< 0.001</td></tr><tr><td>Chronic conditions</td><td></td><td></td><td></td></tr><tr><td> Heart failure</td><td>19.6</td><td>9.0</td><td>< 0.001</td></tr><tr><td> Cirrhosis</td><td>0.9</td><td>0.6</td><td>0.638</td></tr><tr><td> Diabetes</td><td>26.1</td><td>13.1</td><td>< 0.001</td></tr><tr><td> Dementia</td><td>4.8</td><td>2.9</td><td>0.107</td></tr><tr><td> Prostatic hypertrophy</td><td>17.0</td><td>7.5</td><td>< 0.001</td></tr><tr><td>Drugs with nephrotoxic potential</td><td></td><td></td><td></td></tr><tr><td> NSAIDs</td><td>28.3</td><td>22.5</td><td>0.038</td></tr><tr><td> Aminoglycoside nebuliser</td><td>1.3</td><td>0.1</td><td>0.001</td></tr><tr><td> Aminoglycoside injection</td><td>1.3</td><td>0.7</td><td>0.227</td></tr><tr><td> ACEI or ARBs</td><td>35.2</td><td>21.9</td><td>< 0.001</td></tr><tr><td> Diuretics</td><td>44.8</td><td>29.5</td><td>< 0.001</td></tr><tr><td>Sepsis diagnosis</td><td>12.2</td><td>1.0</td><td>< 0.001</td></tr></table> |
4716b6b386fea62fc4414fd3aa6e60030098a316554a03ec23eb505eb559fa8b.png | complex | <table><tr><td colspan="3">Among plants in population</td><td colspan="2">Among populations</td></tr><tr><td>Population</td><td>Range of length</td><td>Average length</td><td>Population pair</td><td>Length</td></tr><tr><td><i>Uss</i></td><td>8-41</td><td>17.33</td><td><i>Uss - Spa</i></td><td>24</td></tr><tr><td><i>Spa</i></td><td>9-30</td><td>22.57</td><td><i>Uss - Dgor</i></td><td>22</td></tr><tr><td><i>Dgor</i></td><td>15-38</td><td>23.0</td><td><i>Uss - Part</i></td><td>33</td></tr><tr><td><i>Pozh</i></td><td>14-43</td><td>28.0</td><td><i>Part - Drech</i></td><td>50</td></tr><tr><td><i>Nad</i></td><td>21-36</td><td>29.07</td><td><i>Drech - Chu</i></td><td>25</td></tr><tr><td><i>Part</i></td><td>12-30</td><td>22.06</td><td><i>Part - Yak</i></td><td>19</td></tr><tr><td><i>Yak</i></td><td>22-57</td><td>35.13</td><td><i>Yak - Olg</i></td><td>35</td></tr><tr><td><i>Chu</i></td><td>15-44</td><td>25.0</td><td><i>Pozh -Nad</i></td><td>24</td></tr><tr><td><i>Drech</i></td><td>12-51</td><td>24.88</td><td><i>Pozh - Part</i></td><td>27</td></tr><tr><td><i>Olg</i></td><td>14-52</td><td>36.5</td><td></td><td></td></tr><tr><td>Average</td><td></td><td>26.35</td><td></td><td>28.78</td></tr></table> |
98716be544d9a2f760b841856ed8bfca121956bf8b985ccbf560a05b52a90bd4.png | simple | <table><tr><td></td><td>Normal range</td><td>ED admission</td><td>ICU admission</td></tr><tr><td>HR, bpm</td><td>—</td><td>143</td><td>117</td></tr><tr><td>MAP, mmHg</td><td>—</td><td>65</td><td>77</td></tr><tr><td>PaO2/FiO2</td><td>—</td><td>72,7</td><td>120</td></tr><tr><td>Body temperature, °C</td><td>—</td><td>38.1</td><td>37.9</td></tr><tr><td>Lactate, mmol/L</td><td>0.5–1.6</td><td>3.4</td><td>1.4</td></tr><tr><td>Creatinine, mg/dl</td><td><1.2</td><td>1.95</td><td>1.41</td></tr><tr><td>GOT, U/L</td><td><35</td><td>202</td><td>290</td></tr><tr><td>GPT, U/L</td><td><45</td><td>248</td><td>320</td></tr><tr><td>gGT, U/L</td><td><55</td><td>316</td><td>238</td></tr><tr><td>CK, U/L</td><td><190</td><td>1014</td><td>1553</td></tr><tr><td>Troponin T, ng/ml</td><td>0–0.03</td><td>0.274</td><td>Na</td></tr><tr><td>CRP, mg/dl</td><td><1</td><td>5.51</td><td>9.27</td></tr><tr><td>WBC, G/L</td><td>4.0–10.0</td><td>10.35</td><td>8.77</td></tr></table> |
59865f4098f720027ec00e1248bf8c4d3cfca18ada29be80929da175c5c1fda3.png | complex | <table><tr><td></td><td>Factor</td><td>Odds ratio (95 % confidence interval)</td><td><i>p</i>-value</td></tr><tr><td rowspan="2">Time period</td><td>Pre-intervention</td><td>Reference</td><td></td></tr><tr><td>Post-intervention</td><td>1.543 (0.956–2.491)</td><td>0.074</td></tr><tr><td rowspan="2">Monthly trend</td><td>Pre-intervention</td><td>1.009 (0.983–1.036)</td><td>0.487</td></tr><tr><td>Post-intervention</td><td>1.048 (1.007–1.091)</td><td>0.023</td></tr><tr><td rowspan="2">Season</td><td>Dry</td><td>Reference</td><td></td></tr><tr><td>Wet</td><td>0.974 (0.845–1.123)</td><td>0.708</td></tr><tr><td>Total outpatient attendance</td><td>Per 1,000</td><td>0.919 (0.883–0.956)</td><td><0.001</td></tr></table> |
42c15157f75bbf6aaee9878e3868e852f1c581d4078eb11b5e11447e0d1769f5.png | complex | <table><tr><td></td><td colspan="5">% G<sub>2</sub>/M cells</td></tr><tr><td>Time (hr)</td><td>ABZ (nM)</td><td>A2058</td><td>A375</td><td>H1530</td><td>H446</td></tr><tr><td>0</td><td>0</td><td>10.6</td><td>4.7</td><td>4.3</td><td>0.9</td></tr><tr><td>12</td><td>100</td><td>10.0</td><td>13.1</td><td>3.0</td><td>5.2</td></tr><tr><td>12</td><td>500</td><td>29.3</td><td>65.2</td><td>38.6</td><td>47.7</td></tr><tr><td>12</td><td>1000</td><td>32.3</td><td>87.1</td><td>46.3</td><td>71.4</td></tr></table> |
af9922ebe448f0a79b2859d7bb48119dc14bededff5d4a7b61348d72e60d1b91.png | simple | <table><tr><td>Year</td><td>2011</td><td>2010</td><td>2009</td><td>2008</td><td>2007</td><td>2006</td></tr><tr><td>Number of police road stops</td><td>26</td><td>26</td><td>26</td><td>26</td><td>24</td><td>20</td></tr><tr><td>Median number of drivers</td><td>425</td><td>294.5</td><td>300</td><td>323.1</td><td>236.9</td><td>648.1</td></tr><tr><td>Body mass index (> 25 Kg/m<sup>2</sup>)(%)</td><td>64.5</td><td>63.8</td><td>64.9</td><td>65.5</td><td>55.2</td><td>58.5</td></tr><tr><td>Neck circumference (≥ 40 cm)(%)</td><td>13.9</td><td>11.1</td><td>12.5</td><td>7.5</td><td>13.9</td><td>11.1</td></tr><tr><td>Abdominal circumference (≥ 102 cm) (%)</td><td>52.8</td><td>50.3</td><td>49.8</td><td>43.8</td><td>19.8</td><td>52.8</td></tr><tr><td>Diabetes (%)</td><td>11</td><td>11.9</td><td>10.1</td><td>11.8</td><td>14.9</td><td>14.4</td></tr><tr><td>Hypertension (%)</td><td>25.9</td><td>24</td><td>27.7</td><td>36.3</td><td>39.6</td><td>36.3*</td></tr><tr><td>Overtime hours (> 8h) (%)</td><td>42.8</td><td>43.4</td><td>20.9</td><td>28.7</td><td>52.2</td><td>49.9*</td></tr><tr><td>Illicit drug use (% yes)</td><td>8.1</td><td>8.5</td><td>5.8</td><td>4.8</td><td>5.5</td><td>4.1</td></tr><tr><td>Alcohol (% yes)</td><td>23</td><td>30.9</td><td>24.2</td><td>30.3</td><td>32</td><td>36.6*</td></tr><tr><td>Smoking (% yes)</td><td>17.7</td><td>19.6</td><td>18.4</td><td>20.5</td><td>20.3</td><td>19.1</td></tr><tr><td>Hypercholesterolemia (%)</td><td>13.7</td><td>12.5</td><td>8.8</td><td>8.5</td><td>13.9</td><td>4.4*</td></tr><tr><td>Sleepiness (%)</td><td>14.7</td><td>14.8</td><td>13.6</td><td>10</td><td>6.9</td><td>4.9*</td></tr><tr><td>Waist circumference (> 109 cm) (%)</td><td>52.8</td><td>50.3</td><td>49.8</td><td>43.8</td><td>19.8</td><td>NA</td></tr><tr><td>Body fat (%)</td><td>62.4</td><td>60.6</td><td>63.8</td><td>56.1</td><td>NA</td><td>NA</td></tr><tr><td>Hypertriglyceridemia (%)</td><td>39.1</td><td>39.6</td><td>33.4</td><td>25.8*</td><td>NA</td><td>NA</td></tr><tr><td>Cargo vehicles accidents (%)</td><td>15.1</td><td>16.1</td><td>16.6</td><td>17.4</td><td>12.9</td><td>NA</td></tr></table> |
506f01105486baed0cb2bcc0d41da5f61ed876703dcb76899fd2b69f381be3dc.png | simple | <table><tr><td>Microorganism Isolated</td><td>Total No. 241 (100)</td></tr><tr><td><i>Pseudomonas aeruginosa</i></td><td>51 (21.16)</td></tr><tr><td><sup>a</sup>MDR <i>Pseudomonas aeruginosa</i></td><td>16 (6.64)</td></tr><tr><td>Methicillin susceptible <i>Staphylococcus aureus</i></td><td>11 (4.56)</td></tr><tr><td>Methicillin resistant <i>Staphylococcus aureus</i></td><td>6 (2.49)</td></tr><tr><td><i>Acinetobacter sp</i></td><td>3 (1.24)</td></tr><tr><td><i>Moraxella catarrhalis</i></td><td>7 (2.9)</td></tr><tr><td><i>Stenotrophomonas maltophilia</i></td><td>4 (1.66)</td></tr><tr><td><i>Enterobacteriaceae</i></td><td>12 (4.98)</td></tr><tr><td> <i>Escherichia coli</i></td><td>5 (2.07)</td></tr><tr><td> <i>Proteus spp</i></td><td>3 (1.24)</td></tr><tr><td> <i>Klebsiella pneumonia</i></td><td>3 (1.24)</td></tr><tr><td> <i>Serratia spp</i></td><td>1 (0.41)</td></tr><tr><td><i>Haemophilus influenzae</i></td><td>27 (11.2)</td></tr><tr><td><i>Streptococcus pneumoniae</i></td><td>25 (10.37)</td></tr><tr><td><i>Achromobacter xylosoxidans</i></td><td>5 (2.07)</td></tr><tr><td><i>Mycoplasma pneumoniae</i></td><td>6 (2.49)</td></tr><tr><td><i>Chlamydia pneumoniae</i></td><td>1 (0.41)</td></tr><tr><td><i>Atypical mycobacteria</i></td><td>4 (1.66)</td></tr><tr><td><i>Aspergillus spp</i></td><td>12 (4.98)</td></tr><tr><td><i>Candida spp</i></td><td>15 (6.22)</td></tr><tr><td>Virus</td><td>25 (10.37)</td></tr><tr><td> Coronavirus</td><td>1 (0.41)</td></tr><tr><td> Metapneumovirus</td><td>4 (1.65)</td></tr><tr><td> Rhinovirus</td><td>10 (4.14)</td></tr><tr><td> Influenza A</td><td>3 (1.24)</td></tr><tr><td> Influenza B</td><td>2 (0.82)</td></tr><tr><td> Parainfluenza 3</td><td>2 (0.82)</td></tr><tr><td> Respiratory Syncytial virus</td><td>3 (1.24)</td></tr><tr><td>Others</td><td>11 (4.56)</td></tr></table> |
16f8212b8dfa47a144f7a188addc274fd97e628f8de004482c988c548915bdfa.png | complex | <table><tr><td rowspan="2">Maintenance Time (ms)</td><td colspan="2">Rise Time (ms)</td></tr><tr><td>Doped LC</td><td>VA LC</td></tr><tr><td>3</td><td>4.72</td><td>193</td></tr><tr><td>5</td><td>6.96</td><td>115</td></tr><tr><td>10</td><td>–</td><td>108</td></tr></table> |
4b96b6115f141e90bc866f1329527aa32900f45ce4eefa0dbd1d1b8053f0fbba.png | simple | <table><tr><td>#</td><td>Misincorporation</td><td>Untemplated</td><td>Sequence 5′-GCAUGGGCCC ... -3′</td></tr><tr><td>24</td><td></td><td>+C</td><td>AUGC <underline>C</underline> AUGC AUGC UUGC N<sub>0-3</sub></td></tr><tr><td>20</td><td></td><td>+CC</td><td>AUGC <underline>CC</underline> AUGC AUGC UUGC N<sub>0-3</sub></td></tr><tr><td>2</td><td>G→C</td><td>+C</td><td>AU<underline>C</underline>C <underline>C</underline> AUGC AUGC UUGC N<sub>0-3</sub></td></tr><tr><td>38</td><td>G→C</td><td></td><td>AU<underline>C</underline>C AUGC AUGC UUGC N<sub>0-3</sub></td></tr><tr><td>14</td><td>(U/G)→C</td><td></td><td>A<underline>C</underline>C AUGC AUGC UUGC N<sub>0-3</sub></td></tr><tr><td>4</td><td></td><td>+A(C/U)C</td><td>AUGC <underline>A(C/U)C</underline> AUGC AUGC UUGC</td></tr><tr><td>1</td><td></td><td></td><td>AUGC AUGC UUGC</td></tr><tr><td>1</td><td></td><td>ΔG</td><td>AUC AUGC UUGC</td></tr></table> |
859e81529eb2362e8b04cb779aa5bbd6a64edeb6adc81ec82dee612b48cfef08.png | complex | <table><tr><td>Site</td><td colspan="2">Eligible visits</td><td colspan="3">BMD testing</td><td colspan="3">Initiation of any osteoporosis medication</td><td colspan="3">Initiation of any nutritional supplements (calcium, vitamin D)</td></tr><tr><td></td><td>Median (IQR)</td><td>Total</td><td>Median (IQR)</td><td>Total</td><td>Rate<sup>‡</sup>(95% CI)</td><td>Median (IQR)</td><td>Total</td><td>Rate (95% CI)</td><td>Median (IQR)</td><td>Total</td><td>Rate (95% CI)</td></tr><tr><td>Combined<sup>†</sup></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Overall</td><td>240.0 (51.75)</td><td>12,445</td><td>10.00 (7.00)</td><td>550</td><td>4.42 (4.07-4.80)</td><td>1.00 (2.00)</td><td>82</td><td>0.66 (0.53-0.82)</td><td>3.00 (3.75)</td><td>191</td><td>1.53 (1.32-1.77)</td></tr><tr><td>Pre-Intervention</td><td>238.0 (49.75)</td><td>6,139</td><td>7.00 (5.25)</td><td>180</td><td>2.93 (2.53-3.39)</td><td>1.00 (1.00)</td><td>25</td><td>0.41 (0.27-0.61)</td><td>2.00 (2.25)</td><td>60</td><td>0.98 (0.75-1.27)</td></tr><tr><td>Post-Intervention</td><td>247.0 (60.50)</td><td>6,306</td><td>14.00 (16.25)</td><td>370</td><td>5.87 (5.31-6.48)</td><td>2.00 (2.25)</td><td>57</td><td>0.90 (0.69-1.17)</td><td>4.50 (4.25)</td><td>131</td><td>2.08 (1.75-2.47)</td></tr><tr><td>Site One</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Overall</td><td>72.50 (25.50)</td><td>3,683</td><td>3.00 (3.00)</td><td>189</td><td>5.13 (4.45-5.91)</td><td>0.00 (1.00)</td><td>21</td><td>0.57 (0.36-0.89)</td><td>0.00 (0.00)</td><td>14</td><td>0.38 (0.21-0.65)</td></tr><tr><td>Pre-Intervention</td><td>69.0 (23.50)</td><td>1,852</td><td>2.00 (3.00)</td><td>68</td><td>3.67 (2.88-4.66)</td><td>0.00 (1.00)</td><td>9</td><td>0.49 (0.24-0.96)</td><td>0.00 (0.00)</td><td>4</td><td>0.22 (0.07-0.59)</td></tr><tr><td>Post-Intervention</td><td>76.50 (30.75)</td><td>1,831</td><td>4.50 (3.25)</td><td>121</td><td>6.61 (5.53-7.87)</td><td>0.00 (1.00)</td><td>12</td><td>0.66 (0.36-1.18)</td><td>0.00 (1.00)</td><td>10</td><td>0.55 (0.28-1.04)</td></tr><tr><td>Site Two</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Overall</td><td>53.50 (15.75)</td><td>2,618</td><td>1.50 (2.00)</td><td>123</td><td>4.70 (3.93-5.60)</td><td>0.00 (1.00)</td><td>20</td><td>0.76 (0.48-1.20)</td><td>2.00 (2.00)</td><td>94</td><td>3.59 (2.93-4.39)</td></tr><tr><td>Pre-Intervention</td><td>52.50 (19.25)</td><td>1,219</td><td>1.00 (2.00)</td><td>40</td><td>3.28 (2.38-4.48)</td><td>0.00 (1.00)</td><td>8</td><td>0.66 (0.31-1.34)</td><td>1.00 (2.00)</td><td>38</td><td>3.12 (2.24-4.30)</td></tr><tr><td>Post-Intervention</td><td>57.00 (19.50)</td><td>1,399</td><td>2.50 (3.00)</td><td>83</td><td>5.93 (4.78-7.33)</td><td>0.00 (1.00)</td><td>12</td><td>0.86 (0.47-1.54)</td><td>2.00 (3.00)</td><td>56</td><td>4.00 (3.06-5.20)</td></tr><tr><td>Site Three</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Overall</td><td>114.50 (28.00)</td><td>6,144</td><td>4.00 (4.25)</td><td>238</td><td>3.87 (3.41-4.39)</td><td>0.00 (1.00)</td><td>41</td><td>0.67 (0.49-0.91)</td><td>1.00 (3.00)</td><td>83</td><td>1.35 (1.08-1.68)</td></tr><tr><td>Pre-Intervention</td><td>114.00 (31.00)</td><td>3,068</td><td>2.00 (3.00)</td><td>72</td><td>2.34 (1.85-2.96)</td><td>0.00 (1.00)</td><td>8</td><td>0.26 (0.12-0.54)</td><td>0.00 (1.00)</td><td>18</td><td>0.59 (0.36-0.95)</td></tr><tr><td>Post-Intervention</td><td>117.50 (31.75)</td><td>3,076</td><td>5.50 (5.00)</td><td>166</td><td>5.40 (4.64-6.27)</td><td>1.00 (1.25)</td><td>33</td><td>1.07 (0.75-1.52)</td><td>2.00 (3.00)</td><td>65</td><td>2.11 (1.65-2.70)</td></tr></table> |
a5fbc8a91561efa4d42a5f231a321151bee78e4a45c9d8800acbbd0cce10813d.png | complex | <table><tr><td>Model</td><td>BC (0.94 × 10<sup>−5</sup>/m)a</td><td>PM<sub>2.5</sub> (1.58 μg/m<sup>3</sup>)a</td><td>NO<sub>2</sub> (8.4 μg/m<sup>3</sup>)a</td><td>NO (13.2 μg/m<sup>3</sup>)a</td></tr><tr><td colspan="5">Hospitalization</td></tr><tr><td> Model 1: unadjusted single pollutant</td><td>1.04 (1.03–1.06)</td><td>1.03 (1.01–1.05)</td><td>1.02 (1.00–1.04)</td><td>0.99 (0.97–1.02)</td></tr><tr><td> Model 2: + sex, age, comorbidity, SES</td><td>1.01 (1.00–1.03)</td><td>1.00 (0.98–1.02)</td><td>0.97 (0.95–0.99)</td><td>0.96 (0.94–0.98)</td></tr><tr><td> Model 3: + two other pollutantsb</td><td>1.03 (1.01–1.05)</td><td>1.02 (1.00–1.05)</td><td>0.96 (0.94–0.98)</td><td>0.95 (0.92–0.97)</td></tr><tr><td colspan="5">Mortality</td></tr><tr><td> Model 1: unadjusted single pollutant</td><td>1.14 (1.11–1.17)</td><td>1.13 (1.09–1.16)</td><td>1.19 (1.15–1.23)</td><td>1.13 (1.09–1.17)</td></tr><tr><td> Model 2: + sex, age, comorbidity, SES</td><td>1.06 (1.03–1.09)</td><td>1.01 (0.98–1.05)</td><td>1.04 (1.01–1.08)</td><td>1.06 (1.02–1.10)</td></tr><tr><td> Model 3: + two other pollutantsb</td><td>1.06 (1.03–1.09)</td><td>1.00 (0.96–1.03)</td><td>1.03 (0.99–1.07)</td><td>1.03 (0.99–1.08)</td></tr></table> |
15266687e9007f107d0da92a024b82f9a929aaf1f681ad6d80b00f639fdbb30b.png | complex | <table><tr><td> </td><td colspan="3">Chi-square tests</td></tr><tr><td> </td><td>Value</td><td>df</td><td>Asymp. Sig. (2-sided)</td></tr><tr><td>Pearson chi-square</td><td>.036<sup>a</sup></td><td>3</td><td>.998</td></tr><tr><td>Likelihood ratio</td><td>.036</td><td>3</td><td>.998</td></tr><tr><td>Fisher's exact test</td><td>.074</td><td> </td><td> </td></tr><tr><td>Linear-by-linear</td><td>.004<sup>c</sup></td><td>1</td><td>.952</td></tr><tr><td>Association</td><td> </td><td> </td><td> </td></tr><tr><td><i>N</i> of valid cases</td><td>288</td><td> </td><td> </td></tr></table> |
22e7c015a19439e570097fb51ebfc489270c031246fc57a9bb1a7b81cd4fbdb1.png | complex | <table><tr><td></td><td></td><td colspan="5">3 months</td><td colspan="5">6 months</td></tr><tr><td></td><td></td><td colspan="2">Intervention <i>n</i> = 152–155</td><td colspan="2">Control <i>n</i> = 157–159</td><td></td><td colspan="2">Intervention <i>n</i> = 124–127</td><td colspan="2">Control <i>n</i> = 133–141</td><td></td></tr><tr><td></td><td></td><td>Median</td><td>IQR</td><td>Median</td><td>IQR</td><td><i>p</i>-value<sup>*</sup></td><td>Median</td><td>IQR</td><td>Median</td><td>IQR</td><td><i>p</i>-value<sup>*</sup></td></tr><tr><td rowspan="6">Psychological symptoms</td><td>Somatisation</td><td>0.7</td><td>0.3–1.1</td><td>0.8</td><td>0.3–1.3</td><td>0.09</td><td>0.6</td><td>0.3–1.0</td><td>0.7</td><td>0.3–1.3</td><td>0.20</td></tr><tr><td>Anxiety</td><td>0.6</td><td>0.2–1.1</td><td>0.8</td><td>0.3–1.3</td><td>0.04</td><td>0.4</td><td>0.2–0.9</td><td>0.6</td><td>0.2–1.2</td><td>0.09</td></tr><tr><td>Interpersonal sensitivity</td><td>0.7</td><td>0.4–1.2</td><td>0.9</td><td>0.4–1.6</td><td>0.08</td><td>0.7</td><td>0.2–1.2</td><td>1.0</td><td>0.3–1.4</td><td>0.10</td></tr><tr><td>Depression</td><td>1.0</td><td>0.5–1.7</td><td>1.3</td><td>0.7–2.3</td><td>0.02</td><td>0.8</td><td>0.5–1.5</td><td>1.1</td><td>0.5–1.9</td><td>0.19</td></tr><tr><td>Phobic anxiety</td><td>0.1</td><td>0.0–0.6</td><td>0.1</td><td>0.0–0.6</td><td>0.29</td><td>0.1</td><td>0.0–0.4</td><td>0.1</td><td>0.0–0.4</td><td>0.27</td></tr><tr><td>Obsessive-compulsive</td><td>1.0</td><td>0.5–1.8</td><td>1.2</td><td>0.7–2.0</td><td>0.12</td><td>0.8</td><td>0.4–1.5</td><td>1.0</td><td>0.6–1.7</td><td>0.05</td></tr><tr><td rowspan="4">Locus of control</td><td>Internal LOC</td><td>23.0</td><td>19.0–28.0</td><td>20.0</td><td>16.0–25.0</td><td><0.001</td><td>24.0</td><td>19.5–28.0</td><td>21.0</td><td>16.0–25.0</td><td><0.001</td></tr><tr><td>Chance</td><td>14.0</td><td>11.0–18.0</td><td>14.5</td><td>11.0–18.0</td><td>0.23</td><td>14.0</td><td>9.0–18.0</td><td>14.0</td><td>10.0–18.0</td><td>0.43</td></tr><tr><td>Doctors</td><td>12.0</td><td>10.0–14.0</td><td>12.0</td><td>10.0–14.0</td><td>0.50</td><td>12.0</td><td>9.0–13.0</td><td>12.0</td><td>10.0–13.0</td><td>0.76</td></tr><tr><td>Other people</td><td>11.0</td><td>9.0–13.0</td><td>11.0</td><td>8.0–13.0</td><td>0.39</td><td>10.0</td><td>8.0–12.0</td><td>10.0</td><td>8.0–12.0</td><td>0.88</td></tr><tr><td rowspan="4">Mental health related QoL</td><td>Vitality</td><td>45.0</td><td>30.0–60.0</td><td>45.0</td><td>25.0–60.0</td><td>0.32</td><td>50.0</td><td>30.0–65.0</td><td>50.0</td><td>25.0–65.0</td><td>0.54</td></tr><tr><td>Social functioning</td><td>75.0</td><td>62.5–100.0</td><td>87.5</td><td>62.5–100.0</td><td>0.98</td><td>87.5</td><td>75.0–100.0</td><td>87.5</td><td>62.5–100.0</td><td>0.58</td></tr><tr><td>Role limitations due to emotional problems</td><td>66.7</td><td>33.3–100.0</td><td>66.7</td><td>0.0–100.0</td><td>0.33</td><td>66.7</td><td>33.3–100.0</td><td>66.7</td><td>33.3–100.0</td><td>0.71</td></tr><tr><td>Mental health</td><td>64.0</td><td>52.0–76.0</td><td>60.0</td><td>44.0–76.0</td><td>0.04</td><td>68.0</td><td>56.0–80.0</td><td>68.0</td><td>52.0–78.0</td><td>0.41</td></tr></table> |
10616f366c44a55521f5ae3156c14f1c7ee450435a764583fd1df1131fc833ad.png | simple | <table><tr><td>State</td><td>Description</td><td>Probability*</td></tr><tr><td>Normal</td><td>No abnormality</td><td>0.78</td></tr><tr><td>Adenoma <10 mm</td><td>Individual has adenoma that is <10 mm in diameter</td><td>0.1668</td></tr><tr><td>Adenoma ≥10 mm</td><td>Individual has adenoma that is ≥10 mm in diameter</td><td>0.0464</td></tr><tr><td>Surveillance</td><td>Individuals are in the surveillance state once they have had an adenoma ≥ 10 mm removed</td><td>0</td></tr><tr><td>CRC Dukes’ A</td><td>Individual has developed CRC and is at Dukes stage A</td><td>0.0036</td></tr><tr><td>Treatment Dukes’ A</td><td>Individual with Dukes stage A has been diagnosed and will not take part in any further screening</td><td>0</td></tr><tr><td>CRC Dukes’ B</td><td>Individual has developed CRC and is at Dukes stage B</td><td>0.0016</td></tr><tr><td>Treatment Dukes’ B</td><td>Individual with Dukes stage B has been diagnosed and will not take part in any further screening</td><td>0</td></tr><tr><td>CRC Dukes’ C</td><td>Individual has developed CRC and is at Dukes stage C</td><td>0.0012</td></tr><tr><td>Treatment Dukes’ C</td><td>Individual with Dukes stage C has been diagnosed and will not take part in any further screening</td><td>0</td></tr><tr><td>CRC Dukes’ D</td><td>Individual has developed CRC and is at Dukes stage D</td><td>0.0004</td></tr><tr><td>Treatment Dukes’ D</td><td>Individual with Dukes stage D has been diagnosed and will not take part in any further screening</td><td>0</td></tr><tr><td>Dead CRC</td><td>Death from CRC</td><td>0</td></tr><tr><td>Dead other causes</td><td>Death from colonoscopy</td><td>0</td></tr></table> |
9f2cb63a237890b5518cc2b4613091d492db0959505b0888d9959268c66022e1.png | complex | <table><tr><td rowspan="2">Factors (Number)</td><td colspan="3">Univariate model</td><td colspan="3">Multivariate model #1</td><td colspan="3">Multivariate model #2</td></tr><tr><td>HR</td><td>95% CI</td><td><i>P</i></td><td>HR</td><td>95% CI</td><td><i>P</i></td><td>HR</td><td>95% CI</td><td><i>P</i></td></tr><tr><td> Age (years)</td><td>1.008</td><td>0.980–1.036</td><td>0.584</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> Gender (Male/Female) (83/20)</td><td>2.070</td><td>0.808–5.303</td><td>0.130</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"> Primary site</td></tr><tr><td>Parotid gland (69)</td><td>1 (Ref.)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Non-parotid gland (34)</td><td>1.718</td><td>0.912–3.237</td><td>0.094</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"> TN categories</td></tr><tr><td>T3–4/T1–2 (45/58)</td><td>1.986</td><td>1.048–3.761</td><td>0.035</td><td>0.984</td><td>0.460–2.103</td><td>0.967</td><td></td><td></td><td></td></tr><tr><td>N1–3/N0 (48/55)</td><td>4.489</td><td>2.241–8.994</td><td>< 0.001</td><td>4.693</td><td>1.990–11.069</td><td>< 0.001</td><td>4.650</td><td>1.967–10.994</td><td>< 0.001</td></tr><tr><td colspan="10"> Pathological diagnosis</td></tr><tr><td>Salivary duct carcinoma (67)</td><td>1 (Ref.)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Squamous cell carcinoma, primary (9)</td><td>0.226</td><td>0.031–1.661</td><td>0.114</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Adenoid cystic carcinoma, solid type (8)</td><td>1.289</td><td>0.451–3.685</td><td>0.635</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Mucoepidermoid carcinoma, high-grade (7)</td><td>0.851</td><td>0.258–2.806</td><td>0.791</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Adenocarcinoma, high-grade (6)</td><td>0.283</td><td>0.040–2.162</td><td>0.229</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Others (6)</td><td>1.847</td><td>0.556–6.138</td><td>0.317</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"> Treatment modalities</td></tr><tr><td>Surgery (13)</td><td>1 (Ref)</td><td></td><td></td><td>1 (Ref)</td><td></td><td></td><td>1 (Ref)</td><td></td><td></td></tr><tr><td>Surgery + radiation (62)</td><td>1.294</td><td>0.450–3.719</td><td>0.632</td><td>0.917</td><td>0.303–2.778</td><td>0.879</td><td>0.912</td><td>0.301–2.758</td><td>0.870</td></tr><tr><td>Surgery + radiation + chemotherapy (28)</td><td>1.068</td><td>0.339–3.359</td><td>0.911</td><td>0.421</td><td>0.125–1.425</td><td>0.164</td><td>0.421</td><td>0.125–1.424</td><td>0.164</td></tr><tr><td>Surgery of primary tumor (R1/R0) (6/97)</td><td>1.126</td><td>0.347–3.660</td><td>0.843</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Neck dissection/no neck dissection (72/31)</td><td>1.489</td><td>0.739–3.000</td><td>0.266</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"> Pathological risk factors</td></tr><tr><td>Perineural invasion (Y/N) (13/90)</td><td>1.111</td><td>0.434–2.846</td><td>0.827</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Lymphovascular invasion (Y/N) (16/87)</td><td>1.132</td><td>0.440–2.915</td><td>0.797</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Extra-parenchymal extension (Y/N) (45/58)</td><td>2.045</td><td>1.077–3.886</td><td>0.029</td><td></td><td></td><td></td><td>1.006</td><td>0.469–2.157</td><td>0.988</td></tr><tr><td>Extra-capsular spread (Y/N) (26/77)</td><td>3.236</td><td>1.665–6.290</td><td>0.001</td><td>1.799</td><td>0.850–3.811</td><td>0.125</td><td>1.792</td><td>0.846–3.795</td><td>0.128</td></tr></table> |
b12d6588348b99e473a7cfeb7f2c64c2f47b26c645f303208a422f0d268ae46d.png | simple | <table><tr><td></td><td>Peak (1999)</td><td>Crash (2000)</td><td>Peak (2002)</td><td>Crash (2003)</td><td>Peak (2005)</td><td>Crash (2006)</td></tr><tr><td>Peak (1999)</td><td></td><td>0.07000</td><td>0.02667*</td><td>0.01333*</td><td>0.00333*</td><td>0.00333*</td></tr><tr><td>Crash (2000)</td><td>0.0002</td><td></td><td>0.87000</td><td>0.08667</td><td>0.19333</td><td>0.00667*</td></tr><tr><td>Peak (2002)</td><td>0.0032</td><td>−0.0010</td><td></td><td>0.24000</td><td>0.06667</td><td>0.01000*</td></tr><tr><td>Crash (2003)</td><td>0.0019</td><td>0.0013</td><td>−0.0012</td><td></td><td>0.12000</td><td>0.01667</td></tr><tr><td>Peak (2005)</td><td>0.0040</td><td>0.0009</td><td>0.0053</td><td>0.0033</td><td></td><td>0.00333*</td></tr><tr><td>Crash (2006)</td><td>0.0104</td><td>0.0090</td><td>0.0083</td><td>0.0049</td><td>0.0102</td><td></td></tr></table> |
78a35d93939abc602621a6604b9f2fdab65f37c69cb3532a7d8c3fe7ab7f140e.png | complex | <table><tr><td rowspan="2">Characteristic</td><td>Intervention arm</td><td>Control arm</td></tr><tr><td>N = 609</td><td>N = 667</td></tr><tr><td>Children’s characteristics</td><td> </td><td> </td></tr><tr><td>Female sex, n (%)</td><td>329 (54.0)</td><td>336 (50.4)</td></tr><tr><td>Mean age, months (SD)</td><td>30.4 (15.9)</td><td>31.5 (16.4)</td></tr><tr><td>Caregivers’ characteristics</td><td> </td><td> </td></tr><tr><td>Female sex, n (%)</td><td>562 (92.3)</td><td>625 (93.7)</td></tr><tr><td>Age in years, mean (SD)</td><td>30.9 (9.4)</td><td>30.5 (8.7)</td></tr><tr><td>Education level, n (%)*</td><td> </td><td> </td></tr><tr><td>None</td><td>59 (9.7)</td><td>62 (10.4)</td></tr><tr><td>Primary</td><td>381 (62.7)</td><td>450 (67.7)</td></tr><tr><td>Post primary</td><td>168 (27.6)</td><td>146 (22.0)</td></tr><tr><td>Religion, n (%)*#</td><td> </td><td> </td></tr><tr><td>Catholic</td><td>30 (4.9)</td><td>65 (9.8)</td></tr><tr><td>Protestant</td><td>244 (40.1)</td><td>223 (33.5)</td></tr><tr><td>Muslim</td><td>310 (51.0)</td><td>335 (50.4)</td></tr><tr><td>Other</td><td>24 (4.0)</td><td>42 (6.3)</td></tr><tr><td>Marital status, n (%)**</td><td> </td><td> </td></tr><tr><td>Married</td><td>559 (92.1)</td><td>592 (88.8)</td></tr><tr><td>Single</td><td>23 (3.8)</td><td>27 (4.1)</td></tr><tr><td>Divorced</td><td>19 (3.1)</td><td>37 (5.6)</td></tr><tr><td>Widowed</td><td>6 (1.0)</td><td>11 (1.7)</td></tr><tr><td>Rural residence, n (%)</td><td>499 (81.9)</td><td>600 (90.0)</td></tr></table> |
56f3e5de4abb048a77a141eb33effd49e566e33920cb413e52a771bd5ca57a6f.png | complex | <table><tr><td rowspan="2">Outcome and instrument</td><td rowspan="2">Method</td><td colspan="3">Data collection time</td></tr><tr><td>T0</td><td>T1</td><td>T2</td></tr><tr><td>Degree of integration</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Self-constructed questionnaire</td><td>Mailed questionnaire</td><td>x</td><td> </td><td>x</td></tr><tr><td>Satisfaction health professionals</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Self-constructed questionnaire</td><td>Mailed questionnaire</td><td>x</td><td> </td><td>x</td></tr><tr><td>Relational coordination Survey</td><td>Mailed questionnaire</td><td>x</td><td> </td><td>x</td></tr><tr><td>Self-reported satisfaction</td><td>Diaries</td><td>x</td><td>x</td><td> </td></tr><tr><td rowspan="2"> </td><td>Interviews</td><td> </td><td> </td><td>x</td></tr><tr><td>Focus groups</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Satisfaction frail elderly</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>CQ-index</td><td>Interview elderly</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Self-constructed questionnaire</td><td>Interview elderly</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Satisfaction caregiver</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>CQ-index</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td>x</td><td>x</td></tr><tr><td>Self-constructed questionnaire</td><td>Interview caregiver or mailed questionnaire</td><td>x</td><td>x</td><td>x</td></tr></table> |
cea850ceffb8445c2c1a60e6590bc37dad1bc671fc2777c7be3eb4918a00a77b.png | complex | <table><tr><td> </td><td colspan="3">Fetal cotyledonary tissue</td><td colspan="3">Maternal caruncular tissue</td></tr><tr><td> </td><td> </td><td colspan="2">fdPAG (mg) and [PAG/TP ratio (%)]</td><td> </td><td colspan="2">fdPAG (mg) and [PAG/TP ratio (%)]</td></tr><tr><td>Purification step</td><td>TP (mg)</td><td>RIA-438</td><td>RIA-706</td><td>TP (mg)</td><td>RIA-438</td><td>RIA-706</td></tr><tr><td>20-40% A.S.</td><td>1,401.6</td><td>3.16 [0.23]</td><td>0.12 [0.01]</td><td>1,956.5</td><td>1.23 [0.06]</td><td>0.06 [0]</td></tr><tr><td>40-80% A.S.</td><td>2,014.9</td><td>10.59 [0.53]</td><td>0.44 [0.02]</td><td>815.2</td><td>3.95 [0.48]</td><td>0.31 [0.04]</td></tr></table> |
e8ce128f0d3d053a9313dcb3605c31cb67b1b0601ef89b3c0804b7651a1890e0.png | complex | <table><tr><td>Factor</td><td>Bup</td><td>Bup+Dex(3)</td><td>Bup+Dex(5)</td><td>F</td><td><i>P</i> value</td></tr><tr><td colspan="6">Apgar score</td></tr><tr><td> 1min</td><td>9.0(8.0,9.0)</td><td>9.0(8.0,9.0)</td><td>9.0(8.0,9.0)</td><td>0.59</td><td>0.7450</td></tr><tr><td> 5min</td><td>10.0(9.0,10.0)</td><td>10.0(9.0,10.0)</td><td>10.0(9.5,10.0)</td><td>0.31</td><td>0.8556</td></tr><tr><td>Umbilical oxygen partial pressure(mmHg)</td><td>24.8±10.3</td><td>25.7±8.4</td><td>27.6±9.0</td><td>0.48</td><td>0.6217</td></tr><tr><td>Umbilical dioxide partial pressure(mmHg)</td><td>41.9±5.1</td><td>43.1±5.4</td><td>43.6±5.9</td><td>0.49</td><td>0.6162</td></tr><tr><td>Umbilical glucose(mmol/L)</td><td>3.5±0.6</td><td>3.6±0.4</td><td>3.6±0.6</td><td>0.12</td><td>0.8838</td></tr><tr><td>Umbilical lactate(mmol/L)</td><td>1.5(1.4,1.6)</td><td>1.5(1.3,1.7)</td><td>1.4(1.2,1.6)</td><td>1.33</td><td>0.5136</td></tr><tr><td>Umbilical blood PH</td><td>7.4±0.0</td><td>7.3±0.0</td><td>7.3±0.0</td><td>1.99</td><td>0.1460</td></tr></table> |
dd22bd6d9263effdb6906d3f866692bf58d2a36576322b6858db6b0c9456970b.png | complex | <table><tr><td>Red light</td><td> </td></tr><tr><td>GO term</td><td><i>P </i>value</td></tr><tr><td>MF: structural constituent of ribosome</td><td>3.95E–29</td></tr><tr><td>CC: ribosome</td><td>9.50E–25</td></tr><tr><td>BP: translation</td><td>1.22E–22</td></tr><tr><td>CC: integral to membrane</td><td>1.19E–06</td></tr><tr><td>BP: cell redox homeostasis</td><td>1.96E–06</td></tr><tr><td>CC: mitochondrion</td><td>8.95E–05</td></tr><tr><td>MF: glycerone kinase activity</td><td>9.31E–05</td></tr><tr><td colspan="2">A total of 1,000 genes were submitted to the GOBU functional enrichment tool, which resulted in 689 unique genes with annotations. Terms are ranked by <i>P</i> value of over–representation and are included in list if <i>P</i> <1E–04. BP: Biological process; CC: Cellular component; MF: Molecular function.</td></tr><tr><td>Blue light</td><td> </td></tr><tr><td>GO term</td><td><i>P </i>value</td></tr><tr><td>CC: chloroplast</td><td>4.67E–33</td></tr><tr><td>MF: structural constituent of ribosome</td><td>1.66E–29</td></tr><tr><td>CC: ribosome</td><td>5.14E–27</td></tr><tr><td>BP: translation</td><td>1.63E–20</td></tr><tr><td>BP: reductive pentose–phosphate cycle</td><td>1.47E–16</td></tr><tr><td>CC: photosystem II</td><td>2.36E–10</td></tr><tr><td>BP: photosynthesis, light harvesting</td><td>6.62E–10</td></tr><tr><td>CC: photosystem I</td><td>8.56E–10</td></tr><tr><td>CC: stromule</td><td>2.32E–09</td></tr><tr><td>MF: chlorophyll binding</td><td>2.53E–08</td></tr><tr><td>CC: thylakoid</td><td>6.47E–08</td></tr><tr><td>BP: photorespiration</td><td>1.00E–07</td></tr><tr><td>CC: chloroplast envelope</td><td>1.12E–07</td></tr><tr><td>BP: photosynthesis</td><td>3.92E–07</td></tr><tr><td>CC: oxygen evolving complex</td><td>5.16E–07</td></tr><tr><td>CC: cytosolic ribosome</td><td>3.22E–06</td></tr><tr><td>MF: rRNA binding</td><td>1.68E–05</td></tr><tr><td>BP: cell redox homeostasis</td><td>2.21E–05</td></tr><tr><td>BP: translational elongation</td><td>2.26E–05</td></tr><tr><td>MF: ribulose–bisphosphate carboxylase activity</td><td>2.86E–05</td></tr><tr><td>BP: nitrate assimilation</td><td>5.10E–05</td></tr><tr><td>MF: glycerone kinase activity</td><td>7.63E–05</td></tr></table> |
69c9be13ca194694adb29034dc3ab1e00a0f77a037dfecf52a3a0dfd2a81cc42.png | complex | <table><tr><td rowspan="2">INNO-LIA</td><td rowspan="2">p31</td><td rowspan="2">LAg-Avidity EIA</td><td rowspan="2">BED CEIA</td><td></td><td></td><td colspan="6">Decision tree</td></tr><tr><td>n</td><td></td><td>Seroconversion</td><td>Very early</td><td>Early</td><td>Recent</td><td>Long term</td><td>Advanced</td></tr><tr><td>Negative/ID</td><td>Recent</td><td>Recent</td><td>Recent</td><td>24</td><td rowspan="5">Congruent</td><td>24</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>Recent</td><td>Recent</td><td>Recent</td><td>81</td><td></td><td>81</td><td></td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>Long-term</td><td>Recent</td><td>Recent</td><td>56</td><td></td><td></td><td>56</td><td></td><td></td><td></td></tr><tr><td>Positive</td><td>Long-term</td><td>Long-term</td><td>Recent</td><td>74</td><td></td><td></td><td></td><td>71</td><td></td><td>3</td></tr><tr><td>Positive</td><td>Long-term</td><td>Long-term</td><td>Long-term</td><td>313</td><td></td><td></td><td></td><td></td><td>313</td><td></td></tr><tr><td>Positive</td><td>Recent</td><td>Long-term</td><td>Recent</td><td>8</td><td rowspan="3">Incongruent</td><td></td><td></td><td></td><td></td><td></td><td>8</td></tr><tr><td>Positive</td><td>Long-term</td><td>Recent</td><td>Long-term</td><td>1</td><td></td><td></td><td></td><td></td><td>1</td><td></td></tr><tr><td>Positive</td><td>Recent</td><td>Long-term</td><td>Long-term</td><td>9</td><td></td><td></td><td></td><td></td><td>9</td><td></td></tr><tr><td></td><td></td><td></td><td></td><td>566</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr></table> |
e81e5d13b327c2f78bf37bc434cbb7552e0992aa10cfaadf7fb397998ac311c8.png | simple | <table><tr><td>Type of health services</td><td>% use</td><td>CHE<sup>a</sup></td><td>Impoverisment<sup>a</sup></td></tr><tr><td>Dental care</td><td>7.0</td><td>1.88 [1.78-1.99]***</td><td>1.88 [1.78-1.99]***</td></tr><tr><td>Inpatient care</td><td>4.2</td><td>3.93 [3.70-4.17]***</td><td>3.24 [2.99-3.53]***</td></tr><tr><td>Outpatient care</td><td>14.1</td><td>3.11 [3.01-3.31]***</td><td>2.57 [2.47-2.73]***</td></tr><tr><td>Traditional medicine</td><td>6.1</td><td>1.82 [1.72-1.92]***</td><td>1.81 [1.67-1.96]***</td></tr><tr><td>Medications or drugs</td><td>42.7</td><td>4.13 [3.97-4.28]***</td><td>3.49 [3.29-3.70]***</td></tr><tr><td>Health care products</td><td>3.5</td><td>1.88 [1.75-2.02]***</td><td>1.76 [1.56-1.95]***</td></tr><tr><td>Medical tests</td><td>6.3</td><td>3.80 [3.62-3.99]***</td><td>2.88 [2.68-3.09]***</td></tr><tr><td>Other health services</td><td>4.1</td><td>1.92 [1.80-2.05]***</td><td>1.53 [1.38-1.69]***</td></tr></table> |
6314a390106989086de34a4e26d7d118dfc84a01721a4cd9cd08399b56e3244f.png | simple | <table><tr><td>ECLS strategy</td><td>Possible indication(s)</td></tr><tr><td>VV ECMO + atrial septostomy</td><td>Refractory hypoxia and/or pulmonary hypertension on VV ECMO avoiding sternotomy</td></tr><tr><td>VV ECMO + transeptal return to left atrium</td><td>Refractory hypoxia and/or pulmonary hypertension on VV ECMO avoiding sternotomy</td></tr><tr><td>Venoarterial ECMO + transeptal access from left atrium and right atrium</td><td>Refractory left ventricular distension on venoarterial ECMO</td></tr></table> |
dc2d76e2cae776c6fa88bb00fa3ddc25e253c1fb6d49b44873e3f86f757333ef.png | complex | <table><tr><td></td><td></td><td>VHV</td><td>Health center</td></tr><tr><td colspan="4">MEAN</td></tr><tr><td>Direct cost 
(Kina; Kina 1 = USD 0.48)</td><td></td><td colspan="2">−1.2977*** 
(0.408)</td><td colspan="2"></td></tr><tr><td>Walking distance (km)</td><td></td><td colspan="2">−0.6843*** 
(0.198)</td><td colspan="2"></td></tr><tr><td>Antimalarial drug availability (no = 0/yes = 1)</td><td></td><td colspan="2">2.0290*** 
(0.742)</td><td colspan="2"></td></tr><tr><td>Gender of patient 
(female = 0/male = 1)</td><td></td><td>−1.0621** 
(0.514)</td><td>−1.8564** 
(0.862)</td></tr><tr><td>Age of patient (year)</td><td></td><td>−0.2646 
(0.178)</td><td>−0.7626** 
(0.311)</td></tr><tr><td>Illness severity 
(mild = 0/moderate or severe = 1)</td><td></td><td>1.4926** 
(0.602)</td><td>3.4261*** 
(1.191)</td></tr><tr><td>Education of caretaker (year)</td><td></td><td>−0.2177** 
(0.102)</td><td>−0.1925 
(0.214)</td></tr><tr><td>Economic status 
(low = base)</td><td>Middle</td><td>0.835 
(0.672)</td><td>0.1147 
(0.779)</td></tr><tr><td></td><td>High</td><td>0.6924 
(0.594)</td><td>−3.9198 
(2.586)</td></tr><tr><td>Constant</td><td></td><td>0.9367 
(0.981)</td><td>6.6108*** 
(2.508)</td></tr><tr><td colspan="4">SD</td></tr><tr><td>Direct cost</td><td></td><td colspan="2">0.0039 
(0.291)</td></tr><tr><td>Walking distance</td><td></td><td colspan="2">0.0039 
(0.181)</td></tr><tr><td>Antimalarial drug availability</td><td></td><td colspan="2">1.1833 
(1.358)</td></tr><tr><td>Economic status</td><td>Middle</td><td>2.5479* 
(1.543)</td><td>0.0603 
(1.964)</td></tr><tr><td></td><td>High</td><td>0.0170 
(2.680)</td><td>4.2573 
(2.903)</td></tr><tr><td>Sample size</td><td></td><td colspan="2">210</td></tr><tr><td>Log likelihood</td><td></td><td colspan="2">−148.98</td></tr><tr><td>Pseudo R2</td><td></td><td colspan="2">0.3280</td></tr></table> |
209843db5f95f4463c97473be8cdc6fa9c24a44939307db2566a960f8d0a4153.png | complex | <table><tr><td rowspan="2">Assemblers</td><td colspan="4">Repeat</td><td colspan="5">Contigs (kb)</td><td rowspan="2"><i>E</i>-size</td><td rowspan="2">Assembly size (kb)</td><td rowspan="2">Genome coverage (%)</td></tr><tr><td>TRC</td><td>NNC</td><td>Rep-size</td><td>Rep-acc</td><td>Num.C</td><td>N90</td><td>Mean</td><td>N50</td><td>Max</td></tr><tr><td>SWA</td><td>13</td><td>1774</td><td>7.8 kb</td><td>44.5%</td><td>1787</td><td>1.3</td><td>2.6</td><td>4.2</td><td>29.4</td><td>5812</td><td>4600.3</td><td>99.94</td></tr><tr><td>ABySS</td><td>13</td><td>1910</td><td>8.3 kb</td><td>44.5%</td><td>1915</td><td>1.1</td><td>2.5</td><td>4.2</td><td>54.7</td><td>6877</td><td>4969.5</td><td>108</td></tr><tr><td>Allpaths-LG</td><td>2</td><td>202</td><td>1.4 kb</td><td>6.7%</td><td>204</td><td>11.5</td><td>22.5</td><td>34.4</td><td>106</td><td>35973</td><td>4587.8</td><td>99.6</td></tr><tr><td>Bambus2</td><td>2</td><td>175</td><td>1.3 kb</td><td>9.2%</td><td>177</td><td>6.1</td><td>8.5</td><td>12.8</td><td>279</td><td>16281</td><td>4371.6</td><td>94.9</td></tr><tr><td>CABOG</td><td>1</td><td>312</td><td>0.3 kb</td><td>8.9%</td><td>322</td><td>6.5</td><td>13</td><td>17.9</td><td>88.5</td><td>21539</td><td>4238</td><td>92</td></tr><tr><td>MSR-CA</td><td>7</td><td>388</td><td>4.1 kb</td><td>25.4%</td><td>395</td><td>5.7</td><td>11.3</td><td>19</td><td>83.7</td><td>21579</td><td>4465</td><td>97</td></tr><tr><td>SGA</td><td>9</td><td>3053</td><td>3.9 kb</td><td>64.3%</td><td>3067</td><td>0.66</td><td>1.4</td><td>2.9</td><td>29.5</td><td>4067</td><td>4502.7</td><td>97</td></tr><tr><td>SOAPdenovo</td><td>9</td><td>195</td><td>3.7 kb</td><td>84.5%</td><td>204</td><td>7.8</td><td>11.8</td><td>14.3</td><td>376</td><td>18553</td><td>4596</td><td>99.8</td></tr><tr><td>Velvet</td><td>5</td><td>578</td><td>2.2 kb</td><td>24.5%</td><td>583</td><td>4.6</td><td>7.7</td><td>14.5</td><td>60.7</td><td>16711</td><td>4503</td><td>97.8</td></tr></table> |
b285872d7021cd54dd51e78bcf5d243542cc0c9858c13e26c31c4f6babf43bb6.png | complex | <table><tr><td></td><td colspan="2">Regular Menus</td><td colspan="2">Carbohydrate-Controlled Menus</td><td colspan="2">3000 mg Menus</td><td colspan="2">2000 mg Menus</td></tr><tr><td></td><td>Standard (<i>n</i> = 21)</td><td>Standard Range</td><td>Standard (<i>n</i> = 21)</td><td>Standard Range</td><td>Standard (<i>n</i> = 21)</td><td>Standard Range</td><td>Standard (<i>n</i> = 21)</td><td>Standard Range</td></tr><tr><td>Calories (kcal)</td><td>1673 ± 362</td><td>1296–3007</td><td>1808 ± 175</td><td>1516–2067</td><td>1600 ± 210</td><td>1281–2168</td><td>1687 ± 228</td><td>1342–2091</td></tr><tr><td>Protein (g)</td><td>63 ± 9 <sup>b</sup></td><td>49–86</td><td>77 ± 10 <sup>a</sup></td><td>61–96</td><td>66 ± 22</td><td>52–159</td><td>67 ± 14</td><td>51–102</td></tr><tr><td>% Total Energy from Protein</td><td>18 ± 5</td><td>12–31</td><td>22 ± 9</td><td>14–38</td><td>19 ± 5</td><td>13–29</td><td>18 ± 4</td><td>13–28</td></tr><tr><td><10% of kcal [5]</td><td>0 (0%)</td><td></td><td>0 (0%)</td><td></td><td>0 (0%)</td><td></td><td>0 (0%)</td><td></td></tr><tr><td>Protein (g/kg) <sup>e</sup></td><td>0.9 ± 0.1 <sup>b</sup></td><td>0.7–1.2</td><td>1.1 ± 0.1 <sup>a</sup></td><td>0.9–1.4</td><td>1.0 ± 0.3</td><td>0.7–2.3</td><td>1.0 ± 0.2</td><td>0.7–1.5</td></tr><tr><td>Fat (g)</td><td>52 ± 13</td><td>30–83</td><td>61 ± 8 <sup>c,d</sup></td><td>48–76</td><td>48 ± 13<sup>b</sup></td><td>28–73</td><td>50 ± 14<sup>b</sup></td><td>33–74</td></tr><tr><td>% Total Energy from Fat</td><td>28 ± 3</td><td>21–34</td><td>30 ± 3 <sup>c,d</sup></td><td>25–35</td><td>26 ± 5<sup>b</sup></td><td>18–34</td><td>26 ± 4<sup>b</sup></td><td>20–32</td></tr><tr><td>>35% of kcal [5]</td><td>0 (0%)</td><td></td><td>0 (0%)</td><td></td><td>0 (0%)</td><td></td><td>0 (0%)</td><td></td></tr><tr><td>Carbohydrate (g)</td><td>240 ± 60</td><td>193–483</td><td>242 ± 24</td><td>206–295</td><td>226 ± 23</td><td>191–278</td><td>246 ± 26</td><td>202–288</td></tr><tr><td>% Total Energy from Carbohydrate</td><td>57 ± 3 <sup>b</sup></td><td>52–64</td><td>54 ± 3 <sup>a,d</sup></td><td>47–58</td><td>57 ± 6</td><td>38–68</td><td>59 ± 5<sup>b</sup></td><td>50–68</td></tr><tr><td><45% of kcal [5]</td><td>0 (0%)</td><td></td><td></td><td>0 (%)</td><td>1 (5%)</td><td></td><td>0 (0%)</td><td></td></tr><tr><td>Sodium (mg)</td><td>2896 ± 606 <sup>b,c,d</sup></td><td>1746–4531</td><td>3406 ± 544 <sup>a,c,d</sup></td><td>2532–4425</td><td>2401 ± 389 <sup>a,b,d</sup></td><td>1755–3487</td><td>1504 ± 296 <sup>a,b,c</sup></td><td>1114–2149</td></tr><tr><td>Fiber (g)</td><td>17.6 ± 4.2</td><td>10.6–24.0</td><td>25.1 ± 4.9</td><td>18.0–33.3</td><td>17.0 ± 4.4</td><td>10.6–27.1</td><td>19.2 ± 6.6</td><td>10.0–34.1</td></tr><tr><td><30g</td><td>14 (100)</td><td></td><td>10 (71)</td><td></td><td>14 (100%)</td><td></td><td>13 (93%)</td><td></td></tr><tr><td>Cholesterol (mg)</td><td>282 ± 133</td><td>131–496</td><td>333 ± 136</td><td>136–498</td><td>295 ± 185</td><td>111–641</td><td>148 ± 80</td><td>58–359</td></tr><tr><td>Vitamin C (mg)</td><td>106 ± 75</td><td>11–248</td><td>114 ± 60</td><td>27–236</td><td>106 ± 74</td><td>7–214</td><td>107 ± 75</td><td>21–215</td></tr><tr><td><75 mg</td><td>6 (43%)</td><td></td><td>2 (14%)</td><td></td><td>6 (43%)</td><td></td><td>7 (50%)</td><td></td></tr><tr><td>Iron (mg)</td><td>11.9 ± 4.2</td><td>6.3–22.3</td><td>12.7 ± 2.9</td><td>8.2–17.2</td><td>11.7 ± 3.0</td><td>7.9–17.7</td><td>11.7 ± 2.9</td><td>7.6–16.2</td></tr><tr><td><6 mg</td><td>0 (0%)</td><td></td><td>0 (0%)</td><td></td><td>0 (0%)</td><td></td><td>0 (0%)</td><td></td></tr><tr><td>Calcium (mg)</td><td>682 ± 148</td><td>469–1002</td><td>1086 ±174</td><td>845–1375</td><td>658 ± 121</td><td>512–917</td><td>547 ± 145</td><td>367–920</td></tr><tr><td><1000 mg</td><td>13 (93%)</td><td></td><td>6 (43%)</td><td></td><td>14 (100%)</td><td></td><td>14 (100%)</td><td></td></tr></table> |
4a8b045cb7398c0f06e9fe81a14f93918f41c355ce0182d2c10a58b2416ce036.png | complex | <table><tr><td rowspan="2">Groups</td><td rowspan="2">Standard error</td><td rowspan="2">Mean difference</td><td rowspan="2">Significance (<i>P</i> ≤ 0.05)</td><td colspan="2">95% Confidence interval for mean</td></tr><tr><td>Lower bound</td><td>Upper bound</td></tr><tr><td>Dentistry versus medicine</td><td>0.775</td><td>−0.536</td><td>0.489</td><td>−2.06</td><td>0.99</td></tr><tr><td>Dentistry versus arts</td><td>0.632</td><td>−1.784</td><td>0.005</td><td>−3.02</td><td>−0.54</td></tr><tr><td>Dentistry versus computer science</td><td>0.727</td><td>−1.766</td><td>0.015</td><td>−3.19</td><td>−0.34</td></tr></table> |
8e882870259264984787c5b6b20056df079d2238e82594f5dcebc41540fc8daf.png | simple | <table><tr><td>Unique region ID</td><td>VFDB ID</td><td>GIs</td><td>Gene</td><td>Putative functions</td><td>Organisms</td><td>% Identity</td><td>E-value</td></tr><tr><td>C8R1</td><td>VFG1693</td><td>GI 1</td><td><i>int</i></td><td>Prophage P4 integrase</td><td><i>Escherichia coli</i> CFT073</td><td>33</td><td>1.1E-45</td></tr><tr><td>C10R1</td><td>VFG0893</td><td>-</td><td><i>papA_2</i></td><td>PapA protein</td><td><i>Escherichia coli</i> CFT073</td><td>33</td><td>2.1E-16</td></tr><tr><td>C10R1</td><td>VFG0075</td><td>-</td><td><i>InlA</i></td><td>Internalin A</td><td><i>Listeria monocytogenes</i> (serovar 1/2a) EGD-e</td><td>30</td><td>1.4E-16</td></tr><tr><td>C13R2</td><td>VFG0783</td><td>-</td><td><i>intL</i></td><td>Putative integrase for prophage 933L and the LEE pathogenicity island</td><td><i>Escherichia coli</i> O157:H7 EDL933</td><td>27</td><td>1.3E-16</td></tr><tr><td>C15R4</td><td>VFG0038</td><td>GI 2</td><td><i>bplA</i></td><td>probable oxidoreductase</td><td><i>Bordetella pertussis</i> Tohama I</td><td>28</td><td>2.3E-19</td></tr><tr><td>C15R4</td><td>VFG0344</td><td>GI 2</td><td><i>hitC</i></td><td>iron(III) ABC transporter, ATP</td><td><i>Haemophilus influenzae</i> Rd</td><td>33</td><td>6.7E-23</td></tr><tr><td>C15R5</td><td>VFG0082</td><td>-</td><td><i>aldA</i></td><td>aldehyde dehydrogenase</td><td><i>Vibrio cholerae</i> N16961</td><td>31</td><td>1.2E-47</td></tr><tr><td>C15R6</td><td>VFG0598</td><td>-</td><td><i>intC</i></td><td>Sai integrase</td><td><i>Shigella flexneri</i> (serotype 2a) 301</td><td>47</td><td>4.9E-93</td></tr><tr><td>C18R3</td><td>VFG0672</td><td>GI 6</td><td><i>int</i></td><td>integrase</td><td><i>Shigella flexneri</i> (serotype 2a)</td><td>66</td><td>5E-162</td></tr><tr><td>C20R4</td><td>VFG1124</td><td>-</td><td><i>VC1791</i></td><td>conserved hypothetical protein</td><td><i>Vibrio cholerae</i> N16961</td><td>41</td><td>4.2E-39</td></tr><tr><td>C20R7</td><td>VFG0925</td><td>-</td><td><i>fepC</i></td><td>Ferric enterobactin transport ATP</td><td><i>Escherichia coli</i> CFT073</td><td>33</td><td>2.3E-23</td></tr><tr><td>C20R7</td><td>VFG0922</td><td>-</td><td><i>chuU</i></td><td>Putative permease of iron compound ABC transport system</td><td><i>Escherichia coli</i> CFT073</td><td>39</td><td>3.8E-29</td></tr><tr><td>C20R8</td><td>VFG0358</td><td>-</td><td><i>fyuA/psn</i></td><td>yersiniabactin receptor protein</td><td><i>Yersinia pestis</i> CO92</td><td>26</td><td>1.4E-34</td></tr><tr><td>C20R8</td><td>VFG0167</td><td>-</td><td><i>pchR</i></td><td>transcriptional regulator PchR</td><td><i>Pseudomonas aeruginosa</i> PAO1</td><td>41</td><td>1.1E-26</td></tr><tr><td>C26R1</td><td>VFG1102</td><td>GI 12</td><td><i>hsdM</i></td><td>DNA methylase HsdM</td><td><i>Vibrio cholerae</i> N16961</td><td>25</td><td>4.6E-17</td></tr><tr><td>C26R1</td><td>VFG1098</td><td>GI 12</td><td><i>hsdR</i></td><td>type I restriction enzyme HsdR</td><td><i>Vibrio cholerae</i> N16961</td><td>24</td><td>1.3E-21</td></tr><tr><td>C26R2</td><td>VFG2417</td><td>-</td><td><i>ecpE</i></td><td>hypothetical protein</td><td><i>Escherichia coli</i> O157:H7 EDL933</td><td>47</td><td>5.7E-41</td></tr><tr><td>C26R2</td><td>VFG2416</td><td>-</td><td><i>ecpD</i></td><td>putative receptor</td><td><i>Escherichia coli</i> O157:H7 EDL933</td><td>56</td><td>1.2E-108</td></tr><tr><td>C26R2</td><td>VFG2415</td><td>-</td><td><i>ecpC</i></td><td>putative enzyme</td><td><i>Escherichia coli</i> O157:H7 EDL933</td><td>55</td><td>8.5E-142</td></tr><tr><td>C26R2</td><td>VFG2412</td><td>-</td><td><i>ecpB</i></td><td>hypothetical protein</td><td><i>Escherichia coli</i> O157:H7 EDL933</td><td>48</td><td>1.1E-50</td></tr><tr><td>C26R2</td><td>VFG2414</td><td>-</td><td><i>ecpA</i></td><td>hypothetical protein</td><td><i>Escherichia coli</i> O157:H7 EDL933</td><td>57</td><td>7.2E-44</td></tr><tr><td>C26R2</td><td>VFG2044</td><td>-</td><td><i>bvgA</i></td><td>Virulence factors transcription regulator</td><td><i>Bordetella pertussis</i> Tohama I</td><td>47</td><td>7.7E-53</td></tr><tr><td>C27R1</td><td>VFG1433</td><td>GI 13</td><td><i>csvA</i></td><td>CS7 fimbria major subunit CsvA precursor</td><td><i>Escherichia coli</i></td><td>39</td><td>6.8E-22</td></tr><tr><td>C27R1</td><td>VFG0584</td><td>GI 13</td><td><i>yjcC</i></td><td>putative diguanylate cyclase</td><td><i>Salmonella enterica</i> (serovar <i>typhimurium</i>) LT2</td><td>29</td><td>4.8E-28</td></tr><tr><td>C32R1</td><td>VFG1584</td><td>GI 14</td><td><i>orf50</i></td><td>hypothetical protein</td><td><i>Escherichia coli</i> 536</td><td>26</td><td>1.9E-13</td></tr><tr><td>C32R1</td><td>VFG1584</td><td>GI 14</td><td><i>orf50</i></td><td>hypothetical protein</td><td><i>Escherichia coli</i> 536</td><td>26</td><td>4.7E-18</td></tr><tr><td>C32R2</td><td>VFG1888</td><td>-</td><td><i>letS</i></td><td>sensory box histidine kinase</td><td><i>Legionella pneumophila</i> Philadelphia 1</td><td>39</td><td>1.1E-41</td></tr><tr><td>C32R2</td><td>VFG0584</td><td>-</td><td><i>yjcC</i></td><td>putative diguanylate cyclase</td><td><i>Salmonella enterica</i> (serovar typhimurium) LT2</td><td>32</td><td>6.9E-32</td></tr><tr><td>C36R3</td><td>VFG1092</td><td>GI 16</td><td><i>int3</i></td><td>integrase, phage family</td><td><i>Vibrio cholerae</i> N16961</td><td>26</td><td>9.3E-15</td></tr><tr><td>C36R3</td><td>VFG1443</td><td>GI 16</td><td><i>ompA</i></td><td>outer membrane protein A</td><td><i>Escherichia coli</i></td><td>38</td><td>1.8E-54</td></tr><tr><td>C36R3</td><td>VFG1548</td><td>GI 16</td><td><i>prfC</i></td><td>PrfC protein</td><td><i>Escherichia coli</i> 536</td><td>39</td><td>1E-164</td></tr><tr><td>C36R3</td><td>VFG1547</td><td>GI 16</td><td><i>prfD</i></td><td>PrfD protein</td><td><i>Escherichia coli</i> 536</td><td>51</td><td>2.7E-61</td></tr><tr><td>C39R1</td><td>VFG0266</td><td>-</td><td><i>hmbR</i></td><td>hemoglobin receptor</td><td><i>Neisseria meningitidis</i> MC58 (serogroup B)</td><td>31</td><td>1.4E-45</td></tr><tr><td>C39R1</td><td>VFG0266</td><td>-</td><td><i>hmbR</i></td><td>hemoglobin receptor</td><td><i>Neisseria meningitidis</i> MC58 (serogroup B)</td><td>36</td><td>6.5E-34</td></tr></table> |
5004bf7e3a0486e4a6f7ff93a9c9fbff3489f25fd3a469578cd85e63e65dfd74.png | complex | <table><tr><td>HAART years</td><td>Mean and standard deviation</td><td>Significance</td></tr><tr><td>1–3</td><td>43.4 ± 23.5</td><td rowspan="4">0.000<sup><i>♣</i></sup></td></tr><tr><td>4–6</td><td>29.9 ± 20.1</td></tr><tr><td>7–10</td><td>30.8 ± 15.9</td></tr><tr><td>>11</td><td>23.4 ± 15.5</td></tr><tr><td> </td><td>Mean and standard deviation</td><td>Significance</td></tr><tr><td>1–3</td><td> </td><td> </td></tr><tr><td> 4–6</td><td>13.5 ± 4.0</td><td>0.006<sup><i>◆</i></sup></td></tr><tr><td> 7–10</td><td>12.6 ± 4.5</td><td>0.048<sup><i>◆</i></sup></td></tr><tr><td> >11</td><td>20.0 ± 4.5</td><td>0.000<sup><i>◆</i></sup></td></tr><tr><td>4–6</td><td> </td><td> </td></tr><tr><td> 1–3</td><td>−13.5 ± 4.0</td><td>0.006<sup><i>◆</i></sup></td></tr><tr><td> 7–10</td><td>−0.9 ± 4.7</td><td>1.000<sup><i>◆</i></sup></td></tr><tr><td> >11</td><td>6.5 ± 4.7</td><td>0.673<sup><i>◆</i></sup></td></tr><tr><td>7–10</td><td> </td><td> </td></tr><tr><td> 1–3</td><td>−12.6 ± 5.4</td><td>0.048<sup><i>◆</i></sup></td></tr><tr><td> 4–6</td><td>0.9 ± 4.7</td><td>1.000<sup><i>◆</i></sup></td></tr><tr><td> >11</td><td>7.4 ± 5.1</td><td>0.634<sup><i>◆</i></sup></td></tr><tr><td>>11</td><td> </td><td> </td></tr><tr><td> 1–3</td><td>−20.6 ± 4.5</td><td>0.000<sup><i>◆</i></sup></td></tr><tr><td> 4–6</td><td>−6.4 ± 4.7</td><td>0.673<sup><i>◆</i></sup></td></tr><tr><td> 7–10</td><td>−7.4 ± 5.1</td><td>0.634<sup><i>◆</i></sup></td></tr></table> |
b2e67e051110cff7f22725f161e1ad83e74953028c9ffdd6f005a2f4a02fe87e.png | complex | <table><tr><td></td><td colspan="2">Photoelectric</td><td colspan="2">Detector with CO Sensor </td></tr><tr><td></td><td>CO Concentration (ppm)</td><td>CO Dose (ppm minute)</td><td>CO Concentration (ppm)</td><td>CO Dose (ppm minute)</td></tr><tr><td rowspan="9">Shortest time of alarm</td><td>576</td><td>30,859</td><td>25</td><td>587</td></tr><tr><td>733</td><td>31,384</td><td>38</td><td>425</td></tr><tr><td>502</td><td>17,855</td><td>53</td><td>1121</td></tr><tr><td>639</td><td>22,690</td><td>52</td><td>802</td></tr><tr><td>643</td><td>18,985</td><td>35</td><td>276</td></tr><tr><td>993</td><td>57,893</td><td>36</td><td>515</td></tr><tr><td>-</td><td>-</td><td>44</td><td>965</td></tr><tr><td>-</td><td>-</td><td>30</td><td>437</td></tr><tr><td>-</td><td>-</td><td>47</td><td>902</td></tr><tr><td rowspan="9">Mean time of alarm</td><td>664</td><td>37,593</td><td>35</td><td>875</td></tr><tr><td>1453</td><td>63,957</td><td>42</td><td>766</td></tr><tr><td>638</td><td>24,371</td><td>62</td><td>1236</td></tr><tr><td>907</td><td>39,325</td><td>61</td><td>965</td></tr><tr><td>933</td><td>32,547</td><td>35</td><td>315</td></tr><tr><td>1075</td><td>64,184</td><td>37</td><td>554</td></tr><tr><td>-</td><td>-</td><td>46</td><td>1019</td></tr><tr><td>-</td><td>-</td><td>36</td><td>489</td></tr><tr><td>-</td><td>-</td><td>46</td><td>960</td></tr></table> |
cd43577af05e2315b7c44fb0bf50e456699135df22d47017bdeffc407701ef8f.png | complex | <table><tr><td>Factors</td><td>Weight</td><td>Parameters</td><td>Weight</td></tr><tr><td rowspan="5">1. Environmental background</td><td rowspan="5">0.10</td><td>1.1 elevation</td><td>0.25</td></tr><tr><td>1.2 Slope</td><td>0.07</td></tr><tr><td>1.3 geomorphological types</td><td>0.36</td></tr><tr><td>1.4 accumulated temperature (> 0 °C)</td><td>0.11</td></tr><tr><td>1.5 wetness index</td><td>0.21</td></tr><tr><td rowspan="3">2. Water/land resources</td><td rowspan="3">0.37</td><td>2.1 precipitation</td><td>0.22</td></tr><tr><td>2.2 river density</td><td>0.11</td></tr><tr><td>2.3 land-use types</td><td>0.67</td></tr><tr><td rowspan="3">3. Socio-economic development</td><td rowspan="3">0.53</td><td>3.1 railway density</td><td>0.25</td></tr><tr><td>3.2 road density</td><td>0.13</td></tr><tr><td>3.3 population density</td><td>0.62</td></tr></table> |
d64b689c7661f2e4679c785adfa8b84bbe260f84d0fca80b584cefd9636c0bf1.png | simple | <table><tr><td>Hypothesis</td><td>Cyt <i>b</i></td><td>16S</td><td>Concatenated</td></tr><tr><td>Monophyly of “Mixed Genera” and “<i>Parougia</i>”</td><td>n.a.1</td><td>0.501</td><td>n.a.1</td></tr><tr><td>Monophyly of “Mixed Genera” and “<i>Ophryotrocha</i>”</td><td>0.097</td><td>n.a.1</td><td>0.227</td></tr><tr><td>Monophyly of <i>Ophryotrocha</i></td><td>0.003</td><td>0.010</td><td>0.001</td></tr><tr><td>Monophyly of <i>Ophryotrocha</i> Seep 1 and 2</td><td>n.a.2</td><td><0.001</td><td>n.a.2</td></tr><tr><td>Monophyly of <i>Ophryotrocha</i> Seep 3–5</td><td>0.229</td><td>n.a.1</td><td>n.a.1</td></tr><tr><td>Monophyly of <i>Ophryotrocha</i> Seep 1–5</td><td>n.a.3</td><td><0.001</td><td>n.a.3</td></tr></table> |
8e06c374c706fe36c9ac5c7d6f718e8afa06fa54dcf03f855d739481efb2a90b.png | simple | <table><tr><td></td><td>Control (n=10)</td><td>MSG (n=10)</td><td>P value</td><td></td></tr><tr><td>Urine Volume (ml/day)</td><td>26.9 ± 7.2</td><td>51.5 ± 23.6</td><td>< 0.01</td><td></td></tr><tr><td>Urine pH</td><td>6.6 ± 0.6</td><td>8.7 ± 0.4</td><td>< 0.001</td><td></td></tr><tr><td>Sodium (mEq/day)</td><td>1.0 ± 0.5</td><td>6.1 ± 2.9</td><td>< 0.001</td><td></td></tr><tr><td>Potassium (mEq/day)</td><td>4.1 ± 1.2</td><td>4.8 ± 1.5</td><td>NS</td><td></td></tr><tr><td>Chloride (mEq/day)</td><td>1.3 ± 0.6</td><td>1.8 ± 0.7</td><td>NS</td><td></td></tr><tr><td>Calcium (mg/day)</td><td>3.9 ± 1.2</td><td>4.1 ± 1.2</td><td>NS</td><td></td></tr><tr><td>Phosphate (mg/day)</td><td>36 ± 15</td><td>39 ± 5</td><td>NS</td><td></td></tr><tr><td>Citrate (mmol/day)</td><td>0.43 ± 13</td><td>0.77 ± 0.16</td><td>< 0.001</td><td></td></tr><tr><td>Ammonium (mmol/day)</td><td>1.41 ± 0.39</td><td>0.38 ± 0.19</td><td>< 0.001</td><td></td></tr><tr><td>Magnesium (mg/day)</td><td>4.1 ± 0.9</td><td>2.0 ± 1.1</td><td>< 0.001</td><td></td></tr></table> |
ef1575cacd579ac919eb5a89016336dee48f99022426ab8d8aff7a8987b873dc.png | complex | <table><tr><td></td><td>n</td><td>Males</td><td>n</td><td>Females</td></tr><tr><td colspan="5">Height (cm)</td></tr><tr><td> Birth</td><td>981</td><td>48.4(2.7)</td><td>897</td><td>47.9(2.8)</td></tr><tr><td> 3 mo</td><td>834</td><td>58.4(3.1)</td><td>779</td><td>57.4(3.0)</td></tr><tr><td> 6.5 y</td><td>874</td><td>107.0(5.4)</td><td>806</td><td>106.3(5.5)</td></tr><tr><td> 15 y</td><td>558</td><td>150.5(9.0)</td><td>550</td><td>148.8(6.1)</td></tr><tr><td> Adult</td><td>981</td><td>166.4(6.6)</td><td>897</td><td>153.9(5.9)</td></tr><tr><td colspan="5">Weight(kg)</td></tr><tr><td> Birth</td><td>981</td><td>2.84(0.49)</td><td>897</td><td>2.75(0.49)</td></tr><tr><td> 3 mo</td><td>834</td><td>4.99(0.82)</td><td>779</td><td>4.68(0.72)</td></tr><tr><td> 6.5 y</td><td>874</td><td>16.0(2.0)</td><td>806</td><td>15.8(2.0)</td></tr><tr><td> 15 y</td><td>558</td><td>35.7(6.7)</td><td>550</td><td>37.3(6.0)</td></tr><tr><td> Adult</td><td>981</td><td>57.2(11.2)</td><td>897</td><td>49.1(10.4)</td></tr><tr><td colspan="5">BMI(kg/m<sup>2</sup>)</td></tr><tr><td> Birth</td><td>981</td><td>12.1(1.8)</td><td>897</td><td>12.0(1.8)</td></tr><tr><td> 3 mo</td><td>834</td><td>14.7(2.1)</td><td>779</td><td>14.2(1.9)</td></tr><tr><td> 6.5 y</td><td>874</td><td>13.9(1.4)</td><td>806</td><td>14.0(1.4)</td></tr><tr><td> 15 y</td><td>558</td><td>15.6(1.5)</td><td>550</td><td>16.8(2.0)</td></tr><tr><td> Adult</td><td>981</td><td>20.6(3.4)</td><td>897</td><td>20.7(4.0)</td></tr><tr><td colspan="5">Adult variables</td></tr><tr><td> Age (y)</td><td>981</td><td>28.0(1.0)</td><td>897</td><td>28.2(0.9)</td></tr><tr><td> WC (cm)</td><td>981</td><td>77.3(10.5)</td><td>897</td><td>70.8(9.4)</td></tr><tr><td> Hip circumference(cm)</td><td>981</td><td>86.8(7.3)</td><td>897</td><td>88.7(8.7)</td></tr><tr><td> SBP (mm Hg)</td><td>981</td><td>112.2(11.2)</td><td>897</td><td>101.4(10.8)</td></tr><tr><td> DBP (mm Hg)</td><td>981</td><td>72.7(9.3)</td><td>897</td><td>72.4(8.6)</td></tr><tr><td> Total cholesterol (mmol/L)</td><td>981</td><td>4.0(0.9)</td><td>897</td><td>3.9(0.8)</td></tr><tr><td> HDL cholesterol (mmol/L)</td><td>970</td><td>0.98(0.24)</td><td>893</td><td>1.09(0.24)</td></tr><tr><td> LDL cholesterol (mmol/L)</td><td>968</td><td>2.5(0.7)</td><td>893</td><td>2.4(0.7)</td></tr><tr><td> Triglyceride (mmol/L)*</td><td>980</td><td>1.0(0.8,1.5)</td><td>897</td><td>0.8(0.6,1.1)</td></tr><tr><td> Fasting glucose (mg/dL)*</td><td>981</td><td>98(92,104)</td><td>897</td><td>96(90,102)</td></tr><tr><td> 2-h glucose(mg/dL)*</td><td>981</td><td>110(94,131)</td><td>897</td><td>115(99,134)</td></tr><tr><td> Fasting insulin (mIU/mL)*</td><td>981</td><td>5.7(2.6,9.7)</td><td>897</td><td>3.2(1.2,6.2)</td></tr><tr><td> 2-h insulin (mIU/mL)*</td><td>981</td><td>21.7(11.9,39.1)</td><td>897</td><td>20.8(10.7,37.3)</td></tr><tr><td> HOMA-IR*</td><td>981</td><td>1.35(0.60,2.41)</td><td>897</td><td>0.77(0.28,1.49)</td></tr><tr><td> Urban at birth(%)</td><td>981</td><td>29.7</td><td>897</td><td>26.1</td></tr><tr><td> Urban as adult(%)</td><td>981</td><td>45.7</td><td>897</td><td>41.8</td></tr><tr><td> Education: ≤ primary (%)</td><td>981</td><td>18</td><td>897</td><td>36.7</td></tr><tr><td> Education: middle and high (%)</td><td>981</td><td>57.1</td><td>897</td><td>48.9</td></tr><tr><td> Education: > high (%)</td><td>981</td><td>24.9</td><td>897</td><td>14.3</td></tr><tr><td> Material possessions score</td><td>981</td><td>5(3.8)</td><td>897</td><td>5(2.7)</td></tr><tr><td> Current smoker (%)</td><td>981</td><td>42.9</td><td>897</td><td>2.7</td></tr><tr><td> Alcohol consumption: any (%)</td><td>981</td><td>54</td><td>897</td><td>0.8</td></tr><tr><td> Physical activity score</td><td>981</td><td>1407(832,1890)</td><td>897</td><td>1854(1427,2409)</td></tr></table> |
71233a9d76508c8cf280784820db4fa72bcbede01883072f678a81fc9295ca1f.png | simple | <table><tr><td>Strategy</td><td>Country</td><td>Cases</td><td>Tests</td><td>Prevalence (per 10,000)</td><td>CI 95%</td></tr><tr><td>Intensified monitoring in AS positive flocks</td><td>Finland</td><td>0</td><td>36</td><td>0</td><td>0 - 973.9</td></tr><tr><td></td><td>France</td><td>11</td><td>14965</td><td>7.4</td><td>3.7 - 13.1</td></tr><tr><td></td><td>Greece</td><td>0</td><td>67</td><td>0</td><td>0 - 535.7</td></tr><tr><td></td><td>Norway</td><td>0</td><td>75</td><td>0</td><td>0 - 480.0</td></tr><tr><td></td><td>Portugal</td><td>3</td><td>4612</td><td>6.5</td><td>1.3 - 19.0</td></tr><tr><td></td><td>Sweden</td><td>0</td><td>47</td><td>0</td><td>0.0 - 754.9</td></tr><tr><td>Intensified monitoring in CS positive flocks</td><td>France</td><td>7</td><td>31113</td><td>2.2</td><td>0.9 - 4.6</td></tr><tr><td>Selective culling in AS positive flocks</td><td>Belgium</td><td>0</td><td>223</td><td>0</td><td>0 - 164.1</td></tr><tr><td></td><td>Denmark</td><td>0</td><td>168</td><td>0</td><td>0 - 217.2</td></tr><tr><td></td><td>France</td><td>5</td><td>10462</td><td>4.8</td><td>1.6 - 11.1</td></tr><tr><td></td><td>Italy</td><td>1</td><td>2260</td><td>4.4</td><td>0.1 - 24.6</td></tr><tr><td></td><td>The Netherlands</td><td>0</td><td>60</td><td>0</td><td>0 - 596.3</td></tr><tr><td></td><td>Norway</td><td>0</td><td>1033</td><td>0</td><td>0 - 35.6</td></tr><tr><td></td><td>Portugal</td><td>2</td><td>1763</td><td>11.3</td><td>1.4 - 40.9</td></tr><tr><td>Selective culling in CS positive flocks</td><td>Belgium</td><td>0</td><td>295</td><td>0</td><td>0 - 124.3</td></tr><tr><td></td><td>France</td><td>4</td><td>12087</td><td>3.3</td><td>0.9 - 8.5</td></tr><tr><td></td><td>Greece</td><td>3</td><td>10310</td><td>2.9</td><td>0.6 - 8.5</td></tr><tr><td></td><td>Italy</td><td>2</td><td>8565</td><td>2.3</td><td>0.3 - 8.4</td></tr><tr><td>Special genetic selection in AS positive flocks</td><td>Italy</td><td>0</td><td>351</td><td>0</td><td>0 - 104.5</td></tr><tr><td>Stamping out in AS positive flocks</td><td>Denmark</td><td>0</td><td>17</td><td>0</td><td>0 - 1950.6</td></tr><tr><td></td><td>Finland</td><td>0</td><td>173</td><td>0</td><td>0 - 211.0</td></tr><tr><td></td><td>Iceland</td><td>1</td><td>467</td><td>21.4</td><td>0.5 - 118.7</td></tr><tr><td></td><td>Italy</td><td>1</td><td>1309</td><td>7.6</td><td>0.2 - 42.5</td></tr><tr><td></td><td>Norway</td><td>0</td><td>1156</td><td>0</td><td>0 - 31.9</td></tr><tr><td></td><td>Sweden</td><td>0</td><td>195</td><td>0</td><td>0 - 187.4</td></tr><tr><td>Stamping out in CS positive flocks</td><td>Iceland</td><td>0</td><td>367</td><td>0</td><td>0 - 100.0</td></tr><tr><td></td><td>Italy</td><td>0</td><td>3231</td><td>0</td><td>0 - 11.4</td></tr><tr><td></td><td>Norway</td><td>0</td><td>343</td><td>0</td><td>0 - 107.0</td></tr></table> |
c6946c058d82faef0ccba22ee20a94092653f736a11b4c531634167327341a2e.png | simple | <table><tr><td></td><td>Attended predictable</td><td>Attended unpredictable</td><td>Unattended predictable</td><td>Unattended unpredictable</td></tr><tr><td>Mean</td><td>175.38</td><td>171.38</td><td>171.81</td><td>173.50</td></tr><tr><td>Range</td><td>165–182</td><td>141–187</td><td>142–188</td><td>161–181</td></tr></table> |
114466071cf1f9c3f745b066d1392cad072fa87e408a48941173cc1476ed8bbf.png | complex | <table><tr><td rowspan="2">Texture analysis parameter</td><td colspan="3">Main effects (<i>P</i> value)</td><td colspan="4">Effect interactions (<i>P</i> value)</td></tr><tr><td>(1) Exp. day</td><td>(2) Potency</td><td>(3) Replicate</td><td>1-2</td><td>1-3</td><td>2-3</td><td>1-2-3</td></tr><tr><td>Cluster_prominence</td><td><0.0001*</td><td>0.0436</td><td>0.2143</td><td>0.0005</td><td>0.1135</td><td>0.3126</td><td>0.1706</td></tr><tr><td>Cluster_shade</td><td><0.0001*</td><td>0.0004*</td><td>0.1296</td><td>0.3264</td><td>0.2145</td><td>0.4365</td><td>0.5069</td></tr><tr><td>Correlation</td><td><0.0001*</td><td>0.0039</td><td>0.5376</td><td>0.0001*</td><td>0.1567</td><td>0.0918</td><td>0.1896</td></tr><tr><td>Diagonal_moment</td><td><0.0001*</td><td>0.0002*</td><td>0.0508</td><td>0.2998</td><td>0.0943</td><td>0.6176</td><td>0.3498</td></tr><tr><td>Difference_energy</td><td><0.0001*</td><td>0.0076</td><td>0.3948</td><td>0.0040</td><td>0.2444</td><td>0.1625</td><td>0.1077</td></tr><tr><td>Difference_entropy</td><td><0.0001*</td><td>0.0059</td><td>0.5062</td><td>0.0009</td><td>0.2248</td><td>0.1288</td><td>0.1592</td></tr><tr><td>Energy</td><td><0.0001*</td><td>0.0055</td><td>0.4246</td><td>0.0143</td><td>0.3051</td><td>0.1684</td><td>0.1437</td></tr><tr><td>Entropy</td><td><0.0001*</td><td>0.0150</td><td>0.2997</td><td>0.0006</td><td>0.1970</td><td>0.1947</td><td>0.1318</td></tr><tr><td>Inertia</td><td><0.0001*</td><td>0.0041</td><td>0.5262</td><td>0.0001*</td><td>0.1567</td><td>0.0978</td><td>0.1934</td></tr><tr><td>Inverse_different_moment</td><td><0.0001*</td><td>0.0024</td><td>0.0166</td><td>0.0001*</td><td>0.0893</td><td>0.2193</td><td>0.0138</td></tr><tr><td>Kappa</td><td><0.0001*</td><td>0.0023</td><td>0.0112</td><td><0.0001*</td><td>0.0923</td><td>0.2521</td><td>0.0124</td></tr><tr><td>Maximum_probability</td><td><0.0001*</td><td>0.0022</td><td>0.0528</td><td>0.2930</td><td>0.1958</td><td>0.1342</td><td>0.0886</td></tr><tr><td>Sum_energy</td><td><0.0001*</td><td>0.0002*</td><td>0.4163</td><td>0.0046</td><td>0.0902</td><td>0.0397</td><td>0.3965</td></tr><tr><td>Sum_entropy</td><td><0.0001*</td><td>0.0013</td><td>0.7932</td><td>0.0001*</td><td>0.1380</td><td>0.0387</td><td>0.1780</td></tr><tr><td>Sum_variance</td><td><0.0001*</td><td>0.0030</td><td>0.6470</td><td><0.0001*</td><td>0.1622</td><td>0.0507</td><td>0.1598</td></tr></table> |
a14609c69827aa930bdd8521baf8c89348db858831563650967054b3d0816516.png | simple | <table><tr><td>nr</td><td>Item description</td><td>loading</td><td>α1</td><td>α2</td><td>ITC</td></tr><tr><td></td><td><i>Factor 1: Communication with ophthalmologist</i></td><td></td><td>0.89</td><td></td><td></td></tr><tr><td>Q7</td><td>Ophthalmologist treated me with respect</td><td>0.88</td><td></td><td>0.88</td><td>0.66</td></tr><tr><td>Q8</td><td>Ophthalmologist listened carefully</td><td>0.90</td><td></td><td>0.87</td><td>0.73</td></tr><tr><td>Q9</td><td>Ophthalmologist explained things clearly</td><td>0.75</td><td></td><td>0.88</td><td>0.67</td></tr><tr><td>Q10</td><td>Ophthalmologist spent enough time</td><td>0.85</td><td></td><td>0.87</td><td>0.74</td></tr><tr><td>Q11</td><td>Ophthalmologist went seriously into merits of my questions</td><td>0.81</td><td></td><td>0.87</td><td>0.78</td></tr><tr><td>Q12</td><td>Ophthalmologist shared decision making</td><td>0.68</td><td></td><td>0.87</td><td>0.74</td></tr><tr><td>Q13</td><td>Ophthalmologist took specific wishes into account</td><td>0.68</td><td></td><td>0.87</td><td>0.74</td></tr><tr><td>Q16</td><td>Ophthalmologist talked about things that went wrong</td><td>0.40</td><td></td><td>0.91</td><td>0.49</td></tr><tr><td></td><td><i>Factor 2: Communication with nurses</i></td><td></td><td>0.72</td><td></td><td></td></tr><tr><td>Q30</td><td>Nurses treat me with respect</td><td>0.84</td><td></td><td>0.66</td><td>0.56</td></tr><tr><td>Q31</td><td>Nurses listened carefully</td><td>0.84</td><td></td><td>0.59</td><td>0.63</td></tr><tr><td>Q32</td><td>Nurses explained things clearly</td><td>0.80</td><td></td><td>0.62</td><td>0.56</td></tr><tr><td>Q38</td><td>Information was adequately coordinated*</td><td>0.41</td><td></td><td>0.76</td><td>0.41</td></tr><tr><td></td><td><i>Factor 3: Communication about medication</i></td><td></td><td>0.79</td><td></td><td></td></tr><tr><td>Q50</td><td>Questions asked about allergic iodine</td><td>0.91</td><td></td><td>0.69</td><td>0.65</td></tr><tr><td>Q51</td><td>Questions asked about allergic medication</td><td>0.92</td><td></td><td>0.58</td><td>0.74</td></tr><tr><td>Q52</td><td>Clear information about side-effects medication</td><td>0.61</td><td></td><td>0.83</td><td>0.51</td></tr><tr><td></td><td><i>Factor 4: Rest items</i></td><td></td><td>0.52</td><td></td><td></td></tr><tr><td>Q16</td><td>Ophthalmologist talked about things that went wrong</td><td>0.41</td><td></td><td>0.43</td><td>0.33</td></tr><tr><td>Q38</td><td>Information was adequately coordinated</td><td>0.53</td><td></td><td>0.36</td><td>0.44</td></tr><tr><td>Q39</td><td>Care was adequately coordinated</td><td>0.57</td><td></td><td>0.36</td><td>0.40</td></tr><tr><td>Q63</td><td>How often did insurers compensate for costs medication</td><td>0.46</td><td></td><td>0.61</td><td>0.12</td></tr></table> |
b020e2937fe5aef7458a83fc2c0ca8ad7f10c1439d2ba61c3f3e1dca27849a25.png | simple | <table><tr><td></td><td></td><td></td><td>GRADING</td><td>ADC</td><td>fp</td><td>Dp</td><td>Dt</td></tr><tr><td><i>Spearman Correlation Coefficient</i></td><td>GRADING</td><td>Correlation Coefficient</td><td>1,000</td><td>,687*</td><td>,737*</td><td>−,326</td><td>,674*</td></tr><tr><td></td><td></td><td>P value</td><td></td><td>,000</td><td>,000</td><td>,090</td><td>,000</td></tr><tr><td></td><td>ADC</td><td>Correlation Coefficient</td><td>,687*</td><td>1,000</td><td>,483*</td><td>−,128</td><td>,835*</td></tr><tr><td></td><td></td><td>P value</td><td>,000</td><td></td><td>,006</td><td>,518</td><td>,000</td></tr><tr><td></td><td>fp</td><td>Correlation Coefficient</td><td>,737*</td><td>,483*</td><td>1,000</td><td>−,615*</td><td>,245</td></tr><tr><td></td><td></td><td>P value</td><td>,000</td><td>,006</td><td></td><td>,001</td><td>,183</td></tr><tr><td></td><td>Dp</td><td>Correlation Coefficient</td><td>−,326</td><td>−,128</td><td>−,615*</td><td>1,000</td><td>,290</td></tr><tr><td></td><td></td><td>P value</td><td>,090</td><td>,518</td><td>,001</td><td></td><td>,135</td></tr><tr><td></td><td>Dt</td><td>Correlation Coefficient</td><td>,674*</td><td>,835*</td><td>,245</td><td>,290</td><td>1,000</td></tr><tr><td></td><td></td><td>P value</td><td>,000</td><td>,000</td><td>,183</td><td>,135</td><td></td></tr></table> |
99bf1ec416bbbc302adf0caf2787279c052039b99917802152efe4b4881ee1f6.png | simple | <table><tr><td></td><td>n</td><td>Gender female</td><td>Age (years)*</td><td>Height (cm)*</td><td>Weight (kg)*</td><td>BMI (kg/m<sup>2</sup>)*</td></tr><tr><td>Residents</td><td>64</td><td>n = 53 (82.8%)</td><td>83.2 ± 8.1</td><td>161.9 ± 9.3</td><td>72.1 ± 16.1</td><td>27.4 ± 5.4</td></tr><tr><td>Caregivers</td><td>29</td><td>n = 29 (100%)</td><td>42.0 ± 11.7</td><td>166.7 ± 6.2</td><td>76.3 ± 16.6</td><td>27.3 ± 5.9</td></tr></table> |
768cabfa072b136999e316e7303d6048955f29ef59e7c6f3e4456a1e070f66f6.png | simple | <table><tr><td>Material</td><td>Q<sup>4</sup> (%Area)</td><td>Q<sup>3</sup> (%Area)</td><td>Q<sup>2</sup> (%Area)</td></tr><tr><td>FDU-12-H100</td><td>61.75</td><td>30.82</td><td>7.43</td></tr><tr><td>FDU-12-H130</td><td>67.1</td><td>29.46</td><td>3.44</td></tr><tr><td>FDU-12-H150</td><td>70.86</td><td>26.50</td><td>2.64</td></tr><tr><td>FDU-12-H180</td><td>73.86</td><td>23.91</td><td>2.23</td></tr><tr><td>FDU-12-H200</td><td>75.42</td><td>22.94</td><td>1.64</td></tr></table> |
e60d111ed137edc8654b675ac5974de40925dbdd9214917fb12154e960e63642.png | simple | <table><tr><td>CT(A, B)</td><td>McTwo</td><td>CFS</td><td>PAM</td><td>RRF</td></tr><tr><td>McTwo</td><td>0/17/0</td><td>1/2/14</td><td>12/1/4</td><td>15/0/2</td></tr><tr><td>CFS</td><td>14/2/1</td><td>0/17/0</td><td>16/1/0</td><td>17/0/0</td></tr><tr><td>PAM</td><td>4/1/12</td><td>0/1/16</td><td>0/17/0</td><td>13/0/4</td></tr><tr><td>RRF</td><td>2/0/15</td><td>0/0/17</td><td>4/0/13</td><td>0/17/0</td></tr></table> |
97c9542e8256d5cb075db8e1f9acd32d884b9519de031da9701ae6824c6e64c6.png | complex | <table><tr><td rowspan="2">Factors analyzed</td><td colspan="2">RAI (−) patients</td></tr><tr><td>Risk ratio (CI)</td><td><i>p</i> value</td></tr><tr><td>Age (years)</td><td>0.034 (0.000–48.227)</td><td>0.362</td></tr><tr><td>Male gender</td><td>1.170 (0.279–4.911)</td><td>0.830</td></tr><tr><td>Microscopic ETE</td><td>0.794 (0.096–6.551)</td><td>0.830</td></tr><tr><td>Diameter of largest tumor</td><td>0.621 (0.148–2.609)</td><td>0.515</td></tr><tr><td>Sum diameter of all tumors</td><td>1.624 (0.388–6.802)</td><td>0.507</td></tr><tr><td>LLND bilaterality</td><td>2.070 (0.254–16.892)</td><td>0.497</td></tr><tr><td>Multifocality</td><td>1.051 (0.211–5.239)</td><td>0.952</td></tr><tr><td>Bilaterality</td><td>0.443 (0.106–1.855)</td><td>0.265</td></tr><tr><td>With chronic thyroiditis</td><td>0.895 (0.109–7.360)</td><td>0.918</td></tr><tr><td>BRAF mutation</td><td>1.443 (0.177–11.780)</td><td>0.732</td></tr><tr><td>Variants of PTMC</td><td>0.595 (0.073–4.842)</td><td>0.628</td></tr><tr><td>CLNM Ratio</td><td>12.948 (2.610–64.229)</td><td>0.002</td></tr><tr><td>LLNM Ratio</td><td>8.321 (1.234–32.321)</td><td>0.031</td></tr></table> |
419cad103c697e112363aea31d687184f5be4d3f5bac610594ec261dd2851313.png | simple | <table><tr><td>Measure</td><td>Inclusion (<i>n </i>= 165)</td><td>18 months (<i>n </i>= 156)</td><td>30 months (<i>n </i>= 149)</td></tr><tr><td>Mean M-HAQ score (median)</td><td>0.93 ± 0.64 (0.875)</td><td>0.42 ± 0.50 (0.25)</td><td>0.35 ± 0.41 (0.25)</td></tr><tr><td>No. with M-HAQ ≥ 1.0 (%)</td><td>76 (46.1)</td><td>18 (11.6%)</td><td>17 (11.5%)</td></tr><tr><td>Mean DAS28-3 score (median)</td><td>5.01 ± 1.27 (4.94)</td><td>2.94 ± 1.26 (2.66)</td><td>2.81 ± 1.06 (2.46)</td></tr><tr><td>No. with DAS28-3 < 2.6 (%)</td><td>5 (3.0)</td><td>76 (48.7)</td><td>82 (55.0)</td></tr><tr><td>Mean swollen joint count (median)</td><td>12.55 ± 9.57 (10)</td><td>2.83 ± 5.51 (0)</td><td>2.04 ± 3.64 (0)</td></tr><tr><td>Number without synovitis (%)</td><td>n.a.</td><td>72 (46.2)</td><td>82 (55.0)</td></tr><tr><td>Number with persistent arthritis (%)</td><td>n.a.</td><td>137 (87.8)</td><td>125 (83.9)</td></tr><tr><td>No. fulfilling criteria for RA (%)</td><td>133 (80.6)</td><td>36 (23.1)</td><td>28 (18.8)</td></tr><tr><td>No. with severe arthritis (%)</td><td>106 (64.2)</td><td>65 (41.7)</td><td>56 (37.8)</td></tr><tr><td>Mean total SvH score (median)</td><td>6.05 ± 8.38 (4)</td><td>11.34 ± 13.82 (7)</td><td>15.76 ± 18.38 (10)</td></tr><tr><td>Mean erosion SvH score (median)</td><td>3.02 ± 4.99 (1)</td><td>6.94 ± 9.37 (4)</td><td>10.31 ± 13.14 (7)</td></tr><tr><td>Upper third of the total SvH score</td><td>>5</td><td>>10</td><td>>15</td></tr><tr><td>No. on DMARDs (%)</td><td></td><td></td><td></td></tr><tr><td> Total</td><td>31 (18.8)</td><td>120 (76.9)</td><td>116 (77.9)</td></tr><tr><td> RF-positive</td><td>13/68 (19.1)</td><td>60/63 (95.2)</td><td>60/61 (98.4)</td></tr><tr><td> Anti-CCP-positive</td><td>10/53 (18.9)</td><td>49/52 (94.2)</td><td>50/51 (98.0)</td></tr><tr><td> Anti-Sa-positive</td><td>6/46 (13.0)</td><td>43/45 (95.6)</td><td>44/44 (100.0)</td></tr></table> |
7620cb01f76f8b391cede1f7942eb96dc4942ed180c31ae1dfc4acd1da024c2d.png | simple | <table><tr><td>Groups</td><td>I</td><td>N</td><td>Total</td></tr><tr><td>H</td><td>5</td><td>7</td><td>12</td></tr><tr><td>L</td><td>7</td><td>4</td><td>11</td></tr><tr><td>Total</td><td>12</td><td>11</td><td>23</td></tr></table> |
d6a39cae3ff7f2c998270ddec03c21c2fd95294453d735f0ff46adb55dfd49bc.png | complex | <table><tr><td>Effect Type</td><td colspan="4">City</td></tr><tr><td></td><td>Washington</td><td>New York</td><td>Chicago</td><td>Atlanta</td></tr><tr><td>Combined Fallout and Thermal</td><td>188,430</td><td>1,649,587</td><td>614,535</td><td>182,717</td></tr><tr><td>Combined Fallout and Blast</td><td>223,570</td><td>1,733,983</td><td>637,033</td><td>207,025</td></tr><tr><td>All Thermal categories</td><td>39,641</td><td>140,701</td><td>79,451</td><td>36,256</td></tr><tr><td>All Fallout categories</td><td>172,819</td><td>1,592,968</td><td>554,048</td><td>160,224</td></tr><tr><td>All Blast categories</td><td>92,040</td><td>286,587</td><td>104,988</td><td>63,814</td></tr><tr><td>All Thermal categories</td><td>39,641</td><td>140,701</td><td>79,451</td><td>36,256</td></tr><tr><td>> 25 cal cm<sup>2 </sup>Zone</td><td>1,024</td><td>12,336</td><td>11,574</td><td>1,431</td></tr><tr><td>> 13–25 cal cm<sup>2 </sup>Zone</td><td>963</td><td>15,303</td><td>14,685</td><td>1,810</td></tr><tr><td>3rd Degree Burn Zone*</td><td>3,132</td><td>20,660</td><td>12,456</td><td>5,001</td></tr><tr><td>2nd Degree Burn Zone**</td><td>9,876</td><td>22,993</td><td>10,381</td><td>8,593</td></tr><tr><td>1<sup>st </sup>Degree Burn Zone</td><td>24,646</td><td>69,409</td><td>30355</td><td>19,421</td></tr><tr><td>All Fallout Categories where mortality > 0.5%</td><td>172,819</td><td>1,592,968</td><td>554,048</td><td>160,224</td></tr><tr><td>Mortality > 90%</td><td>80,386</td><td>429,172</td><td>252,538</td><td>46,579</td></tr><tr><td> > 50–90%</td><td>14,851</td><td>145,123</td><td>52,182</td><td>11,632</td></tr><tr><td> > 10–50%</td><td>28,335</td><td>358,922</td><td>85,807</td><td>43,970</td></tr><tr><td> > 0.5–10%</td><td>49,247</td><td>661,177</td><td>163,521</td><td>58,043</td></tr><tr><td>All Blast categories over 1psi</td><td>92,040</td><td>286,587</td><td>104,988</td><td>63,814</td></tr><tr><td>> 20psi</td><td>902</td><td>8,616</td><td>4,222</td><td>961</td></tr><tr><td>10–20psi</td><td>658</td><td>10,056</td><td>9,799</td><td>1,342</td></tr><tr><td>3–10psi</td><td>9,194</td><td>46,515</td><td>33,410</td><td>12,949</td></tr><tr><td>2–3psi ***</td><td>22,532</td><td>55,126</td><td>23,360</td><td>15,278</td></tr><tr><td>1–2psi</td><td>58,754</td><td>166,274</td><td>34,197</td><td>33,284</td></tr></table> |
6a9d8094171d1c24043f9ae56be890f4de05d8239889431e3aabf6956b7ce204.png | simple | <table><tr><td>Cluster</td><td>Observed cases</td><td>Expected Cases</td><td>RR</td><td>LLR</td><td><i>P </i>value</td></tr><tr><td>(a) Without covariate adjustment</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Most likely cluster</td><td>3388</td><td>2754.18</td><td>1.27</td><td>78.04</td><td><0.001</td></tr><tr><td>Secondary cluster 1</td><td>496</td><td>319.35</td><td>1.57</td><td>42.43</td><td><0.001</td></tr><tr><td>Secondary cluster 3</td><td>525</td><td>382.84</td><td>1.38</td><td>24.08</td><td><0.001</td></tr><tr><td>Secondary cluster 4</td><td>1992</td><td>1775.27</td><td>1.13</td><td>13.84</td><td><0.001</td></tr><tr><td>Secondary cluster 5</td><td>119</td><td>71.95</td><td>1.66</td><td>12.88</td><td><0.001</td></tr><tr><td>Not significant cluster</td><td>52</td><td>33.23</td><td>1.57</td><td>4.52</td><td>0.654</td></tr><tr><td>(b) With adjustment of race/ethnic status of population</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Most likely cluster</td><td>4550</td><td>3843.34</td><td>1.23</td><td>74.66</td><td><0.001</td></tr><tr><td>Secondary cluster 1</td><td>476</td><td>363.25</td><td>1.32</td><td>16.21</td><td><0.001</td></tr><tr><td>Not significant cluster</td><td>119</td><td>85.39</td><td>1.40</td><td>5.91</td><td>0.26</td></tr><tr><td>Not significant cluster</td><td>1209</td><td>1111.12</td><td>1.09</td><td>4.41</td><td>0.68</td></tr><tr><td>Not significant cluster</td><td>713</td><td>640.85</td><td>1.12</td><td>4.04</td><td>0.80</td></tr><tr><td>Not significant cluster</td><td>413</td><td>370.87</td><td>1.12</td><td>2.35</td><td>1.00</td></tr></table> |
eb84e2167bd5ab3791997c853a9348bb6a312271a9e27d3abdf16d403b2edc60.png | simple | <table><tr><td> </td><td> </td><td>NIHSS</td><td>MMSE</td></tr><tr><td>Man, 84 years</td><td>He fell when he put his glasses on the small table beside his bed</td><td>5</td><td>27</td></tr><tr><td>Man, 86 years</td><td>He fell on his way from the bedroom to the kitchen</td><td>2</td><td>23</td></tr><tr><td>Woman, 73 years</td><td>She fell when the door of the elevator hit her</td><td>6</td><td>29</td></tr><tr><td>Man, 77 years</td><td>The staff at his nursing home found him on the floor in the bathroom</td><td>2</td><td>20</td></tr><tr><td>Woman, 84 years</td><td>She lost the grip and fell when she tried to draw herself up from the wheelchair</td><td>6</td><td>21</td></tr><tr><td>Woman, 94 years</td><td>She fell backwards into the wheelchair but it turned over and she fell on the floor</td><td>12</td><td>15</td></tr><tr><td>Man, 89 years</td><td>He fell on his way from the bedroom to the kitchen</td><td>0</td><td>13</td></tr><tr><td>Man, 58 years</td><td>On his way from the bedroom to the front door, he stumbled on a carpet and fell</td><td>2</td><td>24</td></tr><tr><td>Man, 87 years</td><td>He was going to sit down but missed the chair and fell on the floor</td><td>8</td><td>12</td></tr><tr><td>Man, 69 years</td><td>He was going to sit down in his wheelchair but missed it and fell on the floor</td><td>4</td><td>—</td></tr><tr><td>Woman, 87 years</td><td>During the night she fell in her home</td><td>2</td><td>—</td></tr><tr><td>Man, 81 years</td><td>He arrived at the hospital after fall in her home</td><td>5</td><td>—</td></tr><tr><td>Woman, 76 years</td><td>She fell in her home and hit her hip</td><td>8</td><td>—</td></tr><tr><td>Woman, 86 years</td><td>She fell from a chair</td><td>3</td><td>—</td></tr><tr><td>Woman, 83 years</td><td>She fell during the evening and hit her hip</td><td>2</td><td>—</td></tr><tr><td>Woman, 86 years</td><td>Unspecified fall. She complained from pain in the right leg</td><td>7</td><td>—</td></tr></table> |
6191bdbeb3c7891a9c95d16ae309d183b091e9f4726b04e5063fbb741a0b5921.png | simple | <table><tr><td>Class</td><td>Subclass</td><td>Pathway</td></tr><tr><td>Biosynthesis</td><td>Polyamines</td><td>Betaine biosynthesis</td></tr><tr><td></td><td></td><td>Polyamine biosynthesis</td></tr><tr><td></td><td>Fatty acids and lipids</td><td>Phospholipid biosynthesis</td></tr><tr><td></td><td></td><td>Fatty acid biosynthesis - initial steps</td></tr><tr><td></td><td></td><td>Fatty acid elongation - saturated</td></tr><tr><td></td><td>Cofactors, prosthetic groups, electron carriers</td><td>Pyridine nucleotide biosynthesis</td></tr><tr><td></td><td></td><td>Thioredoxin pathway</td></tr><tr><td></td><td></td><td>Glutathione biosynthesis</td></tr><tr><td></td><td></td><td>Pantothenate and coenzyme A biosynthesis</td></tr><tr><td></td><td></td><td>Pyridoxal 5'-phosphate salvage pathway</td></tr><tr><td></td><td></td><td>Polyisoprenoid biosynthesis</td></tr><tr><td></td><td></td><td>FormylTHF biosynthesis</td></tr><tr><td></td><td>Cell structures</td><td>Colanic acid building blocks biosynthesis</td></tr><tr><td></td><td></td><td>GDP-mannose metabolism</td></tr><tr><td></td><td>Carbohydrates</td><td>Gluconeogenesis</td></tr><tr><td></td><td></td><td>Trehalose degradation - low osmolarity</td></tr><tr><td></td><td>Aminoacyl-tRNAs</td><td>tRNA charging pathway</td></tr><tr><td></td><td>Amino acid biosynthesis</td><td>Proline biosynthesis I</td></tr><tr><td></td><td></td><td>Glycine biosynthesis I</td></tr><tr><td></td><td></td><td>Serine biosynthesis</td></tr><tr><td>Degradation</td><td>Sugars and polysaccharides</td><td>Glucose 1-phosphate metabolism</td></tr><tr><td></td><td></td><td>Galactose metabolism</td></tr><tr><td></td><td></td><td>Trehalose degradation - low osmolarity</td></tr><tr><td></td><td></td><td>Glycogen degradation</td></tr><tr><td></td><td></td><td>Ribose degradation</td></tr><tr><td></td><td>Other degradation</td><td>Removal of superoxide radicals</td></tr><tr><td></td><td>Nucleosides and nucleotides</td><td>(Deoxy)ribose phosphate metabolism</td></tr><tr><td></td><td>Fatty acids</td><td>Fatty acid oxidation pathway</td></tr><tr><td></td><td>Carboxylates, other</td><td>Acetate degradation</td></tr><tr><td></td><td>Amino acids, amines</td><td>L-serine degradation</td></tr><tr><td></td><td>Alcohols</td><td>Glycerol metabolism</td></tr><tr><td>Energy metabolism</td><td></td><td>Pyruvate dehydrogenase</td></tr><tr><td></td><td></td><td>TCA cycle - aerobic respiration</td></tr><tr><td></td><td></td><td>Glycolysis</td></tr><tr><td></td><td></td><td>Oxidative branch of the pentose phosphate pathway</td></tr><tr><td></td><td></td><td>Nonoxidative branch of the pentose phosphate pathway</td></tr></table> |
183e5bdec20b755244ce81fa7c82dd763316b8e4aa5fe3cc7385ea21eda2a172.png | simple | <table><tr><td></td><td>Multiple sclerosis</td><td>Normal controls</td></tr><tr><td>Number</td><td><i>N</i> = 31</td><td><i>N</i> = 18</td></tr><tr><td>Age (years) (mean ± SD)</td><td>43.3 ± 8.7</td><td>43.6 ± 8.1</td></tr><tr><td>Women, number (%)</td><td>21 (68 %)</td><td>14 (78 %)</td></tr><tr><td>Disease category, number (%)</td><td></td><td></td></tr><tr><td> Relapsing-remitting</td><td>26 (84 %)</td><td>-</td></tr><tr><td> Secondary progressive</td><td>4 (13 %)</td><td>-</td></tr><tr><td> Primary progressive</td><td>1 (3 %)</td><td>-</td></tr><tr><td>Disease duration<sup>a</sup> (years) (mean ± SD)</td><td>9.0 ± 8.3</td><td>-</td></tr><tr><td>Expanded Disability Status Scale score (mean ± SD)</td><td>2.1 ± 2.1</td><td>-</td></tr><tr><td>Timed 25-foot walk (mean ± SD)</td><td>6.0 ± 5.2</td><td>-</td></tr><tr><td>T1 normalized cord area (mm<sup>2</sup>) (mean ± SD)</td><td>77.7 ± 10.6</td><td>81.4 ± 7.0</td></tr><tr><td>T2 normalized cord area (mm<sup>2</sup>) (mean ± SD)</td><td>70.2 ± 10.5</td><td>75.1 ± 9.0</td></tr></table> |
74de41c6871aade83706cdf17687df34cc88545064827358918a367d8530d919.png | complex | <table><tr><td rowspan="2"></td><td colspan="2">All</td><td colspan="2">Non-C9/GRN</td><td colspan="2"><i>C9orf72</i></td><td colspan="2"><i>GRN</i></td></tr><tr><td>pTDP-43</td><td>NeuN</td><td>pTDP-43</td><td>NeuN</td><td>pTDP-43</td><td>NeuN</td><td>pTDP-43</td><td>NeuN</td></tr><tr><td>Range</td><td>0-308.8</td><td>0-777.9</td><td>0.3-195.1</td><td>0-777.9</td><td>0-194.2</td><td>0.1-740.2</td><td>0.3-308.8</td><td>0.6-640.7</td></tr><tr><td>Median</td><td>14.0</td><td>118.6</td><td>16.3</td><td>149.8</td><td>15.1</td><td>99.4</td><td>10.1</td><td>39.6</td></tr><tr><td>Mean</td><td>28.9</td><td>148.6</td><td>30.2</td><td>190.8</td><td>25.0</td><td>126.6</td><td>39.5</td><td>110.6</td></tr><tr><td>SD</td><td>41.6</td><td>145.7</td><td>38.4</td><td>155.1</td><td>31.1</td><td>130.7</td><td>72.4</td><td>145.9</td></tr></table> |
8eb82f4cff66f2cb27ff87bc8c4cc9198d53c465c59c49c7694c2bd9b6b4732a.png | complex | <table><tr><td rowspan="2">PWM</td><td colspan="4">GATA-3 bound sequences</td><td colspan="3">GATA-3 not bound sequences</td></tr><tr><td>Total hits</td><td>TP sequences</td><td>FN</td><td>Sensitivity</td><td>Total hits</td><td>Total sequences with hits</td><td>TN</td></tr><tr><td>New-mono</td><td>45095</td><td>21289</td><td>7040</td><td>75%</td><td>39276</td><td>19760</td><td>8569</td></tr><tr><td>New-di</td><td>58409</td><td>23378</td><td>4951</td><td>83%</td><td>52897</td><td>22450</td><td>5879</td></tr><tr><td>Match_minFN</td><td>102257</td><td>27158</td><td>1171</td><td>96%</td><td>97461</td><td>27071</td><td>1258</td></tr><tr><td>Match_minFP</td><td>673</td><td>663</td><td>27666</td><td>2.38%</td><td>639</td><td>630</td><td>27699</td></tr><tr><td>Match_minSUM</td><td>14988</td><td>11436</td><td>16893</td><td>43%</td><td>12330</td><td>9846</td><td>18483</td></tr></table> |
a1d6ccec1652c4cbc56ca4dba230974b338a529ecbfacba9a5c81ba5c6433971.png | complex | <table><tr><td colspan="2">Study</td><td>Conduit</td><td colspan="2">Number of patients</td><td colspan="2">Skeletonized Group</td><td>Key Findings</td><td>Adverse Events</td></tr><tr><td>Ref</td><td>Type</td><td>RA/GEA</td><td>Skel</td><td>Control</td><td>Age (Yrs ± S.D.)</td><td>Gender M/F</td><td></td><td></td></tr><tr><td><i>Kamiya et al [13]</i></td><td>A</td><td>GEA</td><td>70</td><td>98</td><td>60 ± 9.2</td><td>51/80</td><td>Significantly increases luminal diameter Composite grafts effective for multiple grafting</td><td>No deaths 15 Atrial Fibrillation</td></tr><tr><td><i>Rukosujew et al [21]</i></td><td>A</td><td>RA</td><td>20</td><td>20</td><td>n/a</td><td>N/a</td><td>Significantly increases harvesting time Length significantly increased by skeletonization with scissors Endothelial damage seen in all groups</td><td>Not recorded</td></tr><tr><td><i>Amano et al [12]</i></td><td>B</td><td>RA</td><td>131</td><td>112</td><td>65.8 ± 8.9</td><td>102/80</td><td>Proximal diameter of RA significantly larger in skeletonized conduits Significant increase in sequential RA grafting</td><td>2 MI, 2 Respiratory Failures, 4 CVA, 2 Mediastinitis, 2 Deaths</td></tr><tr><td><i>Li et al [20]</i></td><td>C</td><td>GEA</td><td>59</td><td>21</td><td>66.7 ± 8.8</td><td>46/19</td><td>No significant difference in harvest time or number of distal anastomoses</td><td>1 CVA, 1 Respiratory Failure, 1 Death</td></tr><tr><td><i>Kamiya et al [23]</i></td><td>C</td><td>GEA</td><td>168</td><td>60</td><td>65 ± 11.5</td><td>131/47</td><td>Functional patency significantly better in skeletonized group</td><td>20 Atrial Fibrillation, 1 MI, 2 Re-exploration for bleeding</td></tr></table> |
607d28f999cfd0da8bd4c417733e0287557e380eaa3a3e5623e29f2994f7ec92.png | simple | <table><tr><td>Trial Characteristics</td><td>Percent (number) of Trials</td></tr><tr><td>Study Type</td><td></td></tr><tr><td> Individual patient RCT</td><td>76.25% (61/80)</td></tr><tr><td> Factorial RCT</td><td>6.25% (5/80)</td></tr><tr><td> Cluster RCT</td><td>17.5% (14/80)</td></tr><tr><td>Number of study arms</td><td></td></tr><tr><td> Two</td><td>83.75% (67/80)</td></tr><tr><td> Three</td><td>7.5% (6/80)</td></tr><tr><td> Four</td><td>8.75% (7/80)</td></tr><tr><td>Patient Population</td><td></td></tr><tr><td> Adults</td><td>91.25% (73/80)</td></tr><tr><td> Children</td><td>6.25% (5/80)</td></tr><tr><td> Infants</td><td>1.25% (1/80)</td></tr><tr><td> Mixed (Adults & Children)</td><td>1.25% (1/80)</td></tr><tr><td>Study Intervention</td><td></td></tr><tr><td> Drug</td><td>46.25% (37/80)</td></tr><tr><td> Surgery</td><td>8.75% (7/80)</td></tr><tr><td> Education</td><td>10.0% (8/80)</td></tr><tr><td> Other</td><td>27.5% (22/80)</td></tr><tr><td> Procedure</td><td>3.75% (3/80)</td></tr><tr><td> Weight loss</td><td>3.75% (3/80)</td></tr><tr><td>Funding Source</td><td></td></tr><tr><td> Academic</td><td>73.75% (59/80)</td></tr><tr><td> Industry</td><td>26.25% (21/80)</td></tr><tr><td>Trial start-up meeting described</td><td>8.75% YES (7/80)</td></tr><tr><td>Trial run-in phase described</td><td>8.75% YES (7/80)</td></tr><tr><td>GCP adherence reported</td><td>6.25% YES (5/80)</td></tr><tr><td>Lead Investigator reports previous research experience</td><td>62.5% YES (50/80)</td></tr><tr><td>Trial results</td><td></td></tr><tr><td> Harm</td><td>2.5% (2/80)</td></tr><tr><td> Neutral</td><td>32.5% (26/80)</td></tr><tr><td> Positive</td><td>65.0% (52/80)</td></tr><tr><td>Management structure</td><td></td></tr><tr><td> MC, SC & others (explicit structure)</td><td>26.25% (21/80)</td></tr><tr><td> MC or SC only (basic structure)</td><td>21.25% (17/80)</td></tr><tr><td> Not reported</td><td>52.8% (42/80)</td></tr></table> |
18d29053d86beac4a77c7bbb006b4c60fc6c7d4583fb4a295f57952607815b12.png | complex | <table><tr><td></td><td colspan="4">Primary cultures</td></tr><tr><td>Gene</td><td colspan="2">oJIA (n = 12)</td><td colspan="2">pJIA (n = 4)</td></tr><tr><td></td><td>Day 14</td><td>Day 21</td><td>Day 14</td><td>Day 21</td></tr><tr><td><i>Runx2</i></td><td>0.02 (0.01-0.07)</td><td>0.05 (0.02-0.11)</td><td>0.00 (0.00-0.01)</td><td>0.02 (0.00-0.05)</td></tr><tr><td><i>P </i>(vs. pJIA)</td><td>0.02</td><td>0.18</td><td></td><td></td></tr><tr><td><i>P </i>(vs. day 21)</td><td>0.20</td><td></td><td>0.34</td><td></td></tr><tr><td><i>OPG</i></td><td>1.63 (0.39-5.65)</td><td>13.99 (8.22-21.82)</td><td>0.68 (0.40-1.48)</td><td>1.52 (0.50-5.68)</td></tr><tr><td><i>P </i>(vs. pJIA)</td><td>0.47</td><td>0.03</td><td></td><td></td></tr><tr><td><i>P </i>(vs. day 21)</td><td>0.001</td><td></td><td>0.49</td><td></td></tr><tr><td><i>RANKL</i></td><td>0.08 (0.00-0.16)</td><td>0.18 (0.04-0.50)</td><td>0.12 (0.03-0.20)</td><td>0.16 (0.06-0.20)</td></tr><tr><td><i>P </i>(vs. pJIA)</td><td>0.54</td><td>0.90</td><td></td><td></td></tr><tr><td><i>P </i>(vs. day 21)</td><td>0.42</td><td></td><td>0.89</td><td></td></tr><tr><td></td><td colspan="4">P4 cultures</td></tr><tr><td></td><td colspan="2">oJIA (n = 7)</td><td colspan="2">pJIA (n = 4)</td></tr><tr><td></td><td>Day 10</td><td>Day 14</td><td>Day 10</td><td>Day 14</td></tr><tr><td><i>Runx2</i></td><td>0.04 (0.02-0.08)</td><td>0.03 (0.02-0.05)</td><td>0.02 (0.01-0.02)</td><td>0.02 (0.01-0.03)</td></tr><tr><td><i>P </i>(vs. pJIA)</td><td>0.02</td><td>0.32</td><td></td><td></td></tr><tr><td><i>P </i>(vs. day14)</td><td>0.46</td><td></td><td>0.20</td><td></td></tr><tr><td><i>OPG</i></td><td>0.07 (0.04-0.08)</td><td>0.12 (0.08-0.20)</td><td>0.04 (0.01-0.06)</td><td>0.04 (0.01-0.06)</td></tr><tr><td><i>P </i>(vs. pJIA)</td><td>0.23</td><td>0.01</td><td></td><td></td></tr><tr><td><i>P </i>(vs. day14)</td><td>0.04</td><td></td><td>0.89</td><td></td></tr><tr><td><i>RANKL</i></td><td>0.01 (0.01-0.03)</td><td>0.01 (0.01-0.04)</td><td>0.00 (0.00-0.00)</td><td>0.01 (0.00-0.01)</td></tr><tr><td><i>P </i>(vs. pJIA)</td><td>0.04</td><td>0.23</td><td></td><td></td></tr><tr><td><i>P </i>(vs. day14)</td><td>0.53</td><td></td><td>0.06</td><td></td></tr></table> |
0c6dfc850c825e5b3c181348c78e98bd510608b9a7e76a78647f949003762996.png | simple | <table><tr><td>Transmission route</td><td>Cases (n = 30)</td><td>Controls(n = 50)</td><td>Odds ratio</td><td>95% Confidence intervals</td><td><i>P</i> value</td></tr><tr><td>Blood transfusion (without proper screening)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> • Yes</td><td>11</td><td>7</td><td>3.56</td><td>1.061–12.220</td><td>0.038</td></tr><tr><td> • No</td><td>19</td><td>43</td><td>1.00</td><td>(Reference)</td><td></td></tr><tr><td>Mutual sharing of house hold contents</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> • Yes</td><td>25</td><td>42</td><td>7.50</td><td>2.217–26.946</td><td>0.0001</td></tr><tr><td> • No</td><td>05</td><td>08</td><td>1.00</td><td>(Reference)</td><td></td></tr><tr><td>Surgery history</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> • Positive</td><td>9</td><td>5</td><td>3.86</td><td>1.009–15.374</td><td>0.048</td></tr><tr><td> • Negative</td><td>21</td><td>45</td><td>1.00</td><td>(Reference)</td><td></td></tr><tr><td>Dental treatment</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td> • Yes</td><td>12</td><td>11</td><td>3.87</td><td>1.192–12.827</td><td>0.021</td></tr><tr><td> • No</td><td>18</td><td>39</td><td>1.00</td><td>(Reference)</td><td></td></tr></table> |
b73c4930b564bcfdee295ca6ef67a38cb584d372080d92135813d1a22ba5d04e.png | simple | <table><tr><td>Targeted protein</td><td>Peptide number</td><td>Sequence</td><td>Specificity Tm.I/Tm.II<sup>#</sup></td><td>Global proteomics 2007 study (Bertin et al., 2011)</td><td>Cell cultures</td><td>2007 COWG</td><td>2009 COWG</td><td>2009 COWG</td><td>2011 COWG</td><td>2012 COWG</td></tr><tr><td>AioA</td><td>1</td><td>ACVVNQGLSSTR</td><td>Tm.I/Tm.II</td><td>X</td><td>CB1, CB2, CB3, CB6</td><td>X</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>2</td><td>IQIFPAK</td><td>Tm.II (Carn2_0821 only)<sup>*</sup></td><td>X</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>3</td><td>DFIANHTEGFDAAVK</td><td>Tm.II (Carn2_1469 only)<sup>*</sup></td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>4</td><td>DFIANHTEGFEAAVK</td><td>Tm.II (Carn2_0821, Carn2_1330)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>5</td><td>FWINNGR</td><td>Tm.I/Tm.II</td><td>X</td><td>CB1, CB2, CB6</td><td>X</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>6</td><td>YPAADFPIPR</td><td>Tm.I/Tm.II</td><td>X</td><td>CB1, CB2, CB3, CB6</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td></td><td>7</td><td>YPASSVPIPR</td><td><i>T. intermedia</i> K12 (Tm.I)</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>8</td><td>DFIAQHTEGFEAAVK</td><td>Tm.I</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>9</td><td>IQVFPAK</td><td>Tm.I/Tm.II</td><td>–</td><td>CB1, CB2, CB3, CB6</td><td>X</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>10</td><td>ITGVPVAQIK</td><td>Tm.I/Tm.II</td><td>X</td><td>CB1, CB2, CB3, CB6</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td></td><td>11</td><td>LIFTGIQTPTVR</td><td>Tm.I/Tm.II</td><td>X</td><td>CB2, CB3, CB6</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>AioB</td><td>12</td><td>AVAVTGLIYGR</td><td>Tm.I/Tm.II</td><td>X</td><td>CB1, CB6</td><td>X</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td>RpoA</td><td>13</td><td>SETELLK</td><td>Tm.I/Tm.II</td><td>–</td><td>CB1, CB2, CB3, CB6</td><td>X</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>14</td><td>SIGHIVLDASFSPVR</td><td>Tm.I</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr><tr><td></td><td>15</td><td>SIQVEALGPLR</td><td>Tm.II</td><td>X</td><td>–</td><td>–</td><td>X</td><td>X</td><td>X</td><td>X</td></tr><tr><td></td><td>16</td><td>SIQVESLGHNR</td><td>Tm.I</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td><td>–</td></tr></table> |
59bd3bb6c26cf372f936d6d7a85256ec398adf826e424b556e9a99a304a47d51.png | simple | <table><tr><td></td><td>No type 2 diabetes (<i>n</i> = 609)</td><td>Type 2 diabetes (<i>n</i> = 253)</td><td><i>p</i>-value</td></tr><tr><td>Age, years</td><td>58 ± 8.6</td><td>64 ± 7.0</td><td>< 0.001</td></tr><tr><td>Male sex, n (%)</td><td>296 (49 %)</td><td>176 (70 %)</td><td>< 0.001</td></tr><tr><td>Partner, n (%)</td><td>515 (85 %)</td><td>208 (85 %)</td><td>0.98</td></tr><tr><td>Educational level, % low/middle/high</td><td>12/39/49</td><td>28/47/25</td><td><0.001</td></tr><tr><td>HbA1c, %</td><td>5.65 ± 0.37</td><td>6.91 ± 0.88</td><td>< 0.001</td></tr><tr><td>Diabetes duration, years</td><td>-</td><td>7 [3–11]</td><td></td></tr><tr><td>Diabetes medication, % no/oral/insulin</td><td>-</td><td>22/57/21</td><td></td></tr><tr><td>Smoking, % never/former/current</td><td>34/49/17</td><td>22/64/14</td><td></td></tr><tr><td> Pack years</td><td>4 [0–18]</td><td>15 [0–33]</td><td>< 0.001</td></tr><tr><td>Body mass index, kg/m<sup>2</sup></td><td>26.3 ± 4.0</td><td>29.8 ± 4.7</td><td>< 0.001</td></tr><tr><td>Systolic blood pressure, mmHg</td><td>133 ± 18</td><td>146 ± 19</td><td>< 0.001</td></tr><tr><td>Diastolic blood pressure, mmHg</td><td>76 ± 10</td><td>78 ± 10</td><td>0.004</td></tr><tr><td>Total cholesterol, mmol/l</td><td>5.5 ± 1.1</td><td>4.4 ± 1.0</td><td>< 0.001</td></tr><tr><td>HDL cholesterol, mmol/l</td><td>1.40 ± 0.41</td><td>1.12 ± 0.40</td><td>< 0.001</td></tr><tr><td>LDL cholesterol, mmol/l</td><td>3.5 ± 1.0</td><td>2.6 ± 0.9</td><td>< 0.001</td></tr><tr><td>Triglycerides, mmol/l</td><td>1.3 ± 0.9</td><td>1.8 ± 1.0</td><td>< 0.001</td></tr></table> |
9847b4a38334ad81432b0904a509fae2f7ac25a81085c88f6e8cc5f458c04865.png | complex | <table><tr><td>Primary clinical diagnostic category</td><td>All diagnoses included in primary clinical diagnostic categories</td></tr><tr><td rowspan="2">I. Non-Proliferative*</td><td>Non-Proliferative only</td></tr><tr><td>Fibroadenoma</td></tr><tr><td rowspan="6">II. Proliferative changes without atypia</td><td>Usual ductal hyperplasia</td></tr><tr><td>Columnar cell hyperplasia/columnar cell changes</td></tr><tr><td>Sclerosing adenosis</td></tr><tr><td>Radial Scar/complex sclerosing lesion</td></tr><tr><td>Flat epithelial atypia</td></tr><tr><td>Intraductal papilloma w/o atypia</td></tr><tr><td rowspan="2">III. Atypical ductal hyperplasia (ADH)</td><td>Atypical ductal hyperplasia</td></tr><tr><td>Intraductal papilloma with atypia</td></tr><tr><td>IV. Ductal carcinoma in situ (DCIS)</td><td>Ductal carcinoma in situ</td></tr><tr><td>V. Invasive breast cancer</td><td>Invasive (ductal or lobular or other special type)</td></tr></table> |
ab6e7c5f31ef77194822946838d7cf53772eedbbdb1af4b20f115b3278c5aaeb.png | simple | <table><tr><td>Genotype</td><td>Case Number</td><td>Percentage (%)</td></tr><tr><td>CYP2D6*2</td><td>74</td><td>100</td></tr><tr><td> CC</td><td>59</td><td>79.7</td></tr><tr><td> CT</td><td>9</td><td>12.1</td></tr><tr><td> TT</td><td>6</td><td>8.1</td></tr><tr><td>CYP2D6*10</td><td>83</td><td>100</td></tr><tr><td> CC</td><td>16</td><td>19.3</td></tr><tr><td> CT</td><td>8</td><td>9.6</td></tr><tr><td> TT</td><td>59</td><td>71.1</td></tr><tr><td>CYP1A2*1C</td><td>66</td><td>100</td></tr><tr><td> GG</td><td>38</td><td>59.6</td></tr><tr><td> GA</td><td>21</td><td>31.8</td></tr><tr><td> AA</td><td>7</td><td>10.6</td></tr><tr><td>CYP1A2*1 F</td><td>77</td><td>100</td></tr><tr><td> CC</td><td>33</td><td>42.9</td></tr><tr><td> CA</td><td>11</td><td>14.3</td></tr><tr><td> AA</td><td>33</td><td>42.9</td></tr></table> |
1a4ec138716c69fca8e1092d27cdee0adf45568d5fe2aa3fc93d57ce609a8599.png | complex | <table><tr><td></td><td colspan="2">Univariate analysis</td><td colspan="2">Multivariate analysis</td></tr><tr><td></td><td>HR (95 % CI)</td><td><i>P</i>-value</td><td>HR (95 % CI)</td><td><i>P</i>-value</td></tr><tr><td>Control</td><td colspan="4">Reference</td></tr><tr><td>HBV</td><td>1.291 (0.635-2.624)</td><td>0.481</td><td>1.321 (0.612-2.850)</td><td>0.479</td></tr><tr><td>HCV</td><td>3.425 (1.752-6.697)</td><td><0.001</td><td>2.623 (1.289-5.338)</td><td>0.008</td></tr><tr><td>HBV+HCV</td><td>9.273 (2.793-30.788)</td><td><0.001</td><td>9.401 (2.691-32.841)</td><td><0.001</td></tr><tr><td>Age, per year</td><td>1.025 (1.007-1.043)</td><td>0.005</td><td>1.034 (1.013-1.054)</td><td>0.001</td></tr><tr><td>HCC</td><td>3.361 (1.212-9.322)</td><td>0.020</td><td>1.790 0.598-5.356)</td><td>0.298</td></tr><tr><td>Baseline LFTAbnormality<sup>a</sup></td><td>2.702 (1.526-4.784)</td><td>0.001</td><td>2.331 (1.238-4.390)</td><td>0.009</td></tr></table> |
f99690ec84e850d151b440e05bff54ee2254e02587fb2a41daf56abdbe140a81.png | simple | <table><tr><td>Feature</td><td><i>FluxTransgenics</i></td><td><i>Phytotracker</i></td><td><i>QTreds</i></td></tr><tr><td>Operational system</td><td>Web Application, can be accessed from any OS.</td><td>Mac OS or Microsoft Windows.</td><td>Web Application, can be accessed from any OS.</td></tr><tr><td>Data storage</td><td>MySQL Relational Database.</td><td>FileMaker Pro.</td><td>MySQL Relational Database.</td></tr><tr><td>Process support</td><td>Most laboratory processes. Adaptable to any workflow.</td><td>Pre-defined workflow.</td><td>Adaptable to any workflow.</td></tr><tr><td>Access control</td><td>Permissions are granted to user or roles. Roles, or groups, can be created by administrator user.</td><td>Permissions are granted only to users. The concept of roles is non existent.</td><td>Permissions are granted to user or roles. But the roles are fixed (cannot be created).</td></tr></table> |
1f4ec984d1ce2132349d6f69acee5a9919b1356f48bb743628c800f4c78cf08f.png | complex | <table><tr><td>Genetic characteristic</td><td>Frequency,%</td></tr><tr><td colspan="2"><i>VKORC1</i> (N = 96)</td></tr><tr><td colspan="2"> Gene</td></tr><tr><td>GG (wild type)</td><td>84 (87.5)</td></tr><tr><td>GA</td><td>12 (12.5)</td></tr><tr><td>AA</td><td>–</td></tr><tr><td colspan="2"> Allele</td></tr><tr><td>G</td><td>180 (93.8)</td></tr><tr><td>A</td><td>12 (6.2)</td></tr><tr><td colspan="2"><i>CYP4F2</i> (N = 116)</td></tr><tr><td colspan="2"> Gene</td></tr><tr><td>CC (wild type)</td><td>28 (24.1)</td></tr><tr><td>CT</td><td>80 (69.0)</td></tr><tr><td>TT</td><td>8 (6.9)</td></tr><tr><td colspan="2"> Allele</td></tr><tr><td>C</td><td>136 (58.6)</td></tr><tr><td>T</td><td>96 (41.4)</td></tr><tr><td colspan="2"><i>CYP2C9*2</i> (N = 86)</td></tr><tr><td colspan="2"> Gene</td></tr><tr><td>CC (wild type)</td><td>86 (100)</td></tr><tr><td>CT</td><td>–</td></tr><tr><td>TT</td><td>–</td></tr><tr><td colspan="2"> Allele</td></tr><tr><td>C</td><td>172 (100)</td></tr><tr><td>T</td><td>–</td></tr><tr><td colspan="2"><i>CYP2C9*3</i> (N = 84)</td></tr><tr><td colspan="2"> Gene</td></tr><tr><td>AA (wild type)</td><td>84 (100)</td></tr><tr><td>AC</td><td>–</td></tr><tr><td>CC</td><td>–</td></tr><tr><td colspan="2"> Allele</td></tr><tr><td>A</td><td>168 (100)</td></tr><tr><td>C</td><td>–</td></tr></table> |
01d33ba53168ecf20108cc7ea7ee5ab120eeb2a5d970427bf2d6e45dd536bc65.png | complex | <table><tr><td>Variable</td><td>PC1</td><td>PC2</td><td>PC3</td></tr><tr><td>Feeding score in glass-house (Day 7)</td><td>0.278</td><td>–0.245</td><td>0.065</td></tr><tr><td>Feeding score in glass-house (Day 13)</td><td>0.239</td><td>–0.305</td><td>0.014</td></tr><tr><td><i>In vitro</i> M-C feeding damage (12 h)</td><td>0.175</td><td>0.003</td><td>–0.304</td></tr><tr><td><i>In vitro</i> T-C feeding damage (12 h)</td><td>0.235</td><td>–0.018</td><td>0.237</td></tr><tr><td>Glucoiberin</td><td>–0.265</td><td>0.194</td><td>0.221</td></tr><tr><td>Progoitrin</td><td>0.247</td><td>0.372</td><td>–0.070</td></tr><tr><td>Glucoraphanin</td><td>0.286</td><td>–0.019</td><td>0.328</td></tr><tr><td>Sinigrin</td><td>–0.172</td><td>0.318</td><td>0.342</td></tr><tr><td>Gluconapin</td><td>0.227</td><td>–0.201</td><td>0.411</td></tr><tr><td>Glucoiberverin</td><td>–0.233</td><td>0.242</td><td>0.264</td></tr><tr><td>Glucoerucin</td><td>0.295</td><td>0.274</td><td>–0.046</td></tr><tr><td>4-Hydroxyglucobrassicin</td><td>0.296</td><td>0.266</td><td>0.027</td></tr><tr><td>Glucobrassicin</td><td>–0.288</td><td>0.145</td><td>0.092</td></tr><tr><td>4-Methoxyglucobrassicin</td><td>–0.087</td><td>–0.097</td><td>0.494</td></tr><tr><td>Neoglucobrassicin</td><td>0.177</td><td>–0.228</td><td>0.250</td></tr><tr><td>Total glucosinolate</td><td>0.257</td><td>0.352</td><td>0.099</td></tr><tr><td>% Variation explained</td><td>48.2</td><td>20.3</td><td>13.0</td></tr><tr><td><i>P</i>-value</td><td><0.001</td><td><0.001</td><td><0.001</td></tr><tr><td>Cabbage lines</td><td colspan="3">Mean PC scores (±SD)</td></tr><tr><td>Rubra</td><td>1.71 ± 0.51 b</td><td>–2.23 ± 0.18 e</td><td>1.67 ± 0.42 a</td></tr><tr><td>YR gold</td><td>3.61 ± 0.60 a</td><td>2.29 ± 0.37 a</td><td>–0.34 ± 0.65 b</td></tr><tr><td>Ohgane</td><td>–1.30 ± 0.14 cd</td><td>–1.17 ± 0.03 d</td><td>–1.87 ± 0.23 c</td></tr><tr><td>BN3383</td><td>–0.34 ± 0.28 c</td><td>–1.35 ± 0.05 d</td><td>–2.05 ± 0.63 c</td></tr><tr><td>BN4059</td><td>–4.66 ± 0.38 g</td><td>2.57 ± 0.23 a</td><td>2.15 ± 0.16 a</td></tr><tr><td>BN4072</td><td>–2.33 ± 0.11 de</td><td>0.09 ± 0.06 c</td><td>–0.25 ± 0.31 b</td></tr><tr><td>BN4098</td><td>–2.97 ± 0.15 ef</td><td>0.05 ± 0.13 c</td><td>0.33 ± 0.04 b</td></tr><tr><td>BN4303</td><td>–4.00 ± 0.04 fg</td><td>0.96 ± 0.03 b</td><td>–0.25 ± 0.36 b</td></tr></table> |
1fee6d6f2421fd84c7c3978f682eb696fc8da934739a91a136ca1d224bbf59cd.png | complex | <table><tr><td></td><td>ASAQ</td><td>AL</td></tr><tr><td>No. of included patients (intention-to-treat)</td><td>62</td><td>61</td></tr><tr><td colspan="3">PCR-uncorrected responses on day 28</td></tr><tr><td> Withdrawn or lost to follow up: N; % (95 % CI)</td><td>7; 11.3 (4.7–21.9)</td><td>9; 14.8 (7.0–26.2)</td></tr><tr><td> Per protocol population: N; % (95 % CI)</td><td>55; 88.7 (78.1–95.3)</td><td>52; 85.2 (73.8–93.0)</td></tr><tr><td> Failures: N; % (95 % CI)</td><td>4; 7.3 (2.0–17.6)</td><td>4; 7.7 (2.1–18.5)</td></tr><tr><td> ETF: N; % (95 % CI)</td><td>0; 0 (0–5.8)</td><td>1; 1.9 (0–10.3)</td></tr><tr><td> LCF: N; % (95 % CI)</td><td>1; 1.8 (0–9.7)</td><td>1; 1.9 (0–10.3)</td></tr><tr><td> LPF : N; % (95 % CI)</td><td>3; 5.5 (1.1–15.1)</td><td>2; 3.8 (0.5–13.2)</td></tr><tr><td> ACPR: N; % (95 % CI)</td><td>51; 92.7 (82.4–98.0)</td><td>48; 92.3 (81.5–97.9)</td></tr><tr><td colspan="3">PCR-corrected responses on day 28</td></tr><tr><td> Withdrawn + lost-to-follow-up + censured due to new infections: N; % (95 % CI)</td><td>11; 17.7 (9.2–29.5)</td><td>12; 19.7 (10.6–31.8)</td></tr><tr><td> Per protocol population: N; % (95 % CI)</td><td>51; 82.3 (70.5–90.8)</td><td>49; 80.3 (68.2–89.4)</td></tr><tr><td> ETF: N; % (95 % CI)</td><td>0; 0 (0–7.0)</td><td>1; 2.0 (0.1–10.9)</td></tr><tr><td> Recrudescence: N; % (95 % CI)</td><td>0; 0 (0–7.0)</td><td>0; 0 (0–7.2)</td></tr><tr><td> ACPR: N; % (95 % CI)</td><td>51; 100 (93.0–100)</td><td>48; 98.0 (89.1–99.9)</td></tr><tr><td> New infections: n/N (%)</td><td>4/4 (100)</td><td>3/3 (100)</td></tr></table> |
3462aef9a8f46995606d533d610414563f161f6489d35a6084e9d67aa98b25bc.png | simple | <table><tr><td></td><td><1 y</td><td>1-4 y</td><td>5-9 y</td><td>10-14 y</td><td>15-19 y</td><td>20-29 y</td><td><underline>></underline>30 y</td></tr><tr><td></td><td>n=62 (%)</td><td>n=75 (%)</td><td>n=10 (%)</td><td>n=9 (%)</td><td>n=35</td><td>n=41</td><td>n=52</td></tr><tr><td>Bronchopneumonia (n=227)</td><td>46 (74.2%)</td><td>61 (81.3%)</td><td>9 (90.0%)</td><td>7 (77.8%)</td><td>29 (82.9%)</td><td>35 (85.4%)</td><td>40 (76.9%)</td></tr><tr><td>Diarrhea (n=111)</td><td>33 (53.2%)</td><td>32 (42.7%)</td><td>3 (30.0%)</td><td>3 (33.3%)</td><td>8 (22.9%)</td><td>12 (29.3%)</td><td>20 (38.5%)</td></tr><tr><td>Cough with expectoration (n=32)</td><td>1 (1.6%)</td><td></td><td></td><td></td><td>6 (17.1%)</td><td>12 (29.3%)</td><td>13 (25.0%)</td></tr><tr><td>Otitis (n=8)</td><td>4 (6.4%)</td><td>3 (4.0%)</td><td></td><td></td><td></td><td></td><td>1 (1.9%)</td></tr><tr><td>Laringitis (n=8)</td><td>1 (1.6%)</td><td>1 (1.3%)</td><td></td><td></td><td>1 (2.9%)</td><td>3 (7.3%)</td><td>2 (3.8%)</td></tr><tr><td>Febrile convulsions (n=4)</td><td></td><td>4 (5.3%)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Epistaxis (n=2)</td><td></td><td></td><td></td><td></td><td></td><td>2 (4.9%)</td><td></td></tr><tr><td>Chronic bronchitis (n=5)</td><td>3 (4.8%)</td><td>2 (2.7%)</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Asthma (n=4)</td><td>1 (1.6%)</td><td>1 (1.3%)</td><td></td><td></td><td></td><td></td><td>2 (3.8%)</td></tr><tr><td>Epilepsy (n=2)</td><td></td><td>1 (1.3%)</td><td></td><td>1 (11.1%)</td><td></td><td></td><td></td></tr><tr><td>Psychomotor retardation (n=2)</td><td></td><td>1 (1.3%)</td><td></td><td></td><td></td><td>1 (2.4%)</td><td></td></tr><tr><td>Pregnancy (n=9)</td><td></td><td></td><td></td><td></td><td></td><td>6 (14.6%)</td><td>3 (5.8%)</td></tr></table> |
2e7ff15644a74cef39d85b051f5823973fe5f35d5cad506a63bdc036c59ae6de.png | complex | <table><tr><td></td><td></td><td>SKO</td></tr><tr><td colspan="2">WASI matrix reasoning</td><td>18/32 (<i>T</i> = 49)</td></tr><tr><td colspan="2">Digit span forwards</td><td>3 digits</td></tr><tr><td colspan="2">Repetition</td><td>63/90</td></tr><tr><td colspan="2">Reading [from Brown and Ure (1969)]</td><td>11/72</td></tr><tr><td colspan="2">Graded non-word reading test</td><td>0/20</td></tr><tr><td colspan="3">Spoken non-word–written non-word match</td></tr><tr><td colspan="2">Level I (e.g., bep-civ)</td><td>7/10</td></tr><tr><td colspan="2">Level II (e.g., bem-bav)</td><td>5/10</td></tr><tr><td colspan="2">British picture vocabulary scale (short)</td><td>26/32</td></tr><tr><td colspan="3">Pyramid and palm trees test</td></tr><tr><td colspan="2">3 pictures</td><td>45/52</td></tr><tr><td colspan="2">3 written words</td><td>34/52</td></tr><tr><td colspan="3">McKenna and Warrington (1978)</td></tr><tr><td>Naming</td><td>Animals</td><td>3/10 (30%)</td></tr><tr><td></td><td>Man-made artifacts</td><td>3/10 (30%)</td></tr><tr><td></td><td>Colors</td><td>2/10 (20%)</td></tr><tr><td></td><td>Body part</td><td>3/10 (30%)</td></tr><tr><td></td><td>Countries</td><td>9/10 (90%)</td></tr><tr><td></td><td>TOTAL</td><td>20/50 (40%)</td></tr><tr><td>Comprehension</td><td>Animals</td><td>10/10 (100%)</td></tr><tr><td></td><td>Man-made artifacts</td><td>10/10 (100%)</td></tr><tr><td></td><td>Colors</td><td>7/10 (70%)</td></tr><tr><td></td><td>Body part</td><td>6/10 (60%)</td></tr><tr><td></td><td>Countries</td><td>10/10 (100%)</td></tr><tr><td></td><td>TOTAL</td><td>43/50 (86%)</td></tr></table> |
d07bcbebdd8e571392f03ab36bca8eee19f386433aca270ae47be86af062cb6c.png | complex | <table><tr><td>Flow type</td><td>The flow is fast and in vasculitis direction and velocity are important for diagnosis</td></tr><tr><td rowspan="6">PRF and wall filters</td><td>Different PRF for different vessels:</td></tr><tr><td> Temporal and facial arteries, PRF range = 2–3.5 kHz</td></tr><tr><td> Carotis, subclavian and axillary arteries, PRF range = 3–4 kHz</td></tr><tr><td> Vertebral and occipital arteries, PRF range = 0.7–1.5 kHz</td></tr><tr><td>High PRF ensures display of correct flow direction and velocity</td></tr><tr><td>Wall filters are linked controls and with a high PRF, the wall filter will also be high to eliminate motion artefacts from moving arterial walls</td></tr><tr><td rowspan="2">Choice of Doppler</td><td>CD as it displays the mean blood velocity</td></tr><tr><td>Spectral Doppler for indicating correct insonation angle and for calculating the correct velocity of the flow</td></tr><tr><td rowspan="2">Doppler frequency</td><td>Optimal frequency varies according to the location of the vessel</td></tr><tr><td>Higher for temporal arteries lower for the larger arteries because of penetration</td></tr><tr><td>Gain</td><td>Gain should be adjusted according to noise level for both CD and spectral Doppler but with a minimum of blooming</td></tr><tr><td>Colour priority</td><td>If adjustable, then it should be kept high to ensure Doppler filling in the vessel</td></tr><tr><td>Focus</td><td>At the level of region of interest to ensure optimal Doppler sensitivity</td></tr></table> |
31067e64d14ff2d446f556899fea913262bf5f2be2f98c40ea208bfc53a5aed6.png | complex | <table><tr><td>Parameter</td><td colspan="3">Logistic Regression</td></tr><tr><td></td><td>Odds Ratio</td><td>95% CI</td><td><i>P</i>-value</td></tr><tr><td>Women's age (years)</td><td>0.96</td><td>0.87 to 1.06</td><td>0.44</td></tr><tr><td>Men's age (years)</td><td>0.98</td><td>0.91 to 1.05</td><td>0.61</td></tr><tr><td>Duration of infertility (years)</td><td>0.81</td><td>0.63 to 1.03</td><td>0.10</td></tr><tr><td>MSOME (%)-Normal spermatozoa</td><td>1.28</td><td>1.08 to 1.51</td><td>0.003</td></tr><tr><td>Follicles ≥17 mm (n)</td><td>1.40</td><td>0.53 to 3.68</td><td>0.49</td></tr><tr><td>DNA fragmentation (%)</td><td>0.97</td><td>0.97 to 1.02</td><td>0.26</td></tr><tr><td>Total sperm count (x10<sup>6</sup>/ml)</td><td>1.00</td><td>0.99 to 1.01</td><td>0.59</td></tr><tr><td>Motility (% spermatozoa)(rapid + slow progression)</td><td>0.98</td><td>0.96 to 1.01</td><td>0.13</td></tr><tr><td>Leukocytes (x10<sup>6</sup>) (mean ± SD)</td><td>1.77</td><td>0.46 to 6.70</td><td>0.39</td></tr></table> |
aa9dd60931b0a61abb2fa9785792c2c1a834330ec1e11b810471e7ad86ecacf7.png | simple | <table><tr><td>Facilitators</td><td>N</td><td>Barriers</td><td>N</td></tr><tr><td>Concern over impacts of smoking on children’s health</td><td>22</td><td>Light smoking</td><td>10</td></tr><tr><td>Economic concern</td><td>20</td><td>Refusal of use of smoking cessation aids</td><td>9</td></tr><tr><td>Different smoking environment between China and Canada</td><td>22</td><td>Having friends or colleagues who smoke</td><td>7</td></tr><tr><td>Smoking cessation supports from wives and other people</td><td>14</td><td>Difficulty in getting rid of the habit</td><td>6</td></tr><tr><td>Smoking cessation supports from health professionals</td><td>8</td><td>The need for coping stress, and killing time</td><td>8</td></tr><tr><td>Concern over impacts of smoking on own health</td><td>11</td><td></td><td></td></tr></table> |
bd886b527a29e7039a3d37ce375faf26451bebe6e21e9577b4f60435c000eb92.png | simple | <table><tr><td>Position and academic responsibility</td><td>All (n = 993)</td><td>Community-based (n = 294)</td><td>DGH-based (n = 412)</td><td>Tertiary (n = 279)</td></tr><tr><td>Consultants</td><td>84%</td><td>60%</td><td>96%</td><td>96%</td></tr><tr><td>Non-consultant career grades</td><td>12%</td><td>34%</td><td>4%</td><td>1%</td></tr><tr><td>Other positions</td><td>4%</td><td>6%</td><td>1%</td><td>4%</td></tr><tr><td>With academic responsibility</td><td>18%</td><td>9%</td><td>10%</td><td>36%</td></tr></table> |
8cc32d3d165041fa11f24d791ea564d67d9d850bf6b9c13c542db60ff1787823.png | complex | <table><tr><td>Parameter</td><td><i>n</i> (%)</td></tr><tr><td colspan="2">Operational procedure</td></tr><tr><td> TEA</td><td>22 (40.7)</td></tr><tr><td> Thrombectomy/embolectomy</td><td>14 (25.9)</td></tr><tr><td> Bypass</td><td>13 (24.1)</td></tr><tr><td> Resection of the dissection membrane</td><td>11 (20.3)</td></tr><tr><td> SMA-transposition</td><td>7 (13.0)</td></tr><tr><td> Visceral surgery</td><td>8 (14.8)</td></tr><tr><td> Explorative laparotomy</td><td>3 (5.6)</td></tr><tr><td colspan="2">Cause of occlusion</td></tr><tr><td> Arterial embolism</td><td>16 (29.6)</td></tr><tr><td> Arteriosclerosis combined with local thrombosis</td><td>13 (24.0)</td></tr><tr><td> Arterial thrombosis</td><td>12 (22.2)</td></tr><tr><td> Arterial dissection</td><td>9 (16.7)</td></tr><tr><td> Local dissection</td><td>2 (3.7)</td></tr><tr><td> Unclear cause of occlusion</td><td>2 (3.7)</td></tr></table> |
f9e7bbf645d7597be474da3d53c79b620c7d724a765d90b5743dda526d316413.png | complex | <table><tr><td rowspan="3">DNA Source</td><td colspan="8">Position in MYD88 Exon 5 Amplicon</td></tr><tr><td colspan="2">19t</td><td colspan="2">+58g</td><td colspan="2">+1245a</td><td colspan="2">+1524t</td></tr><tr><td>SMRT</td><td>Illumina</td><td>SMRT</td><td>Illumina</td><td>SMRT</td><td>Illumina</td><td>SMRT</td><td>Illumina</td></tr><tr><td>Tumor DLBCL773</td><td>8t + 65C</td><td>8t + 22C</td><td>73g</td><td>All g</td><td>3a + 70G</td><td>1G</td><td>73t</td><td>No reads</td></tr><tr><td>Tumor DLBCL778</td><td>17t + 73C</td><td>5t + 44C</td><td>90g</td><td>All g</td><td>90a</td><td>No reads</td><td>90t</td><td>No reads</td></tr><tr><td>Tumor DLBCL799</td><td>26t + 29C</td><td>16t + 21C</td><td>37g + 18T</td><td>5g + 4T</td><td>55a</td><td>No reads</td><td>55t</td><td>No reads</td></tr><tr><td>Tumor DLBCL816</td><td>88t + 19C</td><td>8t + 3C</td><td>107g</td><td>All g</td><td>53a + 54G</td><td>No reads</td><td>107t</td><td>No reads</td></tr><tr><td>Tumor DLBCL894</td><td>165t + 50C</td><td>27t + 14C</td><td>215g</td><td>All g</td><td>315a</td><td>No reads</td><td>315t</td><td>No reads</td></tr><tr><td>Tumor DLBCL832</td><td>75t</td><td>All t</td><td>75g</td><td>All g</td><td>75a</td><td>No reads</td><td>75t</td><td>No reads</td></tr><tr><td>Cell line Ly3</td><td>79C</td><td>2t + 10C</td><td>79g</td><td>All g</td><td>79G</td><td>No reads</td><td>63t + 16A</td><td>No reads</td></tr><tr><td>Cell line Ly10</td><td>16t + 28C</td><td>7t + 5C</td><td>44g</td><td>All g</td><td>16a + 28G</td><td>No reads</td><td>44t</td><td>No reads</td></tr><tr><td>Cell line SKI</td><td>310t</td><td>All t</td><td>310g</td><td>All g</td><td>151a + 159G</td><td>No reads</td><td>310t</td><td>No reads</td></tr><tr><td>Cell line Karpas422</td><td>11t</td><td>All t</td><td>11g</td><td>All g</td><td>11a</td><td>No reads</td><td>11t</td><td>2t</td></tr><tr><td>Cell line Ly1</td><td>121t</td><td>All t</td><td>121g</td><td>All g</td><td>121a</td><td>No reads</td><td>121t</td><td>No reads</td></tr></table> |
af5aefe0ba4cfe0308cfcba9755a7ad5314fb71dd345f2d99184df5cc58738be.png | simple | <table><tr><td></td><td>Placebo</td><td>Rapid CORT</td><td>Slow CORT</td></tr><tr><td>Reaction times neutral, in ms</td><td>674(17)</td><td>702(23)</td><td>650(20)</td></tr><tr><td>Reaction times aversive, in ms</td><td>687(17)</td><td>709(23)</td><td>664(20)</td></tr><tr><td>Emotional interference on reaction times, in Δms</td><td>12(7)</td><td>7(7)</td><td>14(6)</td></tr><tr><td>Correct responses neutral, in %</td><td>95.03(1.03)</td><td>95.29(0.64)</td><td>96.63(0.64)</td></tr><tr><td>Correct responses aversive, in %</td><td>95.24(0.90)</td><td>93.96(0.77)</td><td>96.80(0.63)</td></tr><tr><td>Emotional interference on correct responses, in Δ%</td><td>0.21(0.44)</td><td>−1.33(0.50)<sup>*</sup></td><td>0.17(0.77)</td></tr><tr><td>–</td><td>–</td><td>–</td><td>–</td></tr></table> |
70110ff4552cbccb4c29a9caed6f40466ec393fcd35557e50462e420d257d3e0.png | complex | <table><tr><td></td><td></td><td colspan="3">Factor</td></tr><tr><td></td><td>Items</td><td>1</td><td>2</td><td>3</td></tr><tr><td>5.</td><td>Did you understand the method for border molding at the buccal side?</td><td>.957</td><td>.029</td><td>−.087</td></tr><tr><td>7.</td><td>Did you understand the method for border molding at the lingual side?</td><td>.953</td><td>−.095</td><td>.010</td></tr><tr><td>4.</td><td>Did you understand the method for border molding at the retromolar pad?</td><td>.821</td><td>.077</td><td>−.053</td></tr><tr><td>3.</td><td>Did you understand how to adjust the custom trays?</td><td>.649</td><td>.113</td><td>−.039</td></tr><tr><td>9.</td><td>Did you understand the mobility of mucosa?</td><td>.643</td><td>−.292</td><td>.134</td></tr><tr><td>1.</td><td>Did you understand how to use the impression material?</td><td>.588</td><td>.061</td><td>−.080</td></tr><tr><td>8.</td><td>Did you understand the image of the denture shapes?</td><td>.449</td><td>.058</td><td>.231</td></tr><tr><td>2.</td><td>Did you understand how to use the alcohol torch?</td><td>.446</td><td>.129</td><td>.117</td></tr><tr><td>19.</td><td>Is practical training well organized?</td><td>−.113</td><td>.794</td><td>−.052</td></tr><tr><td>13.</td><td>Did you understand the instructions of the teacher?</td><td>.083</td><td>.738</td><td>−.094</td></tr><tr><td>21.</td><td>Do you value practical training overall?</td><td>.161</td><td>.645</td><td>.046</td></tr><tr><td>20.</td><td>Is practical training easily comprehensible?</td><td>−.004</td><td>.606</td><td>.106</td></tr><tr><td>12.</td><td>Was the level of practical training appropriate for students?</td><td>−.059</td><td>.538</td><td>.140</td></tr><tr><td>15.</td><td>Did you find proper literature and references?</td><td>.061</td><td>−.081</td><td>.840</td></tr><tr><td>14.</td><td>Did you prepare for or review practical training?</td><td>−.027</td><td>.032</td><td>.785</td></tr><tr><td>16.</td><td>Are you satisfied with what you have learned?</td><td>−.046</td><td>.168</td><td>.652</td></tr><tr><td></td><td>Interfactor correlation</td><td></td><td></td><td></td></tr><tr><td></td><td> 1</td><td>–</td><td>.339</td><td>.459</td></tr><tr><td></td><td> 2</td><td></td><td>–</td><td>.449</td></tr><tr><td></td><td> 3</td><td></td><td></td><td>–</td></tr><tr><td></td><td>Percent of variance explained</td><td>33.309</td><td>13.669</td><td>6.813</td></tr><tr><td></td><td>Cronbach’s alpha</td><td>.893</td><td>.800</td><td>.818</td></tr><tr><td></td><td>Mean</td><td>3.700</td><td>4.390</td><td>3.380</td></tr><tr><td></td><td>SD</td><td>.991</td><td>.748</td><td>1.040</td></tr></table> |
7f07e0b76488300bf312b091d9c4513acd6df3129e7a9bb22d366fa2116537db.png | simple | <table><tr><td>Characteristic</td><td>%</td></tr><tr><td>Males</td><td>67.3</td></tr><tr><td>Age, median (range)</td><td>40 (21–79)</td></tr><tr><td>Education level*</td><td> </td></tr><tr><td> Less than high school</td><td>31.4</td></tr><tr><td> High school</td><td>39.2</td></tr><tr><td> College</td><td>29.4</td></tr><tr><td>Employment status*</td><td> </td></tr><tr><td> Employed</td><td>25.0</td></tr><tr><td> Unemployed</td><td>75.0</td></tr><tr><td>Alcohol use*</td><td>51.5</td></tr><tr><td>Intravenous drug use*</td><td>34.4</td></tr><tr><td>Clinical AIDS</td><td>9.5</td></tr><tr><td>CD4 count <200 cells/μL*</td><td>41.8</td></tr><tr><td>Received antiretroviral treatment</td><td>64.4</td></tr><tr><td>Anemia: Hb < 12 g/dL women, < 13 g/dL men</td><td>41.5</td></tr></table> |
184b2d6c9d0bf5e91f1789954411cbf48a2c311d8b8ca9e039a1d45d57796ed4.png | simple | <table><tr><td>Variable</td><td>No</td><td>ΔCt (Mean ± SD)</td><td> </td></tr><tr><td> </td><td> </td><td><i>SAA1</i></td><td><i>SAA4</i></td></tr><tr><td>NNL tissues</td><td>10</td><td>7.64 ± 2.02</td><td>13.63 ± 3.11</td></tr><tr><td>CC tissues</td><td>21</td><td>2.85 ± 3.02</td><td>9.12 ± 3.05</td></tr><tr><td>ΔΔCt</td><td> </td><td>4.79 (P < 0.000)</td><td>4.51 (P = 0.001)</td></tr><tr><td>2<sup>ΔΔCt</sup></td><td> </td><td>27.67</td><td>22.78</td></tr></table> |
7a1c550ea543817d3200b08ba1e3a909fcc426e952956bd17949029b13c61e05.png | simple | <table><tr><td>Gene Set</td><td>Number of Genes in Original Set</td><td>Number of Genes Present in GWAS Data</td><td>Number of SNPs Present in GWAS Data</td><td>Self-Contained <i>p</i>-Value (α = 2.8 × 10<sup>−3</sup>)</td><td>Competitive <i>p</i>-Value (α = 0.05)</td></tr><tr><td>All synaptic genes</td><td>1028</td><td>956</td><td>61413</td><td>0.0393 *</td><td>0.1733</td></tr><tr><td>Ion balance/transport</td><td>43</td><td>40</td><td>1454</td><td>0.0118</td><td>NA</td></tr><tr><td>Cell metabolism</td><td>57</td><td>51</td><td>1059</td><td>0.0429</td><td>NA</td></tr><tr><td>Endocytosis</td><td>26</td><td>26</td><td>1075</td><td>0.0554</td><td>NA</td></tr><tr><td>Cell adhesion and trans-synaptic signaling</td><td>81</td><td>76</td><td>13550</td><td>0.0709</td><td>NA</td></tr><tr><td>Exocytosis</td><td>87</td><td>83</td><td>4855</td><td>0.0962</td><td>NA</td></tr><tr><td>Protein cluster</td><td>47</td><td>42</td><td>4182</td><td>0.1491</td><td>NA</td></tr><tr><td>Peptide/neurotrophin signals</td><td>28</td><td>25</td><td>1742</td><td>0.1659</td><td>NA</td></tr><tr><td>Structural plasticity</td><td>98</td><td>90</td><td>4655</td><td>0.1764</td><td>NA</td></tr><tr><td>Tyrosine kinase signaling</td><td>7</td><td>7</td><td>1281</td><td>0.2030</td><td>NA</td></tr><tr><td>Neurotransmitter metabolism</td><td>29</td><td>27</td><td>1059</td><td>0.2959</td><td>NA</td></tr><tr><td>RNA and protein synthesis, folding and breakdown</td><td>71</td><td>64</td><td>1152</td><td>0.4994</td><td>NA</td></tr><tr><td>Ligand-gated ion channel signaling</td><td>36</td><td>32</td><td>2935</td><td>0.6500</td><td>NA</td></tr><tr><td>G-protein-coupled receptor signaling</td><td>41</td><td>40</td><td>3129</td><td>0.6578</td><td>NA</td></tr><tr><td>Unassigned</td><td>61</td><td>53</td><td>2258</td><td>0.6644</td><td>NA</td></tr><tr><td>Intracellular signal transduction</td><td>150</td><td>145</td><td>9563</td><td>0.7001</td><td>NA</td></tr><tr><td>G-protein relay</td><td>27</td><td>25</td><td>946</td><td>0.7047</td><td>NA</td></tr><tr><td>Intracellular trafficking</td><td>80</td><td>75</td><td>2024</td><td>0.7334</td><td>NA</td></tr><tr><td>Excitability</td><td>59</td><td>56</td><td>4508</td><td>0.7914</td><td>NA</td></tr></table> |
5db4f6440c128418861e709c350c5c1eed364266813d7a5682d3842af46d8c09.png | complex | <table><tr><td>Perdriolle degree difference</td><td colspan="3">JIS (R2 = 0.40)</td><td colspan="3">AIS (R2 = 0.29)</td></tr><tr><td>Independent variables</td><td>B coefficient</td><td>Standard error</td><td>p</td><td>B coefficient</td><td>Standard error</td><td>p</td></tr><tr><td> </td><td>Complete (reference)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td rowspan="4">Adherence</td><td>Incomplete A</td><td>1.92</td><td>1.19</td><td>0.109</td><td>1.35</td><td>0.78</td></tr><tr><td>Incomplete B</td><td>4.23</td><td>0.89</td><td>0.000</td><td>3.97</td><td>0.56</td></tr><tr><td>Incomplete C</td><td>3.35</td><td>1.22</td><td>0.007</td><td>1.94</td><td>0.44</td></tr><tr><td>Incomplete D</td><td>4.65</td><td>1.27</td><td>0.000</td><td>2.46</td><td>0.54</td></tr><tr><td colspan="2">Gender</td><td>2.15</td><td>1.29</td><td>0.099</td><td>0.18</td><td>0.58</td></tr><tr><td colspan="2">Age baseline</td><td>0.18</td><td>0.31</td><td>0.558</td><td>0.09</td><td>0.13</td></tr><tr><td colspan="2">Length of treatment</td><td>0.05</td><td>0.01</td><td>0.001</td><td>0.05</td><td>0.01</td></tr><tr><td colspan="2">Perdriolle at baseline</td><td>−0.04</td><td>0.08</td><td>0.633</td><td>-0.02</td><td>0.04</td></tr><tr><td rowspan="3">Type of brace</td><td>Lyon (Reference)</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>Milwaukee</td><td>−0.18</td><td>1.08</td><td>0.865</td><td>0.21</td><td>0.52</td></tr><tr><td>Pasb</td><td>−0.47</td><td>1.09</td><td>0.669</td><td>−0.93</td><td>0.34</td></tr></table> |
103b49cab448bb85a664ab108b418d52de8d5fc30c3576a911066de057ca1849.png | simple | <table><tr><td>Disease</td><td>Underlying Disease(s)</td><td>Incidence/Prevalence Used to Estimate Burden</td><td>Comments</td><td>Reference</td></tr><tr><td>Oesophageal candidiasis</td><td>HIV/AIDS</td><td>22% of patients with CD4 counts <200 × 10<sup>6</sup>/mL and 5% of ARV-treated patients</td><td></td><td>[17]</td></tr><tr><td>Candidaemia</td><td>Multiple hospitalized patients</td><td>5/100,000 population, 33% occurring in intensive care</td><td>Few patients managed in ICU currently.</td><td>[18]</td></tr><tr><td>Candida peritonitis</td><td>Major abdominal surgery, pancreatitis</td><td>50% of the ICU population with candidaemia</td><td></td><td>[19]</td></tr><tr><td>Recurrent vaginal candidiasis (<underline>></underline>4×/year)</td><td>Pre-menopausal women</td><td>6% prevalence</td><td>Based on mean self-reported disease in Europe and US, reduced by 33% because of incorrect diagnosis.</td><td>[20]</td></tr><tr><td>Allergic bronchopulmonary aspergillosis</td><td>Asthma</td><td>2.5% of adults with asthma</td><td>Rare in children</td><td>[21]</td></tr><tr><td>Severe asthma with fungal sensitisation</td><td>Severe asthma</td><td>33% of the 10% of the most severe adult asthmatics </td><td>Uncommon in children. Fungal sensitization prevalence not known for Cameroon.</td><td>[22]</td></tr><tr><td>Chronic pulmonary aspergillosis</td><td>Tuberculosis (TB), COPD, prior pneumothorax, asthma, lung surgery</td><td>22% of patients with a cavity of pulmonary TB survivors (22%), 2% of those without a cavity. Patients with other pulmonary conditions contribute an additional 25% of cases</td><td></td><td>[23,24,25]</td></tr><tr><td>Invasive aspergillosis</td><td>Leukaemia, lymphoma, COPD</td><td>10% of acute myeloid leukaemia, an equal number of cases in all other haematological conditions + 1.3% of patients with COPD admitted to hospital</td><td>Patients with other conditions not included, including HIV/AIDS.</td><td>[26]</td></tr><tr><td>Cryptococcal meningitis</td><td>HIV/AIDS</td><td>11% over 2 years in patients with CD4 counts <200 × 10<sup>6</sup>/mL</td><td>The annual incidence rises as the CD4 count falls</td><td>[8,9,10]</td></tr><tr><td><i>Pneumocystis</i> pneumonia</td><td>HIV/AIDS</td><td>15% over 2 years in patients with CD4 counts <200 × 10<sup>6</sup>/mL</td><td>Common in children but not estimated separately. Cases in non-AIDS cases not estimated.</td><td>[27,28]</td></tr><tr><td>Histoplasmosis</td><td>HIV/AIDS</td><td>1.5% over 2 years in patients with CD4 counts <200 × 10<sup>6</sup>/mL</td><td></td><td>[29]</td></tr><tr><td>Tinea capitis</td><td>Children 1–15 years</td><td>8.1%</td><td>The most conservative estimate is 8.1% in school aged children. There will be a slight over-estimate by including babies under 2 years.</td><td>[2]</td></tr></table> |
2815091e6010b4e1a0dfe7cf972505b0a5aaca1fbfb6f4adaefd2b763a720d1c.png | complex | <table><tr><td rowspan="3">Subject number</td><td rowspan="3">Age</td><td rowspan="3">Gender</td><td colspan="2">BCVA</td><td colspan="2">IOP (mmHg)</td><td colspan="4">C/D</td><td colspan="2">VF</td></tr><tr><td rowspan="2">RE</td><td rowspan="2">LE</td><td rowspan="2">RE</td><td rowspan="2">LE</td><td colspan="2">RE</td><td colspan="2">LE</td><td rowspan="2">RE</td><td rowspan="2">LE</td></tr><tr><td>V</td><td>H</td><td>V</td><td>H</td></tr><tr><td>II2</td><td>74</td><td>F</td><td>0.3</td><td>NLP</td><td>17.1</td><td>17.5</td><td>0.8</td><td>0.8</td><td>0.9</td><td>0.9</td><td>N/A</td><td>N/A</td></tr><tr><td>II4</td><td>65</td><td>F</td><td>0.3</td><td>0.5</td><td>7</td><td>22.6</td><td>0.6</td><td>0.7</td><td>0.9</td><td>0.8</td><td>PC</td><td>IZD</td></tr><tr><td>II6</td><td>58</td><td>F</td><td>1.0</td><td>1.2</td><td>15.6</td><td>12.1</td><td>0.4</td><td>0.5</td><td>0.6</td><td>0.7</td><td>N/A</td><td>N/A</td></tr><tr><td>III1</td><td>59</td><td>F</td><td>0.4</td><td>0.7</td><td>16.3</td><td>13.7</td><td>0.9</td><td>0.8</td><td>0.9</td><td>0.8</td><td>N/A</td><td>N/A</td></tr><tr><td>III4</td><td>48</td><td>F</td><td>1.5</td><td>1.2</td><td>27.3</td><td>23</td><td>0.5</td><td>0.5</td><td>0.7</td><td>0.7</td><td>N</td><td>N</td></tr><tr><td>III5</td><td>44</td><td>M</td><td>LP</td><td>1.2</td><td>19</td><td>18</td><td>1.0</td><td>1.0</td><td>0.8</td><td>0.7</td><td>N/A</td><td>N/A</td></tr><tr><td>III7</td><td>38</td><td>F</td><td>1.5</td><td>0.1</td><td>14</td><td>15.4</td><td>0.4</td><td>0.4</td><td>1.0</td><td>0.9</td><td>N/A</td><td>N/A</td></tr><tr><td>III8</td><td>55</td><td>F</td><td>1.0</td><td>0.6</td><td>13</td><td>16</td><td>0.5</td><td>0.6</td><td>0.95</td><td>0.85</td><td>N/A</td><td>N/A</td></tr><tr><td>III19</td><td>35</td><td>M</td><td>1.5</td><td>1.2</td><td>15.2</td><td>17.9</td><td>0.2</td><td>0.2</td><td>0.2</td><td>0.2</td><td>N/A</td><td>N/A</td></tr><tr><td>IV1</td><td>37</td><td>M</td><td>0.1</td><td>LP</td><td>16</td><td>19</td><td>0.9</td><td>1.0</td><td>1.0</td><td>1.0</td><td>N/A</td><td>N/A</td></tr><tr><td>IV2</td><td>36</td><td>M</td><td>1.5</td><td>1.5</td><td>14</td><td>19</td><td>0.2</td><td>0.2</td><td>0.4</td><td>0.5</td><td>N/A</td><td>N/A</td></tr><tr><td>IV8</td><td>26</td><td>F</td><td>1.0</td><td>1.2</td><td>11</td><td>19</td><td>1.0</td><td>1.0</td><td>0.9</td><td>0.9</td><td>IZD</td><td>IZD</td></tr><tr><td>IV9</td><td>21</td><td>F</td><td>1.5</td><td>1.5</td><td>28</td><td>26</td><td>0.3</td><td>0.4</td><td>0.5</td><td>0.5</td><td>N</td><td>N</td></tr><tr><td>IV10</td><td>19</td><td>M</td><td>1.5</td><td>1.2</td><td>36</td><td>37</td><td>0.9</td><td>0.8</td><td>0.55</td><td>0.6</td><td>IZD</td><td>N</td></tr><tr><td>IV11</td><td>18</td><td>M</td><td>1.5</td><td>HM</td><td>8</td><td>7</td><td>0.5</td><td>0.4</td><td>0.3</td><td>0.3</td><td>N/A</td><td>N/A</td></tr><tr><td>IV16</td><td>31</td><td>F</td><td>1.0</td><td>0.9</td><td>10</td><td>16</td><td>0.5</td><td>0.5</td><td>1.0</td><td>1.0</td><td>N/A</td><td>N/A</td></tr><tr><td>IV17</td><td>32</td><td>M</td><td>0.5</td><td>0.6</td><td>8</td><td>8</td><td>0.8</td><td>0.8</td><td>0.8</td><td>0.8</td><td>N/A</td><td>N/A</td></tr></table> |
73717041be39e646bef7e3248f143d0efbe23ba4bcf9d34f8ca7b77085c279fe.png | complex | <table><tr><td rowspan="2"> Tissue</td><td colspan="4">Concentration (μg g<sup>–1</sup> fresh weight of tissue)</td></tr><tr><td>(–)-Kolavenol</td><td>Hardwickiic acid</td><td>Salvinorin B</td><td>Salvinorin A</td></tr><tr><td>Leaf</td><td>0.200 ± 0.031</td><td>2.00 ± 0.27</td><td>31.0 ± 1.6</td><td>30.0 ± 2.3</td></tr><tr><td>Gland</td><td>1100 ± 170</td><td>15 000 ± 1100</td><td>150 000 ± 24 000</td><td>250 000 ± 13 000</td></tr></table> |
82bbbd19a0790ab0c1a988d76c3ddfbb7fe24cf156fe4f2959ac592c5ee4d550.png | simple | <table><tr><td>Ideas for better cooperation</td><td>examples</td></tr><tr><td>Mutual accessibility</td><td>• use of faxes: obligatory processes, standardised forms, notation on urgency• establish telephone consulting hours for the GP• acute telephone calls: availability of mobile number of GP• contact nurse in the nursing home: competent, informed, skilled, cross-shift, one mobile phone per living area (residential unit)</td></tr><tr><td>Fix date for GP’s visit</td><td>• fixed date: nursing home sets date, fixed weekday, timing of a 30 min period of time• announcements and arrangements: via fax, timely cancellation of date by GP• central telephone number in nursing home for information transfer</td></tr><tr><td>PreparationCompany during GPs’visits Postprocessing</td><td>• prior to visit: communication via fax, nurse compiles and prepares records, (standardised) prioritisation of inquiries• preparation: chart round by GP and nurse• resident visit: preferably with nurse, standardised documentation• postprocessing: realisation in the responsibility of the nurse• soft skills: reliability, trust, openness, agreements, sufficient time</td></tr><tr><td>TransparencyDefinition of tasks</td><td>• regular exchange of medical information• periodical assessment of diagnosis and therapy (GP)• reliable/competent reporting (nurse)• name badges• clarification of responsibilities and expectations• information about processes in the nursing home and GP practice</td></tr><tr><td>Appreciation and respect</td><td>• mutual respect, trust, tolerance of mistakes• establishment of a communication culture• acknowledgement of nurse /GP competencies (feedback, enough time, listening, GP asks for suggestions from nurses)• to be on equal level, provision of patient care in partnership</td></tr></table> |
ec05057c817d938500ca2dba08685ad2268e225ab776c2300dee5908ac9079a6.png | complex | <table><tr><td> </td><td> </td><td colspan="2">Mean mitocondrial area (μm<sup>2</sup>)</td></tr><tr><td>Genotype</td><td>Treatment</td><td>Myelinated</td><td>Unmyelinated</td></tr><tr><td rowspan="3">WT</td><td>Naive</td><td>0.102 ± 0.002</td><td>0.135 ± 0.016<sup>#</sup></td></tr><tr><td>Vehicle</td><td>0.117 ± 0.008</td><td>0.164 ± 0.006<sup>##</sup></td></tr><tr><td>Paclitaxel</td><td>0.134 ± 0.007<sup>**</sup></td><td>0.161 ± 0.009<sup>#</sup></td></tr><tr><td rowspan="3">σ<sub>1</sub>R-KO</td><td>Naive</td><td>0.107 ± 0.005</td><td>0.134 ± 0.010<sup>#</sup></td></tr><tr><td>Vehicle</td><td>0.116 ± 0.005</td><td>0.164 ± 0.021<sup>##</sup></td></tr><tr><td>Paclitaxel</td><td>0.115 ± 0.006</td><td>0.170 ± 0.007<sup>##</sup></td></tr></table> |
464bb7993cc53d00d3dfac90201c0e2ed2cb3dbe3450fde9fa352b26dd128953.png | complex | <table><tr><td></td><td>Pregnant women (weeks' gestation)</td><td>Postpartum women (months postpartum)</td></tr><tr><td colspan="3"><i>Questionnaires for the participants</i></td></tr><tr><td>Background, physical activity, diet, psychosocial wellbeing</td><td>8–9</td><td>2</td></tr><tr><td>Physical activity, feedback for physical activity counselling</td><td>16–18</td><td>5</td></tr><tr><td>Diet, feedback for dietary counselling</td><td>22–24</td><td>5</td></tr><tr><td>Background, physical activity, diet, psychosocial wellbeing</td><td>36–37</td><td>10</td></tr><tr><td>Feedback for the physical activity and dietary counselling and the study as a whole</td><td>36–37</td><td>10</td></tr><tr><td colspan="3"><i>Other data collection</i></td></tr><tr><td>Adverse events form</td><td>16–18, 22–24, 32–34 and 36–37</td><td>3, 5, 6 and 10</td></tr><tr><td>A copy of the maternity card (weight development and other data on pregnancy)</td><td>after delivery</td><td>2</td></tr><tr><td>Weight and waist circumference measurement form</td><td>-</td><td>2, 3, 5, 6 and 10</td></tr><tr><td>Blood sample</td><td>9–11 and 36–37</td><td>2–2.5 and 8</td></tr><tr><td>A 3-day food record prior to the blood sample</td><td>9–11 and 36–37</td><td>-</td></tr><tr><td>Nipple aspirate fluid (NAF) sample</td><td>-</td><td>8–12</td></tr></table> |
43296047448c2bfa881d902a22ffeff346a0a0d64dfc7c171c671a2e1b452e04.png | complex | <table><tr><td colspan="5">MSigDB pathway</td><td></td><td></td><td colspan="2">C26 (Fold change)</td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>Gene description</td><td>Gene symbol</td><td>AAV9-ev</td><td>AAV9-dnFoxO*</td></tr><tr><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>collagen, type I, alpha 2</td><td>Col1a2</td><td>−4.26</td><td>−2.31</td></tr><tr><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>collagen, type I, alpha 1</td><td>Col1a1</td><td>−5.20</td><td>−2.44</td></tr><tr><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>collagen, type VI, alpha 1</td><td>Col6a1</td><td>−2.64</td><td>−1.70</td></tr><tr><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>collagen, type VI, alpha 2</td><td>Col6a2</td><td>−2.69</td><td>−1.71</td></tr><tr><td>x</td><td>x</td><td>x</td><td>x</td><td>x</td><td>collagen, type VI, alpha 3</td><td>Col6a3</td><td>−3.55</td><td>−1.75</td></tr><tr><td>x</td><td>x</td><td>x</td><td></td><td></td><td>thrombospondin 2</td><td>Thbs2</td><td>−1.62</td><td>−1.07</td></tr><tr><td>x</td><td>x</td><td>x</td><td></td><td></td><td>tenascin C (hexabrachion)</td><td>Tnc</td><td>−2.43</td><td>−1.45</td></tr><tr><td>x</td><td></td><td>x</td><td></td><td></td><td>integrin, beta 6</td><td>Itgb6</td><td>−10.24</td><td>−2.20</td></tr><tr><td>x</td><td></td><td>x</td><td></td><td></td><td>cartilage oligomeric matrix protein</td><td>Comp</td><td>−2.48</td><td>−1.05</td></tr><tr><td>x</td><td></td><td>x</td><td></td><td></td><td>chondroadherin</td><td>Chad</td><td>−16.34</td><td>−2.40</td></tr><tr><td></td><td>x</td><td></td><td></td><td></td><td>fibrillin 1</td><td>Fbn1</td><td>−2.86</td><td>−1.71</td></tr><tr><td></td><td></td><td>x</td><td></td><td></td><td>Rho-associated, coiled-coil protein kinase2</td><td>Rock2</td><td>−1.98</td><td>−1.16</td></tr><tr><td></td><td></td><td></td><td>x</td><td>x</td><td>collagen, type XIV, alpha 1 (undulin)</td><td>Col14a1</td><td>−2.08</td><td>−1.26</td></tr><tr><td></td><td></td><td></td><td>x</td><td>x</td><td>procollagen C-endopeptidase enhancer</td><td>Pcolce</td><td>−1.81</td><td>−1.10</td></tr><tr><td></td><td></td><td></td><td>x</td><td></td><td>matrix metallopeptidase 15</td><td>Mmp15</td><td>−3.12</td><td>−2.06</td></tr><tr><td colspan="5">DAVID annotation</td><td></td><td></td><td></td><td></td></tr><tr><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td></td><td></td><td></td><td></td></tr><tr><td>x</td><td>x</td><td>x</td><td></td><td></td><td>myozenin 3</td><td>Myoz3</td><td>−5.53</td><td>−1.99</td></tr><tr><td>x</td><td>x</td><td>x</td><td></td><td></td><td>integrin beta 1 binding protein 2 (melusin)</td><td>Itgb1bp2</td><td>−4.25</td><td>−2.07</td></tr><tr><td>x</td><td>x</td><td>x</td><td></td><td></td><td>junctophilin 2</td><td>Jph2</td><td>−3.95</td><td>−2.10</td></tr><tr><td>x</td><td>x</td><td>x</td><td></td><td></td><td>synemin, intermediate filament protein</td><td>Synm</td><td>−2.61</td><td>−1.47</td></tr><tr><td>x</td><td>x</td><td>x</td><td></td><td></td><td>homer homologue 1</td><td>Homer1</td><td>−2.26</td><td>−1.45</td></tr><tr><td>x</td><td>x</td><td>x</td><td></td><td></td><td>LIM domain binding 3/Zasp/Cypher</td><td>Ldb3</td><td>−1.84</td><td>−1.14</td></tr><tr><td></td><td></td><td></td><td>x</td><td>x</td><td>fibromodulin</td><td>Fmod</td><td>−3.29</td><td>−1.29</td></tr><tr><td></td><td></td><td></td><td>x</td><td>x</td><td>keratocan</td><td>Kera</td><td>−14.38</td><td>−3.30</td></tr><tr><td></td><td></td><td></td><td>x</td><td>x</td><td>lumican</td><td>Lum</td><td>−2.47</td><td>−1.43</td></tr></table> |
4a5624dae8ed9e18c68f1c1417a8a7557d58b3252e56b6fcd427cb37e50d467e.png | simple | <table><tr><td>Project</td><td>Number of participants interviewed</td></tr><tr><td>Total non-Indigenous participants</td><td>28 (19 F, 9 M)</td></tr><tr><td>Total Indigenous research participants</td><td>8 (6 F, 2 M)</td></tr><tr><td>TOTAL research participants</td><td>36 (24 F, 11 M)</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.